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THESIS SUMMARY 
Studies regarding the influences of cholecystokinin on anxiety, learning and memory, are rife 
with inconsistency. This thesis attempts to address many of these inconsistencies and to 
elucidate valid arguments for these.  
1. Chlordiazepoxide decreases startle amplitudes without altering spontaneous locomotor 
activity in the acoustic startle chamber. Cholecystokinin forms, CCK-4 and CCK-8s attenuate 
the activity of chlordiazepoxide. A combination of CCK-4 and CCK-8s at half their maximally 
effective doses exerts no effect on startle amplitude. CCK2 antagonists CI-988 and LY-288513 
increase startle amplitudes in an inverse bell-shaped dose response profile, and at higher doses 
inhibit the effects of CCK-4 and CCK-8s.  
2. A similar phenomenon is observed in the elevated plus-maze model of anxiety. 
Chlordiazepoxide increases open arm exploration indicative of an anxiolytic activity. 
Cholecystokinin forms and CI-988 inhibit chlordiazepoxide-induced increases in exploration 
with in an inverse bell shaped dose response profile. Combinations at half their maximally 
effective doses of CCK-4 and CCK-8us/8s exert no effects on these chlordiazepoxide-induced 
increases in open arm exploration. CI-988 and LY-288513 both attenuate the activity of 
cholecystokinin forms on chlordiazepoxide-induced increases. 
These phenomena are explained by a hypothesis highlighting a subtle association between sub-
populations of the CCK2 receptor.  
The effects of cholecystokinin with chlordiazepoxide and cholecystokinin antagonists alone on 
plus-maze behaviour of socially isolated animals are similar to that of those group housed. 
This implies that social isolation increases anxiety-like behaviour but does not alter 
cholecystokinin pharmacology specifically.  
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3. Characterisation of cholecystokinin activity within the two-trial plus-maze paradigm has 
shown that LY-288513 exhibits a similar profile to chlordiazepoxide. Scopolamine is able to 
prevent development of chlordiazepoxide insensitivity but not that of the CCK2 antagonist. A 
similar profile was observed when testing acoustic startle amplitudes post plus-maze exposure. 
Maze naïve animals responded to chlordiazepoxide with a decrease in startle amplitudes.   
Exposure to the plus-maze negated this effect. LY-288513 exhibited no activity in altering 
startle amplitudes. 
Cholecystokinin forms, CCK-4, CCK-8us and CCK-8s did not exhibit any activity in the fear 
potentiated startle paradigm of conditioned fear. 
Experiments within this thesis have also attempted to provide a clear explanation for 
seemingly contradictory data implicating cholecystokinin in either amnestic or promnestic 
activity.  The data and discussion therein has strongly refuted claims of activity for 
cholecystokinin in learning and memory of associative, non-appetitive tasks. It has been 
observed here that freezing-like behaviour occurs in cholecystokinin administered animals 
within the model. This is demonstrated by increases in both passive and active avoidance 
latencies.  
Radioligand binding studies, however, failed to distinguish multiple binding sites / sub-
populations of CCK2 receptors. These have been observed in previous studies. The reasons for 
this failure are discussed within. 
This thesis also highlights the complex nature of cholecystokinin activity regarding animal 
models of anxiety and fear. The inconsistency of putative anxiety-like activity between models 
has drawn attention to the multiplicity of procedural factors and subtle differences in 
neurotransmitter activities underlying minor changes in behaviour within these paradigms. 
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CHAPTER ONE - THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS 
OF CHOLECYSTOKININ - INTRODUCTION 
The Discovery and Characterisation of Cholecystokinin   
The peptide, cholecystokinin, was first discovered in the gastrointestinal tract in 1928 (Ivy and 
Oldberg). In 1975, Vanderhaeghen et al., observed that the vertebrate brain contained a small 
peptide which showed immunoreactivity with gastrin antibodies. Subsequent studies revealed 
that this gastrin-like substance, which for the most part was cholecystokinin, which was able to 
cross react with gastrin antibodies due to the homology of the C-terminal sequence, Trp-Met-
Asp-Phe-NH2, in both molecular structures (Dockray, 1976; Rehfeld, 1977; Muller et al., 
1977). The presence of small, discrete gastrin rich areas are also present within the brain, but 
by comparison are very limited (Rehfeld 1978). In addition, cholecystokinin is also expressed 
in the peripheral nervous system with particular abundance in the distal regions of the gut 
(Larsson and Rehfeld 1979).  Cholecystokinin is generally held to be one of the most 
widespread and abundant peptide neurotransmitters in the central nervous system (Noble et al., 
1999).  
Synthesis of Cholecystokinin peptides in Neurones  
Cholecystokinin peptides are encoded within a single gene containing three exons. At a 
transcriptional level it appears that alternate splicing of the cholecystokinin gene does not 
occur. A probable mechanism, by which production of the numerous molecular forms of 
cholecystokinin appears to be accomplished, is that of post-translational processing.  The 
immediate gene product transcribed from the cholecystokinin mRNA is a 115 amino acid 
residue peptide sequence (Deschenes et al., 1984; Takahashi et al., 1985). This pre-pro-
cholecystokinin contains an N-terminal sequence, a splicing region, containing each of the 
various bioactive forms from CCK-83 to CCK-4; and a C-terminal peptide sequence. Within 
the rough endoplasmic reticular organisation, the cleavage enzyme, signalase, removes a signal 
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sequence, and truncates these cholecystokinin forms. This cleavage yields the pro-
cholecystokinin sequence, which is transported to the Golgi apparatus, where the enzyme 
tyrosyl-protein sulphotransferase confers O-sulphated tyrosine residues (Tyr-77, -92, and -95). 
The action of the enzyme, trypsin-like endopeptidase begins within the Golgi apparatus and 
continues within the small immature vesicle formations with subsequent transportation toward 
the axonal synapse.  This enzyme produces proteolytic cleavage at multiple monobasic sites 
and a single dibasic site along the length of the pro-cholecystokinin peptide. Activity of these 
enzymes at these cleavage sites yields several fragments that subsequently undergo terminal 
processing in the mature synaptic vesicles. The synaptic vesicles contain the necessary 
precursor and enzymes for amidation of the peptide molecule. The enzymes, carboxypeptidase 
E-like exopeptidase and peptidylglycine α-amidating monooxygenase remove the glycoxylate 
group from the glycine extended precursor to the bioactive form. This yields the bioactive α-
carboxyamidated peptides. This process has been characterised in several studies in the rat 
(Goltermann et al., 1980a; Goltermann et al., 1980b; Stengaard-Pedersen et al., 1984), in the 
pig (Eng et al., 1983; Rehfeld and Hansen, 1986), and has been reviewed in the periphery 
(Schwartz, 1990) and in the central nervous system (Rehfeld and Nielsen, 1995). Interestingly, 
Rehfeld and Hansen (1986) proposed that the brain contained three or more subpopulations of 
cholecystokinin neurones, each with distinct post-translational processing pathways. 
Molecular forms of Cholecystokinin in the Central Nervous System 
Cholecystokinin (CCK) exists within the central nervous system in several different molecular 
forms, each with specific transmitter activity. Each of the bioactive peptides present the same 
tetrapeptide amide derived structural sequence (Trp-Met-Asp-Phe-NH2) at their C-terminus. It 
is evident that this sequence is central to binding affinity and possibly efficacy at 
cholecystokinin receptors (Rehfeld and Neilsen 1995).  
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The porcine cerebral cortex region of the central nervous system consists of several different 
molecular forms:  
The octapeptide form, CCK-8, is the most abundant form with a mean concentration of 429.6 
pmoles/g tissue. Of this amount, the predominant isoform (about 99%) is the sulphated-
tyrosine species, CCK-8s [Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2] with a much 
lesser amount (less than 1%) of the nonsulphated-tyrosine form, CCK-8us [Asp-Tyr-Met-Gly-
Trp-Met-Asp-Phe-NH2]. The CCK-8us form is unlikely to be an artefact of the extraction 
process as desulphation by non-enzymatic processes only occurs under highly acidic 
conditions, not found in brain tissue. It appears that within porcine brain tissue there are three 
different forms of CCK-8s, which exhibit different net charges as demonstrated in their 
fractionation pattern on an ion-exchange chromatography analysis (Rehfeld and Hansen 1986).  
The larger molecular forms, CCK-22 (4.7 pmol/g), CCK-33 and CCK-39 (37.9 pmol/g) and 
CCK-58 (142.1 pmol/g), also exhibit bioactivity (Rehfeld and Hansen 1986).  
The pentapeptide form, CCK-5 [Gly-Trp-Met-Asp-Phe-NH2], which differs from synthetic 
pentagastrin [BOC-Ala-Trp-Met-Asp-Phe-NH2], occurs in smaller quantities, 102.6 
pmoles/gram tissue wet weight.   The tetrapeptide form, CCK-4 [Trp-Met-Asp-Phe-NH2] 
appears to occur at yet even smaller quantities within the cerebral cortices, 13.3 pmoles/gram 
tissue wet weight.  
It is as yet unknown whether CCK-5 and CCK-4 are specifically synthesised as active 
transmitter molecules or whether they are merely CCK-8s degradative products (Rehfeld 
1985). According to Rehfeld (2000) there is little or no evidence of CCK-4 synthesis in the 
brain, and it is most likely that CCK-4 is an in-vitro degradation product of the closely related 
CCK-5.  
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Regional Distribution of Cholecystokinin in the Brain 
Neurones containing cholecystokinin either as a co-transmitter or a singular transmitter are 
numerous and widespread within the brain. With the exception of the cerebellum, which shows 
very poor expression, cholecystokinin neurones exhibit an almost ubiquitous distribution 
within the brain (Rehfeld et al., 1992; Eng et al., 1983). Some regions of particularly high 
densities are networks present within the cortical areas; the neocortex and the entorhinal 
cortex. Within these regions, cholecystokinin peptide molecules are located chiefly in the thin 
terminal neuronal processes throughout all layers, with a slightly higher density in the 
molecular, rather than the deeper layers. Cortical staining for cholecystokinin neurones is thus 
broadly represented as a light staining of the entire region with a higher concentration in the 
entorhinal cortex than in the neocortex. Within the lateral and caudal hippocampus, 
cholecystokinin neurones are restricted for the most part to a thin band occupying an area 
beneath the main neuronal cell layer. In the medial and anterior hippocampal regions 
cholecystokinin neurones innervate pyramidal cell soma in the CA1 region. In addition the 
medial and anterior regions contain a small percentage of cholecystokinin neurone soma 
(about 1% of total soma in this region). Cholecystokinin neuronal soma and processes are also 
found within the dendate gyrus (Rehfeld and Neilsen 1995). The amygdaloidal region is also 
rich in cholecystokinin neurones with high density networks detected in the medial 
amygdaloidal nucleus. The caudate nucleus and the putamen contain fairly dense networks of 
cholecystokinin neurones with greater concentrations at the rostal level. The medial preoptic, 
the periventricular and the lateral areas of the hypothalamus are also particularly 
cholecystokinin dense as are regions including the lateral septal nuclei, the midbrain 
periaqueductal grey and the area postrema. There are several very low-density regions 
containing little or no cholecystokinin projections or soma. These include the cerebellum, the 
corpus callosum, the internal capsule, and the commissural organs (Rehfeld and Neilsen 1995). 
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Cholecystokinin as a candidate for a neurotransmitter 
Several criteria necessary for a categorical definition of a neurotransmitter are required. CCK-
8s appears to satisfy these criteria as described forthwith (Rehfeld, 1980; Rehfeld, 1985): 
Neurotransmitters are localised in neurones  
CCK-8 is localised in an extensive network of neurones in the central nervous system (CNS) in 
both soma and terminal regions (Larsson and Rehfeld 1979).  
Neurotransmitters are concentrated in neuronal synapse terminals 
Immunocytochemical techniques have revealed that cholecystokinin peptides are located in 
neuronal synapses. This is confirmed by subcellular fractionation of brain tissue whereby a 
four-fold increase in concentration of cholecystokinin peptides are observed in synaptosomes 
and synaptic vesicles as compared to other neuronal regions (Pinget et al., 1978; Emson et al., 
1980). 
Neurotransmitters exhibit demonstrable synthesis pathways 
Radiolabel chasing techniques using [35S]-methionine via intraventricular pulse administration 
in rat brains is found to be incorporated into large molecular forms of cholecystokinin (CCK-
83 and CCK-58) prior to incorporation into the CCK-33-like fragment and then subsequently 
into the small peptide sequences, CCK-8 and CCK-5. Unlabelled methionine chasing revealed 
subsequent radiolabel dilution with the larger forms followed by CCK-8. The CCK-5 molecule 
appeared to be somewhat independent (Goltermann et al., 1980b). 
Neurotransmitters are released by depolarisation
A calcium dependent release of a CCK-like material can be induced by potassium chloride 
superfusion onto brain slices. This implies that calcium dependent release underlies 
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cholecystokinin  release from synaptic terminals which is a typical neurotransmitter release 
mechanism (Emson et al., 1980; Dodd et al., 1980). 
Upon application, neurotransmitters mimic transmitter effects 
Application of CCK-8 in the femtomole range at the post-synaptic membrane strongly excited 
hippocampal neurones in the rat (Dodd and Kelly, 1981). 
Neurotransmitters are inactivated
Evidence of CCK-8 degrading enzymes have been found within brain tissue (Desholt-
Lanckmann et al., 1981). 
Neurotransmitter activity can be abolished by antagonists  
A review of the many highly specific antagonists with affinity to the cholecystokinin receptor 
is detailed later in this chapter.   
Cholecystokinin Receptors in the Central Nervous System 
Cholecystokinin receptors exist as two major subtypes, CCK1 and CCK2. The CCK1 receptor 
was first characterized in pancreatic acini (Sankaran et al., 1980). The CCK2 receptor subtype 
was discovered in the brain that same year (Innis and Snyder, 1980). A third type of 
cholecystokinin receptor was thought to be the gastrin receptor, mediating gastric acid 
secretion (Song et al., 1993). However, subsequent molecular characterisation has revealed 
that these putative gastrin receptors share identical homology with CCK2 receptors (Kopin et 
al., 1992; Wank, 1995). CCK1 and CCK2 receptors initially were assigned nomenclature of 
CCK-A and CCK-B respectively. This nomenclature was recently revised, especially given 
evidence for the presence of subpopulations of both receptors (Noble et al., 1999) 
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Cholecystokinin Receptor Distribution 
CCK-binding sites were first described in the brain in the early nineteen-eighties (Hays et al., 
1980; Innis and Snyder, 1980; Saito et al., 1980). Various studies using autoradiography, in-
situ hybridisation and immunocytochemistry have investigated regional distribution using 
nonselective cholecystokinin specific ligands in numerous species. These studies demonstrated 
that despite similarities, there are also marked variations in the comparative distribution 
between species.  
CCK1 receptors are located in the pancreatic acini, gastric mucosa, gallbladder, gastrointestinal 
tract and specific areas of the central nervous system.  Rat CCK1 receptors are located in the 
interpeduncular nucleus (Hill et al., 1988), area postrema, and medial nucleus tractus 
solitarius, with additional areas of binding found in the habenular nuclei, dorsomedial nucleus 
of the hypothalamus, and central amygdala (Moran et al., 1986; Hill et al., 1987; Moran and 
McHugh, 1988; Woodruff et al., 1991; Carlberg et al., 1991; Zajac et al., 1996). However, 
studies in primates demonstrated a much greater prevalence and broader distribution of CCK1 
receptors compared to that in rodents (Hill et al., 1988). In the primate, CCK1 receptor-binding 
sites are located in the area postrema, nucleus tractus solitarius, hypothalamic dorsomedial 
nucleus, supraoptic nucleus, paraventricular nucleus, mammillary bodies, supramammillary 
region, infundibular region, dorsal motor nucleus of the vagus, and the neurohypophysis. 
Furthermore, the entire mesostriatal dopaminergic system of the primate, contains CCK1 
receptors (Hill et al., 1990).  
Studies utilising in-situ hybridisation techniques, using mRNA probes, have demonstrated that 
CCK1 receptor mRNA is distributed within the identical regions to those containing CCK1 
receptors in the rat (Honda et al., 1993). This study however revealed other areas containing 
CCK1 receptor mRNA without receptor binding characteristics. Moderate levels were found in 
the forebrain, olfactory region, piriform cortex, neocortex, claustrum, throughout the 
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hippocampal formation, medial nucleus of the amygdala, lateral olfactory tract nucleus, lateral 
septal nucleus, stria terminalis bed nucleus, preoptic nucleus, thalamic reticular nucleus, 
various hypothalamic regions, the arcuate nucleus, and in lateral and posterior hypothalamic 
areas. Light staining was also found in the brainstem, dorsal motor nucleus of the vagus nerve 
and the interpeduncular, caudal linear raphe, and hypoglossal nuclei (Lanaud et al., 1989; 
Hökfelt et al., 1991).  
CCK2 receptors are located throughout the central nervous system with moderate to high 
densities. Certain distinct regions contain only low densities. Interestingly, the absence of 
cholecystokinin binding sites in the cerebellum is species dependent. Cerebellar 
cholecystokinin receptors are detected in the guinea pig, human, and mouse, but not in the rat 
(Sekiguchi and Moroji, 1986; Williams et al., 1986; Dietl et al., 1987). 
Subsequent studies utilising in-situ hybridisation techniques, have demonstrated that CCK2 
receptor mRNA is distributed within regions corresponding to those containing CCK2 
receptors, in the rat (Honda et al., 1993; Hansson et al., 1998), and in the Mastomys natalensis 
(Shigeyoshi et al., 1994; Jagerschmidt et al., 1994).  
This wide ranging morphological distribution of cholecystokinin receptors would seem to 
support the large number of functions attributed to cholecystokinin. 
The Cholecystokinin Receptor Gene  
Despite some evidence for further cholecystokinin receptor subtypes, only two genes have 
been cloned (Noble et al., 1999). The human CCK1 receptor gene was first identified on 
chromosome 4 (Huppi et al., 1995). Subsequent analysis mapped the human CCK1 gene to 
positions 4p15.1-p15.2 (Inoue et al., 1997). The mouse and rat CCK1 receptor genes have also 
been mapped on chromosome 5; 5p16.2-p15.1; (Huppi et al., 1995) and on chromosome 14 
(Takiguchi et al., 1997). The mouse gene again appears in a similar position on chromosome 7 
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(Huppi et al., 1995). The human CCK2 receptor gene was first identified on chromosome 11 
(Song et al., 1993)  and further localised to position 11p15.4  (Huppi et al., 1995).  
Interestingly the CCK1 receptor gene is co-localised with the dopamine D5 receptor gene at 
4p15.1-p15.3 (Sherrington et al., 1993) and the CCK2 receptor gene with the dopamine D4 
receptor gene at 11p15.4-p15.5 (Pisegna et al., 1992). This is particularly poignant given the 
coexistence of cholecystokinin and dopamine in midbrain neurons (Crawley and Corwin, 
1994). 
The genes encoding the CCK1 receptor and the CCK2 receptor in humans are organised in a 
similar manner consisting of five exons and four introns (Miller et al., 1995; Wank, 1995; 
Inoue et al., 1997; Song et al., 1993). Each exon encodes distinct regions of the receptor 
molecule: 
1. The first exon sequence encodes the extracellular N-terminal domains. 
2. The second exon sequence encodes from the transmembrane region I to the beginning of 
region II. 
3. The third exon sequence encodes from the transmembrane region III to the beginning of 
region V. 
4. The fourth exon sequence encodes from the transmembrane region V to the beginning of the 
third intracellular loop. 
5. The fifth exon sequence encodes the remaining receptor structure.  
Interestingly, Jagerschmidt et al., (1994) isolated several distinct CCK2 receptor mRNA forms 
from rat brain tissue, including a truncated mRNA species. These forms typically exhibit 
variation at the 5' end. The precursor mRNA and mature form were located in the cerebral 
cortex, hypothalamus, and hippocampus in apparently differing proportions. This implies 
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that the expression of the CCK2 receptor is modulated at a post-transcriptional level. 
Furthermore, the cerebellum contained only an unspliced mRNA form. This appears to agree 
with studies observing an absence of CCK2 receptor-binding sites in the rat cerebellum 
(Pelaprat et al., 1987). This genetic organisation is similarly conserved between humans and 
animal species. Gene organisation for CCK1 receptors in the mouse (Lacourse et al., 1997) and 
rat (Takata et al., 1995) and for CCK2 receptors in the mouse (Nagata et al., 1996) and rabbit 
(Blandizzi et al., 1994) are organized similarly.  
Cholecystokinin Receptors and Signal Transduction 
Cloning of the CCK1 receptor has revealed a seven-transmembrane receptor structure linked to 
a G-protein second messenger system (Wank et al., 1992a). CCK1 receptor activity has been 
found to be unaffected by pertussis toxin, implying coupling with the Gq family of G proteins 
(Pang and Sternweiss, 1990). Piiper et al., (1997) subsequently demonstrated that CCK1 
receptors in the pancreas are coupled to either Gq or G11, which activates phospholipase C-1.  
However, it has also been demonstrated that in rat pancreatic acini, the CCK1 receptor is 
coupled to the phospholipase A2 enzyme, thus mediating the arachidonic acid messenger 
system (Yoshida et al., 1997b; Yoshida et al., 1997a). Furthermore, CCK1 receptor activation 
in the pancreas has also been shown to activate the adenylyl cyclase signal-transduction 
cascade (Marino et al., 1993). Site-directed mutagenesis studies imply that the CCK1 receptor 
is directly coupled with both Gs and Gq (Wu et al., 1997). 
Pharmacological studies and subsequent cloning, have confirmed that CCK2 receptors also 
belong to the seven-transmembrane receptor family structure, linked to a G-protein second 
messenger system (Wank et al., 1992b; Knapp et al., 1990; Durieux et al., 1992). The signal-
transduction cascade for the CCK2 receptor is however, less extensively characterised, due in 
part to technical considerations of working with isolated neurons and gastric mucosa cells 
(Noble et al., 1999).  
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Physiological studies using CCK2 receptor cDNA transfected cells have demonstrated that the 
CCK2 receptor is coupled to a pertussis-toxin insensitive G protein (Roche et al., 1990), 
possibly of the Gq/G11 family, which activates phospholipase C (Delvalle et al., 1992). It has 
been shown that CCK2 receptors are also coupled to a phospholipase, inducing release of 
arachidonic acid, but interconnected through a pertussis-toxin sensitive G protein (Pommier et 
al., 1999) and to a MAP kinase pathway (Taniguchi et al., 1994).  
Cholecystokinin receptor specific ligands  
Non-selective cholecystokinin Receptor Agonists 
The sulphated octapeptide CCK-8s binds to the CCK1 receptor with a 500- to 1000-fold greater 
affinity than non-sulphated cholecystokinin or sulphated gastrin (Silvente-Poirot et al., 1993). 
The CCK2 receptor binds pentagastrin, CCK-4, CCK-8us and CCK-8s with similar affinity 
(Saito et al., 1980). 
CCK1 Receptor Specific Ligands: Agonists 
Cholecystokinin analogues have been developed with greater specificity for CCK1 receptors 
using the following approaches: 
1. A-71378 [des-NH2-Tyr(SO3H)-Nle-Gly-Trp-Nle-(NMe)Asp-Phe-NH2], with an (NMe)Asp 
residue critical for CCK1 receptor selectivity (Holladay et al., 1992). 
2. A series derived through replacement of the methionine residue of Boc-CCK-4 with side 
chain-substituted Lys derivatives: Boc-Trp-Lys(X)-Asp-(NMe)Phe-NH2, such as A-71623 and 
A-70874 (Lin et al., 1991). 
3. A series of 1,5-benzodiazepines based CCK1 receptor agonists (Aquino et al., 1996).  
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CCK1 Receptor Specific Ligands: Antagonists 
The first cholecystokinin antagonists were derived from a naturally occurring benzodiazepine, 
asperlicin, isolated from the fungus Aspergillus alliacaeus (Chang et al., 1985). Several studies 
support the concept that the natural ligand for the anti-anxiety benzodiazepine receptor is a 
peptide (Guidotti et al., 1983; Alho et al., 1985), suggesting that the 5-phenyl-1,4-
benzodiazepine ring present in the structure of asperlicin and diazepam is in fact a chemical 
structure that recognizes a peptide receptor (Evans et al., 1986). Asperlicin is a nonselective 
antagonist for cholecystokinin receptors.  
A range of highly potent and selective antagonists for the CCK1 receptor has since been 
developed. These are summarised as follows: 
1. An asperlicin derivative, L-364718 (otherwise known as MK-329 or devazepide) is a potent 
cholecystokinin antagonist developed with a high selectivity for CCK1 receptors (IC50 
CCK2/CCK1 = 3750); (Chang et al., 1985) 
2. Glutamic acid derivatives, loxiglumide (CR-1505) or lorglumide (CR-1409), (Makovec et 
al., 1985). 
3. Cholecystokinin C-terminal fragments, 2-naphthalenesulfonyl-1-aspartyl-(2-phenethyl) 
amide (2-NAP), a competitive antagonist at CCK1 receptors (Hull et al., 1993).  
4. Dipeptoids, such as PD-140548, which is a competitive antagonist with a high selectivity for 
the CCK1 receptor (100:1) (Boden et al., 1993).  
5. Synthetic peptides, such as JMV-179 [Tyr(SO3H)-Ahx-Gly-D-Trp-Ahx-Asp-
phenylethylester], are potent CCK1 receptor antagonists  (Lignon et al., 1987). 
6. A serine derivative, (R)-1-[3-(3-carboxypyridine-2-yl)-thio-2-(indol-2-yl) carbonyl-
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amino]propionyl-4-diphenylmethylpiperazine] (TP-680) is a highly selective and irreversible 
antagonist of CCK1 receptors (Akiyama et al., 1996).  
7. CCK-4 restricted analogues containing a 3-oxoindolizidine ring such as IQM-95333 with a 
very high selectivity for CCK1 (8000:1) (Martin-Martinez et al., 1997). 
CCK2 Receptor Specific Ligands: Agonists 
Several approaches have been devised in the design of selective agonists for CCK2 receptors. 
A summary of these is as follows: 
1. CCK-8 degradative enzyme-resistant forms. The first of which was BOC-
[Nle28,31]CCK27-33 (BDNL) (Ruiz-Gayo et al., 1985). Several enzyme-resistant analogues 
have since been synthesised including BC-264 (Durieux et al., 1991).  
2. A peptidase-resistant bioactive analogue [3H]propionyl-BC-264 has been devised by 
replacement of the BOC with a tritiated propionyl group (Durieux et al., 1989).  
3. CCK-8 appears to exist in a folded Asp1 and Gly4 linked configuration in solution (Fournie-
Zaluski et al., 1986). Synthetic high affinity peptide-based CCK2 receptor agonists, such as 
BC-197 and BC-254 utilised this property with amide bond formation between residues 
(Charpentier et al., 1988; Charpentier et al., 1989). A highly selective CCK2 agonist (4000:1), 
SNF-8702, ([N-methyl-Nle28,31]CCK26-33) also relies on this derivation (Knapp et al., 
1990).  
CCK2 Receptor Specific Ligands: Antagonists  
A range of CCK2 antagonists have been developed under four main chemical groups: 
1. Peptide analogues, such as Boc-Trp-Orn(Z)-Asp-NH2 (Gonzalez-Muniz et al., 1990). 
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2. Benzodiazepine derived ligands, such as L-364718 and L-365260 (Bock et al., 1989). A 
major drawback associated with early benzodiazepine-derived CCK2 antagonists was a limited 
bioavailability (Noble et al., 1999). These flaws have been largely addressed with subsequent 
syntheses such as YM022 (Nishida et al., 1994). 
3. Dipeptoids such as CI-988 (see Appendix A.1) are derived from the cholecystokinin 
tetrapeptide (Hughes et al., 1990). CI-988 exhibits 1600-fold selectivity for CCK2 over CCK1 
receptors, although it also displays weak CCK1 receptor agonist properties (Hocker et al., 
1993). Clinical development of CI-988 is limited due to its poor bioavailability, which was 
attributed to poor absorption and efficient hepatic elimination in mice and rats (Trivedi et al., 
1998). Later derivatives have addressed some of these flaws and await further evaluation.  
4. Pyrazolidinone derived ligands are based on structural modification of the asperlicin 
structure (Yu et al., 1991). Pyrazolidinones such as LY-288513 (see Appendix A.1) however 
were prone to adverse effects in preclinical toxicological studies. Therefore development of 
this group has been discontinued (Howbert et al., 1992). 
5. Ureidoacetamide derivatives, such as RP-73,870 are highly selective CCK2 receptor 
antagonists with subnanomolar affinity for CCK2 receptors with 100-1000-fold selectivity over 
CCK1 receptors (Pendley et al., 1995). However bioavailability issues are once again 
prevalent. 
Ligand-Receptor Interactions  
Site-directed mutagenesis studies imply that cholecystokinin interacts with amino acid residues 
Trp39 and Gln40 at the extracellular segment of the first transmembrane sequence on the 
CCK1 receptor. Some controversy arises in determination of residues at which CCK-8 binds. 
Different studies have indicated that either the N-terminal CCK-8 sequence (Kennedy et al., 
1997) or the C- terminal CCK-8 sequence (Ji et al., 1997) interacts with hydrogen binding at 
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these residues. Furthermore, other studies suggest that Met195 (Gigoux et al., 1998) and 
Arg197 (Gigoux et al., 1999) interact with Tyr(SO3H) of CCK-8s, and that Arg336 and 
Asn333 interact with the Asp8 and C-terminal fragment of CCK-9 (Gigoux et al., 1999). Other 
residues implicated in CCK-8 binding are generally based on those conferring tertiary 
structure; such as Ser131 (Kopin et al., 1995); residues 204-208, and Cys205 (which form a 
disulphide bridge with Cys127) (Silvente-Poirot and Wank, 1996). Maintenance of gastrin 
affinity is also attributed to residues at the outer section of the third transmembrane region (Wu 
et al., 1997) and of the outer two thirds of the fifth transmembrane section (Schmitz et al., 
1996).  Several residues are also important in maintaining CCK-8 affinity; His207, Leu103 and 
Phe107 (Silvente-Poirot et al., 1998).  
Cholecystokinin antagonists appear to bind to distinct areas of the receptor. Chimeric and site-
directed mutagenesis studies suggest that the outer third of the sixth and seventh 
transmembrane sections interact with benzodiazepine-derived antagonists, L-364718 and L-
365260. In particular, residues Thr111 and His376 (Kopin et al., 1995) and His381 
(Jagerschmidt et al., 1996) are important in maintaining high affinity.  The lack of effect of 
these transmembrane VI and transmembrane VII residues on agonist affinity suggests that 
agonist- and antagonist-binding sites are, at best, only partially overlapping (Noble et al., 
1999). 
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The Physiology of Cholecystokinin 
Peripheral Physiology 
Peripheral cholecystokinin receptors exert the following physiological effects: 
1. Pancreatic CCK1 receptors stimulate acinar cells to secrete the digestive enzyme pancreatic 
amylase (Jensen et al., 1989). 
2.  In the gallbladder, CCK1 receptors stimulate gallbladder contraction (Chang et al., 1986).  
3. Peripherally administered cholecystokinin produces satiation of feeding behaviour in rats 
(Gibbs et al., 1973); and in man (Sturdevant and Goetz, 1976; Pi-Sunyer et al., 1982). 
Furthermore, CCK1 receptor antagonists increase food consumption and postpone satiety in 
rats (Corwin et al., 1991; Reidelberger et al., 1991; Moran et al., 1992); in rhesus monkeys 
(Moran et al., 1993) and in humans (Wolkowitz et al., 1990). Interestingly, despite some 
contrary evidence, this phenomenon is also produced by CCK2 receptor antagonists in rats 
(Dourish et al., 1989). Lesions of the vagus nerve prevent the CCK-induced satiety phenomena 
(Smith et al., 1981). Furthermore, Moran et al., (1987) demonstrated that entry of food into the 
intestine triggers the release of endogenous cholecystokinin by the intestinal mucosa. These 
findings provide evidence for a hypothesis that cholecystokinin released from the intestine 
activates CCK1 receptors on the vagus nerve to transmit satiation signals to the brain (Smith 
and Gibbs, 1992). 
4. In the stomach, gastrin (Schubert and Shamburek, 1990) and cholecystokinin (Sandvik and 
Waldum, 1991) bind to CCK2 receptors to stimulate gastric acid secretion. This effect is 
blocked by CCK2 receptor antagonists (Bado et al., 1991; Pendley et al., 1995).  
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The behavioural profile of cholecystokinin 
In line with its wide distribution in the brain, cholecystokinin is involved in the 
modulation/control of multiple central functions. In particular, numerous experimental and 
clinical studies have clearly shown that CCK, through its action at CCK1 and CCK2 receptors, 
participates in the neurobiology of anxiety, depression, psychosis, cognition, and nociception 
(Noble et al., 1999). 
There is a significant correspondence between distribution of opioid receptors and of 
cholecystokinin receptors in the brain and spinal cord, particularly within areas associated with 
nociceptive pathways (Pohl et al., 1990). Enkephalin and the cholecystokinin octapeptide are 
co-localized within individual neurons and processes within discrete areas of rat midbrain and 
forebrain (Gall et al., 1987). Numerous studies have shown an antinociceptive effect of 
cholecystokinin agonists in various nociceptive models. In the hot-plate test Derrien et al., 
(1993) demonstrated that the non-selective cholecystokinin agonist, BDNL exhibited 
antinociceptive properties which were attenuated by the CCK1 antagonist MK-329 and by the 
mu-opioid antagonist, naloxone. The selective CCK2 agonist, BC-264 produced a slight 
decrease in lick latency, indicative of potentiation of nociception. Using the tail flick test, 
Rezayat et al., (2000) demonstrated that caerulein augmented antinociceptive effects of 
morphine in mice. However, administration of either CCK1 or CCK2 antagonists attenuated 
this effect (Zarrindast et al., 1998; Zarrindast et al., 1999). Faris et al., (1983) demonstrated 
that systemically or perispinally administered cholecystokinin, antagonised analgesia produced 
by foot shock or morphine. Furthermore, several studies demonstrate that CCK2 receptor 
antagonists potentiate mu-opioid antinociceptive responses (Noble et al., 1995; Xu et al., 
1996; Xu et al., 1997).  Formation of hypotheses based on these seemingly conflicting 
findings, is problematic, however, differences in type of nociceptive stimulus in each model 
and species differences must be taken into account.   
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The discovery of the effects of cholecystokinin on anxiety disorders has generated much 
research interest in this area.  This is further described in chapters two, three and four and in a 
preface following this section. 
Furthermore effects of cholecystokinin on learning and memory processes have been studied 
in some detail. This is illustrated further in chapters four and five. 
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CHOLECYSTOKININ AND ANXIETY DISORDERS - AN INTRODUCTION 
Anxiety Disorders afflict up to ten percent of the general population with a one-year 
prevalence (the disorder lasting for at least one year).  Anxiety disorders encompass a wide 
range of symptoms, differentiated by specific criteria into separate conditions, such as panic 
disorder, obsessive-compulsive disorder, post-traumatic stress disorder and generalised anxiety 
disorder. The symptomology of these conditions frequently overlap (Dubovsky, 1990). 
Generalised anxiety disorder (GAD) accounts for over half of all anxiety diagnoses.  GAD is 
characterised by symptoms of motor tension (fidgeting), autonomic hyperactivity (high 
startle), hypervigilance and scanning. Panic disorder afflicts almost two percent of the 
population.  Patients with panic disorder undergo repeated bouts involving discrete episodes of 
intense anxiety.  These episodes appear to occur spontaneously and may last from a few 
minutes to over an hour.  Panic attacks are perceived as uncontrollable sensations including; 
palpitations, breathing difficulty, chest pain, tremors, paraesthesia, and hallucinations 
accompanied by immobility.  Psychosensorial symptoms such as depersonalisation, fear of 
losing control and fear of dying are very common.  Both GAD and panic disorder appear to be 
familial (Dubovsky, 1990). 
Several neurotransmitter systems have been implicated in the pathogenesis of these anxiety 
disorders.  Research, until quite recently, has concentrated on four major neurotransmitters and 
their interactions: 
The dopaminergic mesocortical system appears to be involved in emotional behaviour, 
including that associated with anxiety.  The dopaminergic regions of the amygdala and 
possibly the nucleus accumbens are implicated (Harro and Vasar, 1991b; Crawley, 1991).  
Noradrenergic systems, focused primarily at the locus coeruleus, have been associated with 
arousal in response to danger signals.  The underlying cause of these anxiety disorders may be 
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linked to altered perception of danger signals (Gray, 1978). 
Serotonergic pathways, focused primarily at the dorsal raphe nuclei, have a variety of different 
effects that appear to influence arousal states. Serotonergic pathways are particularly 
responsive to punished behaviour.  Punished behaviour is frequently anxiogenic (Salzman et 
al., 1993). 
GABA (γ-amino-butyric acid) gated pathways have a multiplicity of inhibitory effects on other 
pathways.  The benzodiazepine group of anxiolytic drugs, through their own receptors, exert 
action upon GABA receptors (to increase the inhibitory action of GABA). Benzodiazepines 
exert general anti-convulsant, anti-anxiety, and sedative effects. Despite currently being the 
most effective treatment of anxiety disorder they are, due to both their sedative effects and 
their abuse potential, far from ideal (File et al., 1996; Olivier et al., 1996). 
Cholecystokinin and Anxiety 
The observation that cholecystokinin may have anxiogenic properties arose, from a study in 
1979, of its satiety effect on sheep.  Infusion of the cholecystokinin agonist, pentagastrin into 
the lateral ventricle produced an abnormal series of behaviours.  These included 'foot stamping' 
and 'vocalisation', i.e.; those behaviours characteristic of an ovine response to fear (Della-Fera 
and Baile, 1979). Fekete et al., (1984) subsequently reported anxiogenic effects with CCK-8, 
injected into the amygdaloid central nucleus of rats.   
A subsequent study also showed that CCK-8s induced excitation of the hippocampal 
pyramidal neurones in rats, is attenuated by a range of benzodiazepine receptor agonists.  In 
addition, this effect was reversed by prior administration of the benzodiazepine antagonist, 
flumazenil.  The dose-response profile, exhibited by these intravenously administered 
benzodiazepines in this study, was analogous to that of their clinical effect in the treatment of 
anxiety disorders (Bradwejn and de Montigny, 1984). 
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Cholecystokinin in Clinical Studies  
Clinical studies demonstrated that a bolus injection of CCK2 receptor agonists, CCK-4 or 
pentagastrin, induces panic attacks in patients with panic disorder (Bradwejn et al., 1990). 
These can be attenuated by antipanic pharmacological agents such as antidepressants (van 
Megen et al., 1997) and by CCK2 antagonists such as L-365260 (Bradwejn et al., 1994). Panic 
attacks and anxiety symptoms were also induced in healthy human subjects by CCK-4 (Shlik 
et al., 1997; de Montigny, 1989; Bradwejn and Koszycki, 1991) and by pentagastrin (McCann 
et al., 1994-1995). The CCK2 antagonist, L-365260 was able to prevent pentagastrin-induced 
anxiogenesis in healthy individuals (Lines et al., 1995).  
Sensitivity to CCK-4 and pentagastrin is enhanced in panic disorder patients relative to healthy 
volunteers (Bradwejn et al., 1991). Furthermore, cerebrospinal fluid concentrations of CCK-8s 
are significantly decreased in patients suffering from panic disorder (relative to controls) 
(Lydiard et al., 1992).  
The anxiogenic/panicogenic behavioural effects of CCK-4 in humans are accompanied by 
marked biological alterations including; robust increases in heart rate, blood pressure, and 
minute ventilation (Bradwejn et al., 1992; Koszycki et al., 1998), increased levels of plasma 
cortisol and prolactin (de Montigny, 1989), an immediate increase in plasma levels of 
adrenaline and noradrenaline, with delayed onset increases in dopamine plasma levels (Jerabek 
et al., 1999), and increased levels of neuropeptide Y (Boulenger et al., 1996). In addition, 
pentagastrin can induce large (up to 520% increases over the baseline) and very rapid, dose-
dependent elevations in adrenocorticotropin (ACTH) and cortisol levels in healthy human 
subjects (Abelson and Liberzon, 1999). Whether these alterations in neurochemistry are 
reproducing those found within spontaneous panic episodes is as yet unclear, however, it 
would appear ostensibly that the cholecystokinin system in patients with panic disorder is 
altered compared to healthy subjects. 
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Studies using CCK2 receptor antagonists have failed to provide consistent evidence of a 
potential in treatment for panic disorder. In using cholecystokinin antagonists, CI-988 (Adams 
et al., 1995) and L-365260 (Kramer et al., 1995), problematic pharmacokinetic profiles were 
observed. Other antagonists have shown toxicological concerns. Given the recent development 
of several different classes of CCK2 antagonists, other suitable agents shall undoubtedly be 
examined in the near future.  
Despite functional imaging studies having been performed in healthy individuals (Benkelfat et 
al., 1995), no studies involving patients with panic disorder have been completed to date.  This 
is significant given that panic disorder patients clearly respond dissimilarly to cholecystokinin 
in addition to actually, exhibiting spontaneous panic episodes. Shlik et al., (1997) proposed 
that structures within the brainstem nuclei, thought to control regulation of respiratory and 
cardiopulmonary function, are significant sites of action for exogenous CCK-4. Animal studies 
have shown that cholecystokinin interacts with brainstem structures to modulate respiratory 
and cardiopulmonary activity, and blood pressure (Denavit-Saubie et al., 1985). Furthermore 
this region has close anatomical and functional links with the locus coeruleus, a brain region 
thought to be involved in the expression of fear and anxiety. Therefore it may be proposed that 
anxiogenic/panicogenic symptoms evoked by CCK-4 may rise from direct activation at 
brainstem structures leading to subsequent activation or inhibition of higher CNS regions 
mediated through neuronal projections (Noble et al., 1999).  
A study of polymorphisms in genes encoding for cholecystokinin pre-pro hormone, 
cholecystokinin peptides and both receptor subtypes were examined in patients with panic 
disorder (according to DSM-IV classification). While cholecystokinin peptide, and CCK1 
receptor gene polymorphisms showed no association, a CCK2 receptor gene polymorphism, 
showed a significant association with panic disorder patients (Kennedy et al., 1999).  
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Although CCK2 receptors are certainly a major component in cholecystokinin inducible 
panicogenesis, it is probable that the range of symptoms observed within panic episodes are 
achieved through interactions between cholecystokinin and other neurotransmitter systems. 
Clinical studies have revealed interactions between cholecystokinin induced anxiogenesis and 
benzodiazepines (de Montigny, 1989), serotonin (Bradwejn and Koszycki, 1994a; van Megen 
et al., 1997), and noradrenaline (Bradwejn and Koszycki, 1994a; Le Melledo et al., 1998). 
Subsequent investigations have revealed that CCK2 receptor agonists are also active in 
generalized anxiety disorder (Brawman-Mintzer et al., 1997), social phobia (van Vliet et al., 
1997), obsessive compulsive disorder (de Leeuw et al., 1996), and premenstrual dysphoric 
disorder (Le Melledo et al., 1995). The physiological properties of cholecystokinin in 
maintenance of appetite and behavioural implications with various anxiety disorders would 
imply a strong underlying role in anorexia and bulimia nervosa. This link was confirmed by 
Lydiard et al., (1993) with measurement of significantly lower CCK-4 levels in CSF of 
bulimic patients. cholecystokinin has also been implicated in anorexia nervosa (Stricker, 
1984).  
The proposal by Lydiard (1994) that panic episodes can result from a cholecystokinin 
imbalance of increased CCK-4 levels and decreased CCK-8 levels can be given some 
credence, but is drawn into question given more recent suggestions that CCK-4 is not in fact an 
endogenous form of cholecystokinin (Rehfeld, 2000). This article proposed that CCK-4 is 
actually an artefact derived from CCK-5, although whether the properties of CCK-5 are 
transferred to those observed with CCK-4 is unresolved. 
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Cholecystokinin in Animal Models of Anxiety  
Concurrently with clinical trials, various animal studies have demonstrated a similar 
anxiogenic activity in several animal models and in several different animal species. However, 
this area of study is rife with inconsistency. Bradwejn and Vasar (1995) proposed that the 
conflicting data reported in the animal literature are attributable in part to the failure to address 
the various factors that potentially influence susceptibility to the anxiogenic-like effects of 
CCK. This is proposed with evidence that rats with low exploratory behaviour (i.e., "anxious" 
rats) have been reported to exhibit a higher density of cholecystokinin receptor-binding sites in 
the frontal cortex and hippocampus, relative to that in rats with high exploratory behaviour 
(i.e., "non-anxious" rats); (Harro et al., 1990a). Subsequently, effects of cholecystokinin 
compounds might suffer inconsistency in effect, due to differing endogenous levels of anxiety 
displayed by rats in each study. Moreover, anxiety levels have shown to vary markedly with 
minor changes in procedure (see chapters two, three and four). 
Given that CCK-8s is a non-specific agonist (at CCK1 and CCK2 receptors), and CCK-4 is 
specific for CCK2 receptors, Bradwejn and Koszycki, (1994b) proposed that an imbalance 
between CCK1 and CCK2 receptors could result in the pathology of anxiety. The 
administration of CCK1 agonists however, has been shown to have little or no effects on 
anxiety related behaviour, although the intra-accumbal anxiogenic-like effect of CCK-8s can 
be blocked by a specific CCK1 receptor antagonist (Dauge et al., 1989a). Furthermore, despite 
inactivity by most CCK1 antagonists, one notable exception is that of a highly CCK1 selective 
antagonist, IQM-95333 which exerts anxiolytic activity (Ballaz et al., 1997; Singh et al., 
1995).  
The anxiogenesis produced by CCK-8s administration is however, blocked by many CCK2 
receptor antagonists.  In addition, most (but not all) CCK2 agonists can induce anxiety-like 
symptoms in both animal models and in clinical studies. 
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Animal studies have demonstrated interactions between cholecystokinin induced anxiogenesis 
and; benzodiazepines (Singh et al., 1992; Chopin and Briley, 1993); serotonin (Vasar et al., 
1993b; Rex et al., 1994; Bickerdike et al., 1994; Bickerdike et al., 1995; Rex et al., 1997; To 
and Bagdy, 1999); noradrenaline (Harro et al., 1995); dopamine (Biro et al., 1997; Nutt et al., 
1998); corticotrophin-releasing factor (Biro et al., 1993); and opioids (Koks et al., 1998; Koks 
et al., 1999).  
The Neuroanatomy of Cholecystokinin Induced Anxiety in Animals 
Cholecystokinin is known to exhibit interactions with a variety of other neurotransmitters in 
the central nervous system: 
1. Cholecystokinin is co-localised with GABA in the rat hippocampal interneurones and is 
found to enhance potassium evoked GABA release in the rat cerebral cortex (Raiteri et al., 
1996).  
2. CCK-8s induced excitation of the hippocampal pyramidal neurones in rats is attenuated by a 
range of benzodiazepine receptor agonists (Bradwejn and de Montigny, 1984). 
3. Cholecystokinin is also found to co-exist with dopamine in the nucleus accumbens. The 
cholecystokinin antagonist, CI-988 has been shown to inhibit dopamine overflow release in the 
rat cerebral cortex (Corwin et al., 1995). 
4. CCK-8 and BC-264 has been demonstrated to increase the basal release of endogenous 
glutamate from rat hippocampal slices. L-365260 reversed these effects (Migaud et al., 1994).  
5. CCK2 receptor activation, however, reduces glutamate-induced depolarisation in slices of rat 
cerebral cortex (Harro et al., 1993). 
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6. The CCK2 receptor agonist BOC-CCK-4 produced 'anxious' behaviour and potentiated the 
rise in cortical 5-HT observed on exposure to the X-maze. L-365260 produced 'anxiolytic' 
behaviour and decreased basal extracellular cortical 5-HT (Rex et al., 1994). 
7. Chemical lesioning of the noradrenergic, locus coeruleus produces an upregulation of 
cholecystokinin receptors in the frontal cortex and the hippocampus (Harro et al., 1992).  
The septohippocampal system (SHS) has been implicated due to its' high cholecystokinin 
content.  The SHS has also been proposed to form a fundamental network for the basis of 
anxiety, gating a behavioural inhibition system. Gray (1978) proposed that anxiety is caused 
by a mismatch in comparison of expected to actual events, which is thought to function within 
this system.  
The midbrain region, the periaqueductal grey (PAG) has also been implicated in anxiety. 
Electrical stimulation of the PAG region in humans produces intense fear-like symptoms 
(Tasker, 1982). Stimulation of the dorsal PAG in animals is reflected by abrupt escape and 
flight reactions (Di Scala et al., 1987). Studies utilising immunohistochemical techniques, have 
shown a large distribution of cholecystokinin neurones in the periaqueductal grey region of the 
rat (Liu et al., 1994).  Distribution is predominantly in the dorsolateral division, where the 
population of CCK-like immunoreactive neurones are largely heterogeneous. These neurons 
are subsequently activated by cholecystokinin application, which is then inhibited by 
antagonists, proglumide and CR1409 (Liu et al., 1994). Furthermore, infusion into the PAG of 
CCK-4 produces intense anxiety-like flight behaviour (Mongeau and Marsden, 1997). 
Bradwejn and Koszycki (1994b) speculated that the opposing effects of CCK1 and CCK2 
agonists on the brain stem region, the nucleus tractus solitarius (NTS), when exhibiting an 
imbalance, might induce anxiety and/or panic episodes.  Given that it has not yet been 
determined whether CCK-4 is permeable to the blood brain barrier, the relative permeability of 
the NTS region is thus highlighted as a possible area of cholecystokinin action in anxiety.  In 
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addition, the NTS contains a relatively high density of cholecystokinin receptors. This area is 
densely innervated and contains projections to the locus coeruleus (an area implicated in panic 
disorder and part of the septohippocampal system). 
The precise neuroanatomical basis of cholecystokinin-induced anxiety states is thus unclear.  
The probability that all these areas interact, in order to produce the various types of anxiety 
disorder, is high.  It is also probable that different interacting regions exhibit a variant activity 
dependent upon the symptomology of the various types. 
Although a role for cholecystokinin in anxiety and panic disorder is evident, the mechanism by 
which this effect is produced is also still undefined. This thesis attempts to elucidate at least 
with regard to certain animal models, the underlying mechanisms controlling the induced 
anxiety-like behaviour. A necessary part of the ensuing hypotheses will be in the detailed 
analysis of preceding studies, in order to encompass and thus explain, both my own findings 
and those of others. 
Aims 
Studies regarding the influences of cholecystokinin on anxiety, learning and memory are rife 
with inconsistency. These discrepancies are described in the following chapters. This thesis 
attempts to address many of these inconsistencies and to elucidate valid arguments for these 
differences. Experimental research within this thesis is devoted to study of hypotheses 
connecting these seemingly contrary pieces of evidence. It is hoped that this thesis has gone 
some way in this endeavour. 
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CHAPTER TWO – ANIMAL MODELS OF GENERALISED ANXIETY: THE 
ACOUSTIC STARTLE REFLEX PARADIGM 
Introduction 
The acoustic startle reflex paradigm is a highly sensitive model of anxiety and fear related 
behaviour. The acoustic startle response is a short latency motor response to a loud and 
unexpected noise. The response involves a rapid sequential activation of muscles along the 
length of the body. The latency of the acoustic startle reflex in the rat is 8-milliseconds, 
measured from tone onset to the beginning of the electromyographic response in the hindleg. 
This extremely short latency may indicate that limited organisations of synapses are involved 
in the acoustic startle response circuit (Frankland et al., 1997). 
Neuroanatomical Organisation 
In a study by Davis et al., (1982) bilateral lesions of the ventral cochlear nucleus, which 
receives the primary auditory input, appeared to abolish the acoustic startle reflex response. In 
addition, they observed that a single pulse electrical stimulation of the ventral cochlear nucleus 
elicits startle-like responses with a latency of about 7 milliseconds. Bilateral lesions of the 
dorsal and ventral nuclei of the lateral lemniscus, which receive direct input from the ventral 
cochlear nuclei, also abolished acoustic startle. Electrical stimulation of these nuclei elicited 
startle-like responses with a latency of about 6 milliseconds. Bilateral lesions of ventral 
regions of the nucleus reticularis pontis caudalis, which contain cell bodies that give rise to the 
reticulospinal tract, again abolishes acoustic startle. Electrical stimulation of these points elicits 
startle-like responses with a latency of about 5 milliseconds. Reaction product from 
horseradish peroxidase, iontophoresed into this area is found in the nuclei of the lateral 
lemniscus. This study suggested that a primary acoustic startle circuit in the rat consists of; the 
auditory nerve, ventral cochlear nucleus, nuclei of the lateral lemniscus, nucleus reticularis 
pontis caudalis, spinal interneuron, lower motor neuron, and muscles. Hence, five synapses, 
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plus the neuromuscular junction, are probably involved (Davis et al., 1982). The modification 
of this reflex circuit, by a more obscure neuronal organisation gating mood and anxiety state, 
may be via either a deficit of inhibitory, or intensification of excitatory modulating influences 
on signal transmission, within the acoustic startle circuitry (Krupina et al., 1994). Lee and 
Davis (1997) observed that the NMDA lesions of the bed nucleus of the stria terminalis 
(BNST) completely blocked corticotropin releasing hormone (CRH) enhanced startle, whereas 
chemical lesions of the ventral hippocampus and the amygdala failed to block CRH-enhanced 
startle.  
Validity of Acoustic Startle as a Model of Anxiety 
Animal models of human clinical conditions are required to satisfy particular validities in order 
to be established as models of the condition itself, or of some aspects of the condition.  
Face Validity: 
Face validity, in the case of animal models of anxiety, implies that the model produces a fear-
like reaction, guided by anxiety-like states in animals, that are analogous to abnormal 
behaviour in clinical anxiety states. Without a general consensus with regard to classification 
of human anxiety, it is difficult to determine the face validity of any particular animal model of 
anxiety. Whether the subjective experience underlying the anxiety-like reactions in animals 
within these models, are analogous to the subjective anxiety experienced by anxious humans, 
is probably an irresolvable question.  
An acoustic startle paradigm, however, probably more than any other animal model of anxiety, 
appears to satisfy face validity criteria. A spontaneous startle reflex following a loud and 
unexpected noise is prevalent across many species. Acoustic startle is observed clinically to be 
increased in amplitude in patients with a range of anxiety disorders (Shalev et al., 1998; 
Rodriguez-Fornells et al., 1999). The observation of a very similar phenomenon in a rodent 
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acoustic startle model may provide a dependable rationale for development of this paradigm as 
a model of generalised anxiety. 
Furthermore, rodent ultrasonic vocalizations (USV) at 22 kHz in response to acoustic startle 
stimuli may perhaps provide additional evidence of the face validity of this model of anxiety, 
in addition to the actual reflex movement (Kaltwasser 1990). An inhibition of vocalisations is 
observed with rats administered diazepam, flunitrazepam, and ipsapirone after induction by 
either acoustic startle or electric shock. FG-7142 had no activity (Kaltwasser 1991). In 
addition, startle-induced USV are sensitive to the "anxiogenic-like" effects of withdrawal from 
chronic diazepam exposure (Vivian et al., 1994). 
Plappert et al., (1993) observed that a group of rats are divided according to their responses to 
startle-eliciting stimuli into two groups, with different emotional states. About half of the 
female rats showed long-lasting freezing behaviour after 1-8 stimuli (10 kHz, 110 dB). In 
freezing rats the startle amplitude was higher than in non-freezing rats, throughout the entire 
sequence. This finding demonstrates that the anxiety state of these animals before the first 
startle-eliciting stimulus, and not just the aversiveness of the stimulus, contributes to freezing 
behaviour. The dichotomous variation in freezing behaviours, coupled to a synchronous and 
matching distribution in acoustic startle responses, again provides further evidence towards the 
face validity of this model of anxiety. In another study by Krupina et al., (1994) sensorimotor 
response was measured by acoustic startle reflex in male rats with innate high and low levels 
of anxiety. The levels of anxiety were determined using a complex multiparameter method for 
evaluating anxiety-phobic states in rats by a ranged scale. Amplitude and prepulse inhibition 
(PPI; see paragraph below) of the acoustic startle response were increased, but latency of the 
startle reflex was decreased in rats with intrinsically high levels of anxiety as compared with 
those with intrinsically low levels.  
 
THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS OF CHOLECYSTOKININ 
 33
Predictive Validity: 
Predictive validity, or correlation, refers to the sensitivity of the model to clinically active 
pharmacological intervention, and insensitivity to other clinically non-active intervention. An 
example of such is where a model of generalised anxiety can be manipulated by using 
clinically active benzodiazepine anxiolytics, and no effects are observed using a clinically 
inactive tricyclic antidepressant treatment. Hijzen et al., (1991) showed that the 
benzodiazepine agonist, midazolam, attenuated acoustic startle sensorimotor amplitude dose-
dependently. This phenomenon has also been observed with anxiogenic pharmacological 
manipulations, whereby the anxiety level is increased, resulting in increased startle response 
amplitudes in rats (Rassnick et al., 1992; Rasmussen et al., 1993; Vivian et al., 1994). Krupina 
et al., (1994) observed that in rats with an intrinsically high level of anxiety, intraperitoneal 
injection of subconvulsive doses of pentylenetetrazol (10 and 15 mg.kg-1) resulted in an 
increase of the amplitude of the acoustic startle response. Swerdlow et al., (1986) observed 
that intracerebroventricular (i.c.v.) administration of the stress hormone, corticotropin-
releasing factor significantly potentiated acoustic startle amplitude. These effects were 
attenuated dose-dependently by pre-treatment with the benzodiazepine, chlordiazepoxide. 
Doses of chlordiazepoxide, that antagonized CRF-potentiated ASR, did not lower startle 
baseline. Liang et al., (1992) also observed that intracerebroventricular infusion of CRF 
produced a significant dose-dependent increase in the magnitude of the acoustic startle reflex 
in rats. This corresponds with observations that CRF levels are decreased by benzodiazepines 
in human subjects with high anxiety levels (Gram and Christensen 1986). 
The eye-blink response following sudden acoustic noise bursts is part of the startle reflex in 
both animal models and in humans. In clinical studies the magnitude of the startle response can 
be attenuated by presentation of a weak stimulus before the startle-eliciting stimulus (prepulse 
inhibition, PPI). The magnitude of PPI in normal human subjects is decreased by increasing 
doses of the benzodiazepine agonist, midazolam. During infusion of flumazenil and in the 
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presence of midazolam, the magnitude of PPI increased, which is consistent with the mode of 
action of flumazenil as a benzodiazepine antagonist (Schachinger et al., 1999).  
Construct validity: 
Construct validity implies homology, or direct correspondence, at a physiological/neurological 
level, between the animal model and the condition being modelled (Rodgers and Cole 1994).  
Indeed, attempts to assess construct validity are compromised by our incomplete 
understanding of human anxiety (Lister 1987). However, where the septohippocampal system 
and the amygdaloid regions have been implicated in anxiety-like behaviour clinically, Decker 
et al., (1995) observed in rats that both septal and fimbria-fornix lesions had marginal effects 
on prepulse inhibition and baseline startle. Amygdaloid lesions markedly impaired prepulse 
inhibition of acoustic startle. 
Cholecystokinin and Acoustic Startle 
It has been observed that systemic administration of the CCK2 agonist, Pentagastrin increases 
startle amplitudes (Zhou et al., 1996).  In addition, pentagastrin, via intra-amygdaloidal 
infusion (Frankland et al., 1997), and pentagastrin and CCK-8s, via intracerebroventricular 
infusion (Frankland et al., 1996),  also increase startle amplitudes.  Intra-amygdaloid 
administrations of pentagastrin potentiated startle responses dose-dependently. With increasing 
intra-amygdaloid doses of pentagastrin, the level of responding compared to the baseline 
(vehicle) group increased exponentially (Frankland et al., 1997). This study also demonstrated 
that these same infusions into the amygdaloid region of pentagastrin had no effect on 
locomotor activity within the same time range. This suggests that changes in the level of startle 
responding were not attributable to changes in spontaneous locomotor activity in the open field 
model (Frankland et al., 1997). However this model differs in its' nature to that of the acoustic 
startle apparatus in which the animal is placed in a chamber in which its' movement is 
restricted. A more reliable model would perhaps be that which is able to measure spontaneous 
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locomotor activity, within the same chamber to that in which the animal was tested for the 
acoustic startle (such as has been studied here). This study also demonstrated that the 
potentiation of startle, by infusions of pentagastrin, was attenuated by a systemically 
administered pre-treatment of the CCK2 receptor specific antagonist L-365260. Systemic 
administration of the quinoline derived CCK2 antagonist, LY-288513, attenuates potentiated 
startle generated by; diazepam withdrawal (Rasmussen et al., 1993), and by chronic nicotine 
withdrawal (Rasmussen et al., 1996). Frankland et al., (1997) demonstrated that L-365260 
only weakly attenuates, without reaching significance, potentiation of startle induced by intra-
amygdaloidal administrations of pentagastrin. Frankland et al., (1997) also demonstrated that 
intra-amygdaloidal administration of the CCK2 antagonist, PD-135158 attenuated the 
potentiation of acoustic startle, induced by intracerebroventricular infusions of pentagastrin. 
This infusion of PD-135158 however, exhibited no effects upon the baseline level (Rasmussen 
et al., 1996). Frankland et al., (1997) also showed that intracerebroventricular administrations 
of pentagastrin were able to potentiate startle responses by 70 to 100%. These increases were 
attenuated by intra-amygdaloidal infusions of another CCK2 receptor specific antagonist, PD-
135158. It was also demonstrated, that neither intra-striatal nor intra-accumbal administration 
of pentagastrin, at several doses, were able to increase the level of startle responding compared 
to the vehicle group. It appears in fact that intra-striatal pentagastrin administration, at a dose 
of 10nM, may decrease the level of acoustic startle compared to vehicle group. Subsequently, 
the Frankland study (1997) provides strong evidence that the pentagastrin increased startle 
responding is gated primarily at the amygdala formation. These studies demonstrate that the 
CCK2 antagonists tested are able to attenuate the potentiation of startle induced by; (1) cue 
conditioned fear (to a stimuli previously paired with a noxious unconditioned event), (2) 
pharmacologically induced fear from intra-amygdaloid and intracerebroventricularly 
administered pentagastrin, and (3) diazepam withdrawal induced anxiety.   Fendt et al., (1995) 
infused CCK-8s into the caudal pontine reticular formation (PnC) and observed an increased 
number of acoustically activated spikes recorded from single PnC units. In addition this 
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infusion produced a modest increase (30-40%) in startle responding, although only at the dose 
of 5-picogram per ml. At higher doses, 2.5 and 10 pg/ml this startle potentiating effect was no 
longer observed.  The giant neurones of the caudal pontine reticular formation are thought to 
form an obligatory relay circuit in mediation of the acoustic startle responses (Frankland et al., 
1996). 
In clinical studies, the endogenous cholecystokinin tetrapeptide, CCK-4, produced an increase 
of eye-blink startle amplitude (in response to a series of acoustic stimuli) from baseline values 
during a continuous intravenous administration in healthy volunteers (Shlik et al., 1999). 
Aims of this study 
This study tested a series of cholecystokinin forms. It was observed previously that 
intraperitoneal administration of these specific forms; CCK-8s (sulphated octapeptide), CCK-
8us (unsulphated octapeptide) and CCK-4 (unsulphated tetrapeptide) at defined doses were 
able to induce an anxiety-like state (in reversal of the effects of chlordiazepoxide) upon the 
elevated plus-maze model of anxiety (see chapter 3). Furthermore it was found that combining 
these forms, at these doses and at half these doses, that this anxiety-like behavioural change 
was no longer observed.  For this reason it was decided to examine whether these phenomena 
are observable upon the acoustic startle model of anxiety. In addition, in order to determine 
whether these effects are produced via the CCK2 receptor subtype, two CCK2 antagonists were 
tested for their ability to alter startle responding. These antagonists, the peptoidal CI-988 and 
the quinoline derived LY-288513 were administered intraperitoneally, either alone or 
concurrently, with one of the three cholecystokinin peptide forms. 
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Materials and Methods 
Animals 
Male rats of the Sprague Dawley strain (Laboratory Animal Centre, National University of 
Singapore, Singapore), 250-320g were housed in groups of five to seven and maintained with 
free access to food and water ad libitum, in an animal room for one week prior to 
experimentation. Room lights were on from 07:00 to 19.00 hours.  Animals were randomly 
assigned treatment groups using a simple computer program, random number sequence 
generator (Random Number Generator v.1.0 by Colin Greengrass, 1998). This simple program 
(see Appendix C.1 for listing) generated random whole numbers within a range corresponding 
to an assigned treatment group. In order to maintain similar animal numbers in each group, 
fulfilment of a criterion of group loading was employed. Thereby, a random number would be 
generated and an animal in sequence would be assigned to the corresponding group number. 
When the maximum number of animals approved for each group had been reached, any 
occurrence of that number in the sequence would be deemed invalid and ignored. The next 
valid number in the sequence would be taken until all the treatment groups were filled. A 30 
minute period, from injection to behavioural testing, was preferred due to an abudance of 
literature pertaining to this time period for efficacy of cholecystokinin forms.   
Drugs and Administration 
Cholecystokinin peptide agonists, CCK-4 (Trp-Met-Asp-Phe-NH2); CCK-8us (Asp-Tyr-Met-
Gly-Trp-Met-Asp-Phe-NH2); (Biotechnology Centre, National University of Singapore), CCK-
8s (Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2; American Peptide Company and 
Princeton Biomolecules) ; the cholecystokinin peptoidal antagonist CI-988 ([R-(R*,R*)]-4-[[2-
[[3-(1H-Indol-3-yl)-2-methyl-1-oxo-2-[[(tricyclo[3.3.1.1.3,7]dec-2-yloxy)carbonyl]-
amino]propyl]-amino]-1-phenylethyl] amino]-4-oxobutanoate 1-deoxy-1-(methylamino)-D-
glucitol; Research Biochemicals International), and LY-288513 ([trans-N-(4-bromophenyl)-3-
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oxo-4, 5-diphenyl-1-pyrazolidinecarboxamide]; kindly donated by Eli Lilly and Company, 
USA) were dissolved in dimethylsulphoxide (DMSO; Merck) with either chlordiazepoxide 
hydrochloride (a generous gift from Roche) at 1.5mg/ml or DMSO alone. The drugs or vehicle 
were administered by intraperitoneal injection in a volume of 1ml per kg body weight. Two 
separate injections were given to each animal. Animals were used only once. Drugs were 
administered intraperitonally 30 minutes prior to testing, as has been previously described in 
literature. Cholecystokinin peptide was stored under desiccation at -70oC. Cholecystokinin 
peptide solutions were prepared freshly each day approximately two hours prior to testing. 
Powdered peptide was dissolved in DMSO and specific concentrations were prepared through 
serial dilution with thorough vortex mixing at each stage.  
Auditory Startle Response Apparatus 
A computer controlled auditory startle chamber was used (SR-LAB, San Diego Instruments 
Inc.). The startle apparatus consisted of a transparent Perspex cylindrical animal chamber, 
8.7cm in diameter, with sliding Perspex gates at both ends. The animal was placed in this 
chamber, with both gates closed, during testing. The animal chamber rested on a weighted 
Perspex frame within a sound proofed isolation cabinet. This cabinet provided inflow-outflow 
ventilation, a constant background white noise level of 70-decibels, and a constant light level. 
Both stimulus noise bursts and background white noise was delivered via a speaker mounted 
approximately 2cm above the animal on the exterior of the animal chamber. Intensity of the 
startle response was determined using a piezoelectric sensor mounted below the animal 
chamber. Motion data was recorded via an interface assembly linked to an IBM computer with 
relevant software (San Diego Instruments, PSR2 Software program). Noise levels, measured in 
decibels, were determined by means of a sound pressure level meter. This allowed precise 
adjustment of noise levels. The chamber was thoroughly cleaned with 70% ethanol between 
sessions and allowed to dry. The test room was maintained with controlled light levels and 
temperature with white noise delivered at 70dB. Behavioural experiments were performed 
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between 14:00-18:00hours. 
An apparatus-naïve animal was placed in the compartment and underwent an acclimatisation 
period for 180 seconds in the presence of 70dB of white noise (background). Ideally within 
this acclimatisation period, peak amplitude readings would have been taken, in order to give a 
measure of spontaneous locomotor activity, however, the operating program software did not 
allow for this option in the protocol. Immediately following this period each animal was 
exposed to twenty-five 100-millisecond bursts of white noise at 120dB with an eight-second 
period of background noise between each burst. The peak amplitude of each startle reflex 
movement was recorded. Sequential recording of peak amplitude of movement (means of five 
responses) exhibits an acoustic startle profile, which is plotted on a chart versus the sequential 
120dB noise burst (in groups of five). The protocol pertaining to measurement of spontaneous 
locomotor activity within the acoustic startle chamber relied on a simple modification of the 
acoustic startle program, whereby the level of the startle stimulus noise was set to that of 
background noise (70dB) and data taken periodically.  
SR-Lab Software Program 
A dedicated computer software program dictated a sequence of twenty-five 100-millisecond 
bursts of 120dB white noise with an intermittent background noise level of 70dB. There was 
an eight second interval between 120dB bursts. This is listed in Appendix C.2. 
Statistical Analysis 
Statistical analysis was performed using statistical software (SPSS V9.0, SPSS Inc. USA). The 
data were subjected to one-way analysis of variance (ANOVA), followed by Bonferroni post 
hoc analysis. Probability (p) <0.05 was considered statistically significant. Data are presented 
as drug group versus startle amplitude means (25 readings in 5 groups of five). Progressive 
session groups, one to five, are represented by five shaded bars of increasing darkness, trial 
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block one is lightest in shade, whereas trial block five is darkest. 
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Results and Data 
A series of preliminary validation experiments were conducted.  
Figure 2.1: Administration of dimethylsulphoxide (DMSO), which was used as a solvent 
throughout the experiment, produced no differences in acoustic startle responding when 
compared to 0.9% Saline.  
Figure 2.2: Chlordiazepoxide, at 3.0 and 5.0mg.kg-1, produced a statistically significant 
decrease in startle amplitudes compared to the DMSO control: chlordiazepoxide; 3.0mg.kg-1, 
(F2,13=14.79, p<0.05 (Trial block 1); F2,13=71.81, p<0.001 (Trial block 2) F2,13=42.87; p<0.001 
(Trial block 3); F2,13=69.36, p<0.001 (Trial block 4); F2,13=23.88, p<0.01 (Trial block 5): 
chlordiazepoxide; 5.0mg.kg-1, p<0.001 in trial blocks 1 to 5.  
Figure 2.3: A protocol by which locomotor activity within the acoustic startle chamber was 
determined showed no significant differences between groups compared to DMSO (control); 
ie. chlordiazepoxide (3.0 mg.kg-1), CCK-4 (0.025 mg.kg-1), CCK-8us (0.01 mg.kg-1), CCK-8s 
(0.001 mg.kg-1), CI-988 (1.0 mg.kg-1) and LY-288513 (10.0 mg.kg-1).  
Figure 2.4: Administration of the cholecystokinin form; CCK-8s (0.001 mg.kg-1) produced a 
significant increase in startle amplitude when compared to DMSO (control), CCK-8s; 0.001 
mg.kg-1, F3,35=10.85, p<0.001 (Trial block 1); F3,35=14.99, p<0.001 (Trial block 2); F3,35=10.40; 
p<0.001 (Trial block 3); but missed significance on trials 4 and 5. CCK-4 (0.025) narrowly 
missed significance on trial 2, p=0.052. CCK-8us (0.01 mg.kg-1) failed to show any increase in 
startle amplitude.  
Figure 2.5: In comparison between chlordiazepoxide (control) and chlordiazepoxide with 
cholecystokinin forms, CCK-4 (0.025 mg.kg-1) and CCK-8s (0.001 mg.kg-1) both showed 
significant increases in startle amplitudes within the first trial period only, CCK-4; 0.025 
mg.kg-1, F6,59=4.50, p<0.05 (Trial block 1), CCK-8s; 0.001 mg.kg-1, F6,59=4.5, p<0.05 (Trial 
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block 1). Combined administration of chlordiazepoxide with cholecystokinin forms; CCK-4, 
CCK-8us and CCK-8s at their peak anxiogenic doses (as determined by elevated plus-maze 
studies - see chapter three) and at half these maximally effective doses, with each other, 
produced several affects on startle amplitude. The anxiogenic-like activity of CCK-4 (at 0.025 
mg.kg-1) was partly attenuated by combination with CCK-8s (0.001 mg.kg-1), whereby 
significant differences with chlordiazepoxide were negated and no significant inhibition was 
observed between CCK-4 and the CCK-4/ CCK-8s combination. CCK-4 (at 0.025 mg.kg-1) in 
combination with CCK-8us (0.01 mg.kg-1) maintained the same significant increase in startle 
amplitude when compared to the chlordiazepoxide vehicle control, (F6,59=4.5, p<0.01 (Trial 
block 1). The anxiogenic-like activity of CCK-8s (at 0.001 mg.kg-1) was also attenuated by 
combination with CCK-8us (0.01 mg.kg-1), again significant differences with chlordiazepoxide 
vehicle group were negated and no significant inhibition was observed between CCK-8s and 
the CCK-8us/ CCK-8s combination. No anxiogenic-like activity was observed for CCK-4 and 
CCK-8s at half their anxiogenic doses, as might be expected. Two CCK2 specific antagonists 
were tested against the anxiogenic doses of cholecystokinin forms. Prior to this step, a dose 
response curve was evaluated for both antagonists. It was found that these antagonists 
produced anxiogenic-like activity with an inverse bell-shaped dose response profile.  
Figure 2.6: Administration of CI-988 at doses, 0.002 mg.kg-1 and 0.02 mg.kg-1 produces an 
increase in startle amplitude compared to vehicle: CI-988; 0.002 mg.kg-1,  F5,42=10.76, p<0.01 
(Trial block 1); F5,42=7.83, p<0.05 (Trial block 2); F5,42=5.31, p<0.05 (trial block 3); F5,42=7.26, 
p<0.01 (trial block 4); F5,42=9.24, p<0.001 (trial block 5): CI-988; 0.02mg.kg-1, F5,42=10.76, 
p<0.001 (Trial block 1); F5,42=7.83, p<0.01 (Trial block 2); F5,42=7.26, p<0.05 (trial block 4); 
F5,42=9.24, p<0.01 (trial block 5).  
Figure 2.7: Administration of  LY-288513 at doses, 0.001 mg.kg-1 and 0.01 mg.kg-1 produces 
an increase in startle amplitude compared to vehicle: LY-288513; 0.001 mg.kg-1,  F7,82=5.71, 
p<0.05 (Trial block 1); F7,82=5.43, p<0.001 (trial block 3); F7,82=5.32, p<0.05 (trial block 4); 
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F7,82=9.48, p<0.001 (trial block 5): LY-288513; 0.01mg.kg-1, F7,82=5.71, p<0.01 (Trial block 
1); F7,82=7.47, p<0.001 (Trial block 2); F7,82=5.32, p<0.05 (trial block 4); F7,82=9.48, p<0.001 
(trial block 5). 
Figure 2.8: The antagonists, CI-988 (at 1.0mg.kg-1) and LY-288513 (at 10.0mg.kg-1) co-
administered with chlordiazepoxide (3.0mg.kg-1) did not modify the anxiolytic-like activity of 
chlordiazepoxide. The significant decrease in startle amplitude was caused by 
chlordiazepoxide and not maintained by the antagonist (DMSO versus chlordiazepoxide; 
3.0mg.kg-1, F3,28=19.63, p<0.001 (Trial block 1); F3,28=6.84, p<0.01 (Trial block 2) F3,28=4.24; 
p<0.05 (Trial block 3): DMSO versus chlordiazepoxide + CI-988; 1.0mg.kg-1, F3,28=19.63, 
p<0.001 (Trial block 1); F3,28=6.84, p<0.01 (Trial block 2), F3,28=4.24; p<0.053 narrowly 
missing significance (Trial block 3): DMSO versus chlordiazepoxide + LY-288513; 
10.0mg.kg-1, F3,28=19.63, p<0.001 (Trial block 1) where subsequent trial blocks did not exhibit 
significant differences.  
Figure 2.9: The increase in startle amplitudes produced by CCK-4 (0.025mg.kg-1) was 
attenuated by CI-988 and LY-288513. CCK-4 (0.025 mg.kg-1) compared to chlordiazepoxide 
(3.0mg.kg-1) F3,27=3.94, p<0.05 (Trial block 1); F3,27=3.87, p<0.05 (Trial block 2) F3,28=4.39; 
p<0.05 (Trial block 3). This effect was abolished by CI-988 (1.0mg.kg-1) and by LY-288513 
(10.0 mg.kg-1) in trial blocks 1 and 2 where the significant amplitude increase by CCK-4 alone 
was attenuated. Within trial block 3, LY-288513 inhibited CCK-4 significantly, F3,28=4.39; 
p<0.05.  
Figure 2.10: CCK-8s (0.001 mg.kg-1) compared to chlordiazepoxide (3.0 mg.kg-1) control 
group, produced a significant increase in startle amplitude, F3,28=4.39, p<0.01 in trial block 1 
and in blocks 2 and 3, F3,28=4.39, p<0.05. Co-administration with CI-988 significantly 
attenuated the increase in amplitude by CCK-8s, F3,29=8.39, p<0.05 in trial block 1 compared 
to CCK-8s alone. LY-288513 attenuated the CCK-8s stimulated amplitude increase to a 
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significant degree, F3,29=8.39, p<0.01 compared to CCK-8s in trial block 1 and in block 2, 
F3,29=4.10, p<0.05. Partial attenuation of effects was observed for trials blocks 2 and 3 (CI-
988) and for 3 (LY-288513) but these missed statistical significance.  
Figure 2.11: CCK-8us (0.01 mg.kg-1) exhibited no significant activity either alone or co-
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 FIG 2.1: Effects of saline (0.9%) and dimethylsulphoxide (DMSO) on acoustic startle peak amplitude, in rats, over twenty-five trials. Five consecutive trial blocks are shown 
for each treatment. These each represent the means of five individual responses to acoustic stimuli (results presented as mean with standard error of the mean (SEM)). 
Consecutive trial blocks are represented from left to right and with darkened shading. Significant differences from the saline group were not observed. 
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FIG 2.2: Effects of chlordiazepoxide at doses, 3.0 and 5.0 mg.kg-1 versus dimethylsulphoxide (DMSO) vehicle, on acoustic startle peak amplitude, in rats, over twenty-five 
trials. Five consecutive trial blocks are shown for each treatment. These each represent the means of five individual responses to acoustic stimuli (results presented as mean 
with SEM). Consecutive trial blocks are represented from left to right and with increased shading. Significant differences from the DMSO group are shown; *p<0.05, 
**p<0.01, ***p<0.001 (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG 2.3: Effects of various drugs at specific doses, versus dimethylsulphoxide (DMSO) vehicle on peak amplitude, in rats, in the absence of acoustic startle stimuli, over 
twenty-five trials. Drugs tested were chlordiazepoxide (3.0mg.kg-1), CCK-4 (0.025mg.kg-1), CCK-8us (0.01mg.kg-1), CCK-8s (0.001mg.kg-1), CI-988 (1.0 mg.kg-1) and LY-
288513 (10.0 mg.kg-1). Five consecutive trial blocks are shown for each treatment (results presented as mean with SEM). These each represent the means of five individual of 
spontaneous locomotor activity movement amplitudes within the acoustic startle chamber. Consecutive trial blocks are represented from left to right and with increased 
shading. Significant differences from the DMSO group were not observed. 
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FIG 2.4: Effects of cholecystokinin forms, CCK-4 (0.025 mg.kg-1), CCK-8us (0.01 mg.kg-1), and CCK-8s (0.001 mg.kg-1) versus dimethylsulphoxide (DMSO) vehicle group, 
on acoustic startle peak amplitude, in rats, over twenty-five trials. Five consecutive trial blocks are shown for each treatment (results presented as mean with SEM). These 
each represent the means of five individual responses to acoustic stimuli. Consecutive trial blocks are represented from left to right and with increased shading. Significant 
differences from the DMSO group are shown, ***p<0.001 (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG. 2.5: Effects of a range of doses (in mg kg-1) of singularly administered and combined cholecystokinin forms; CCK-4, CCK-8us and CCK-8s in combination with 
chlordiazepoxide vehicle, versus the effect of chlordiazepoxide alone, on acoustic startle peak amplitude, in rats, over twenty-five trials. Five consecutive trial blocks are 
shown for each treatment (results presented as mean with SEM). These each represent the means of five individual responses to acoustic stimuli. Consecutive trial blocks are 
represented from left to right and with increased shading. Significant differences from the chlordiazepoxide group are shown; *p<0.05, (Bonferroni post hoc analysis after 
significant one-way ANOVA). 
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FIG. 2.6: Effects of a range of doses (in mg kg-1) of CCK2 antagonist, CI-988 with DMSO vehicle, versus the effect of DMSO, on acoustic startle peak amplitude, in rats, over 
twenty-five trials. Five consecutive trial blocks are shown for each treatment (results presented as mean with SEM). These each represent the means of five individual 
responses to acoustic stimuli. Consecutive trial blocks are represented from left to right and with increased shading. Significant differences from the DMSO group are shown; 
*p<0.05, **p<0.01, ***p<0.001 (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG. 2.7: Effects of a range of doses (in mg kg-1) of CCK2 antagonist, LY-288513 with DMSO vehicle, versus the effect of DMSO, on acoustic startle peak amplitude, in rats, 
over twenty-five trials. Five consecutive trial blocks are shown for each treatment (results presented as mean with SEM). These each represent the means of five individual 
responses to acoustic stimuli. Consecutive trial blocks are represented from left to right and with increased shading. Significant differences from the DMSO group are shown; 
*p<0.05, **p<0.01, ***p<0.001 (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG. 2.8: Effects of doses (in mg kg-1) of CCK2 antagonists, CI-988 (1.0mg.kg-1) and LY-288513 (10mg.kg-1) with chlordiazepoxide (3.0mg.kg-1) vehicle, versus the effect of 
chlordiazepoxide, on acoustic startle peak amplitude, in rats, over twenty-five trials. Five consecutive trial blocks are shown for each treatment (results presented as mean with 
SEM). These each represent the means of five individual responses to acoustic stimuli. Consecutive trial blocks are represented from left to right and with increased shading. 
Significant differences from the DMSO group are shown; *p<0.05, **p<0.01, ***p<0.001 (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG. 2.9: Effects of doses (in mg kg-1) of CCK2 antagonists, CI-988 (1.0 mg.kg-1) and LY-288513 (10.0 mg.kg-1) with chlordiazepoxide vehicle on CCK-4 (0.025 mg.kg-1) 
inhibition of chlordiazepoxide activity, versus the effect of chlordiazepoxide, on acoustic startle peak amplitude, in rats, over twenty-five trials. Five consecutive trial blocks 
are shown for each treatment (results presented as mean with SEM). These each represent the means of five individual responses to acoustic stimuli. Consecutive trial blocks 
are represented from left to right and with increased shading. Significant differences from the chlordiazepoxide group are shown; *p<0.05 (Bonferroni post hoc analysis after 
significant one-way ANOVA). 
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FIG. 2.10: Effects of doses (in mg kg-1) of CCK2 antagonists, CI-988 (1.0 mg.kg-1) and LY-288513 (10.0 mg.kg-1) with chlordiazepoxide vehicle on CCK-8s (0.001 mg.kg-1) 
inhibition of chlordiazepoxide activity, versus the effect of chlordiazepoxide, on acoustic startle peak amplitude, in rats, over twenty-five trials. Five consecutive trial blocks 
are shown for each treatment (results presented as mean with SEM). These each represent the means of five individual responses to acoustic stimuli. Consecutive trial blocks 
are represented from left to right and with increased shading. Significant differences from the chlordiazepoxide group are shown; *p<0.05, **p<0.01, (Bonferroni post hoc 
analysis after significant one-way ANOVA). 
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FIG. 2.11: Effects of doses (in mg kg-1) of CCK2 antagonists, CI-988 (1.0 mg.kg-1) and LY-288513 (10.0 mg.kg-1) with chlordiazepoxide vehicle on CCK-8us (0.001 mg.kg-1) 
with chlordiazepoxide vehicle, versus the effect of chlordiazepoxide, on acoustic startle peak amplitude, in rats, over twenty-five trials. Five consecutive trial blocks are 
shown for each treatment (results presented as mean with SEM). These each represent the means of five individual responses to acoustic stimuli. Consecutive trial blocks are 
represented from left to right and with increased shading. Significant differences from the chlordiazepoxide group were not observed (Bonferroni post hoc analysis and one-
way ANOVA). 
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Discussion 
The series of preliminary validation experiments showed that, chlordiazepoxide 
administration, at doses 3.0 and 5.0mg.kg-1, was able to significantly decrease the acoustic 
startle amplitudes in rats in comparison to the dimethylsulphoxide (DMSO) vehicle, and that 
the DMSO group did not differ from saline. Given that chlordiazepoxide is known to exhibit 
muscle relaxant properties, it might be assumed that this effect underlies the decrease in startle 
amplitudes. Ostensibly this may be partially dismissed given positive chlordiazepoxide effects 
on other non-motor based measures inherent to the acoustic startle stimulus.  
An inhibition of acoustic startle induced ultrasonic vocalisations is observed with rats 
administered diazepam or flunitrazepam (Kaltwasser 1991). This phenomenon however may 
also be affected by the sedative and hypothermic properties of benzodiazepines. Hart et al., 
(1998) observed that cardioacceleratory defensive response, associated with anxiety, is 
enhanced by FG 7142, and attenuated by chlordiazepoxide.  
Given this evidence it is probable that chlordiazepoxide is effective in decreasing anxiety 
levels.  However, validation of this model, thus showing that solely the anxiolytic properties of 
chlordiazepoxide underlie the lowering of startle amplitudes is problematical. There remains a 
possibility that the muscle relaxant properties of chlordiazepoxide are a factor in this 
phenomenon, although perhaps not the major element.  
In order to validate the proposed anxiogenic component of this model, the use of 
cholecystokinin itself, both as validator and ligand of study, was preferred over 
benzodiazepine inverse agonists. Benzodiazepine inverse agonists, such as FG-7142 (N'-
methyl-beta-carboline-3-carboxamide) and DMCM (6,7-dimethoxy-4-ethyl-beta-carboline-3-
carboxylate) have shown non-efficacious results, unexpected of their pharmacological nature, 
in a series of studies. DMCM has been observed to lack any activity in the acoustic startle 
paradigm (Hijzen et al., 1991) or on acoustic startle induced ultrasonic vocalization in the rat 
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(Olivier et al., 1996). FG-7142 has been observed to have no effects on acoustic startle 
(Rochford et al., 1997), nor any effects on acoustic startle induced ultrasonic vocalization in 
the rat (Kaltwasser, 1991; Olivier et al., 1996). Berntson et al., (1997) found that FG-7142 
attenuates both the somatic and cardiovascular components of the acoustic startle response. 
Hence, use of benzodiazepine inverse agonists, in validation of this model was prohibited by 
its' unexpected and somewhat inconsistent nature. Given that CCK-4 and CCK-8, at specific 
doses, have a well-defined anxiogenic-like profile, and that there seemed to be no alternative 
anxiogenic agent, the option of validation with these cholecystokinin agents was elected, in 
addition to a full characterisation of their action. Dimethylsulphoxide (DMSO) was used as a 
solvent throughout the experiment. This was due to the difficulty in dissolving 
chlordiazepoxide in saline, coupled to the ease with which cholecystokinin forms were 
dissolvable in DMSO.  
It may be considered noteworthy that chlordiazepoxide, at 3.0 and 5.0mg.kg-1, produced 
statistically significant decreases in startle amplitudes throughout the trial sequence, whereas 
the anxiogenic cholecystokinin agents used only produced significant increases within the 
initial startle period. Given that clinically, chlordiazepoxide at higher doses produces sedation, 
it was considered necessary to rule out an explanation of sedation underlying this 
phenomenon, rather than anxiolysis. Therefore, an analysis of the gradient during the 
habituation phase was carried out. Examination of the line gradients demonstrates a 
habituation profile with an exponential phase between trial blocks 1 and 2, followed by a 
plateau phase between trial blocks 3 and 5 (DMSO, exponential phase, -59.52 y/x, 
chlordiazepoxide, 3.0mg.kg-1, exponential phase -221.6; 5.0mg.kg-1, exponential phase, -
272.3). It would be expected that a relatively flat habituation profile, would be observed for 
sedated animals, whereby this habituation would not occur. This is clearly not the position here 
with chlordiazepoxide treated animals and the marked exponential phase. In addition, further 
evidence for the anxiolytic-like property of chlordiazepoxide was provided when measuring 
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spontaneous activity in the startle chamber, where chlordiazepoxide showed no inhibition of 
locomotor activity.  
Spontaneous locomotor activity within the acoustic startle chamber was measured and showed 
no significant differences between drug groups tested at their effective doses. This further 
discounts possibility of effects of sedative action or locomotor stimulation on startle amplitude, 
over the range of drugs tested. 
Comparison between chlordiazepoxide (control) and chlordiazepoxide with cholecystokinin 
forms yielded significant increases in startle amplitudes within the first trial period for CCK-4 
(0.025 mg.kg-1) and CCK-8s (0.001 mg.kg-1). CCK-8s at this dose produces an anxiogenic-like 
response in nondrugged animals (versus DMSO vehicle) and drugged animals (co-
administered with chlordiazepoxide). Interestingly, CCK-4 appears to counteract the effects of 
chlordiazepoxide, but is unable to produce an anxiogenic-like action when compared to DMSO 
vehicle. Given that CCK-4 narrowly missed significance in trial block two when compared 
with DMSO, it may be derived that ceiling effects were observed in this case. This effect is 
apparent where an anxiety state of the entire batch of rats used in the experiment was at a 
suitably high level, as such that any further increase in anxiety would be masked by the 
confines of the experiment. This account of ceiling effects, nonetheless, is still rather 
questionable. The maximum startle amplitude measured by this apparatus is around two and a 
half times that which is produced within the CCK-4 group (4095 mV maximal compared to 
1600 mV observed). A fundamental mechanism underlying this phenomenon, although 
derived solely from conjecture, may be that CCK-4 is able to counteract chlordiazepoxide 
activity due to some dampening effect upon benzodiazepine receptor activity, and that it may 
exhibit little or no anxiogenic activity itself within the startle paradigm.  A more plausible 
explanation for these events, however, is that this observation may be apparent whereby the 
anxiety level produced by CCK-8s may be of a higher intensity compared to that of CCK-4 / 
CCK-8us. Where, these anxiety states might be observed as vaguely equivalent on the elevated 
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plus-maze, an acoustic startle paradigm might be less sensitive to anxiety levels. Furthermore, 
ceiling effects regarding high anxiety levels on the plus-maze would make individual anxiety 
levels, conferred by each drug species to be equivalent. Subsequently only, the very high level 
of anxiety induced by a highly efficacious, CCK-8s would observable within the less sensitive, 
acoustic startle paradigm. I feel that this is the most likely explanation of events. It cannot be 
assumed that two quite separate anxiety models, measuring very different behaviour, would be 
identical in their sensitivity to anxiety level. 
It may be plausible to propose that cholecystokinin driven anxiogenesis would be gated via the 
CCK1, whereby CCK-8s has equivalent affinity for CCK1 and CCK2 receptor subtypes, where 
CCK-4 has specific affinity for only CCK2 receptor subtypes (Hunter et al., 1993). However, 
the following study showed that the two CCK2 receptor specific antagonists, CI-988 and LY-
288513, at doses 1 and 10 mg.kg-1 respectively, were able to attenuate the effects of CCK-4 
and CCK-8s. This produced a marked, and statistically significant decrease in startle amplitude 
when co-administered with CCK-8s (in comparison with CCK-8s alone). Administration of 
CI-988 and LY-288513 abolished the significant difference in amplitude increase associated 
with CCK-4, although only reaching significance compared to CCK-4 in trial block three. This 
data implies that the increases in amplitude are gated strongly at the CCK2 receptor. 
Co-administration of cholecystokinin forms, CCK-4 (at 0.025mg.kg-1) and CCK-8s 
(0.001mg.kg-1) with chlordiazepoxide, yielded some interesting data. The individual activities 
of the two forms, at these doses, were negated upon combination. This would be as expected 
where an inverse bell shaped dose response curve were apparent. Within the elevated plus-
maze, such a dose response curve was observed, where subsequently the dose eliciting a 
maximal anxiogenic-like activity was selected for assessment within the startle paradigm. The 
combination of the cholecystokinin forms at these doses would be equivalent to any single 
form at twice the dose, at which it is observed to be relatively inactive in the plus-maze. 
Interestingly, however, a combination of both forms at half this dose did not yield any data 
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indicative of anxiogenesis. If both forms exhibited activity on one receptor subtype in order to 
elicit an anxiety-like effect in this paradigm, then a combination of both forms at half their 
maximally active doses would be expected to elicit an effect similar to that of either form 
individually. This is clearly not the case. It may therefore be hypothesized that these forms 
individually achieve their anxiogenic-like activities via independent mechanisms, most 
probably through distinct sub-populations of the CCK2 receptor subtype.  Furthermore, it may 
be proposed that a combination of activities at both sites will nullify any anxiogenic effects of 
activation at a single site. This equilibrium, underlying the normal non-anxious state, when 
disturbed would result in an anxious state. This may also be supported with evidence from 
dose response studies using CCK2 antagonists. the diphenylpyrazolidinone, LY-288513 and 
peptoidal based, CI-988, antagonists, exhibited bell shaped dose response curves with regard to 
anxiogenic-like behaviour on acoustic startle amplitude. These findings are, however not in 
disagreement with Helton et al., (1996), who observed that LY-288513 had no effects on 
acoustic startle and exhibited anxiolytic properties on the elevated plus-maze. At the highest 
dose tested (10mg.kg-1), it was found that this anxiogenic-like activity was abolished and 
similarly in Helton's study, doses of 100 to 1000mg.kg-1 did not elicit this response. The bell 
shaped dose response curve, with anxiogenic doses of a 100 times smaller magnitude, 
observed here, may be explained again by the two-site hypothesis for CCK2 receptors. If these 
sites had differing affinity for one antagonist, then at a lower dose one such site will be 
activated and at a higher dose, both sites will be activated. This would support my CCK2 
receptor equilibrium hypothesis, whereby activation of either receptor, causes an imbalance 
resulting in an anxious state, whereas activation of both receptor sites forces equilibrium, thus 
a non-anxious state is apparent. This unusual dose response curve, which may be observable 
for both agonists (although not tested here) and antagonists for the same receptor, would be 
explained almost flawlessly by the aforementioned hypothesis. Furthermore, effects of 
cholecystokinin forms in combination showing an absence of activity, is indicative of such a 
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hypothesis.   
Recent biochemical studies have perhaps supported this phenomenon. Pommier et al., (1999) 
demonstrated that CCK2 receptors are coupled to two secondary messenger cascades, a 
pertussis toxin-sensitive (phospholipase C pathway leading to the production of inositol 
phosphate and arachidonic acid), and a pertussis-insensitive G protein pathway (phospholipase 
A2 pathway leading to the release of arachidonic acid). Previous binding studies have 
suggested the existence of two or more affinity states for CCK2 receptors, which could 
correspond to different coupling states of the receptor to G proteins (Harper et al., 1999; 
Harper et al., 1996). According to this model, agonists or antagonists could recognize 
preferentially either conformation of the activated receptor, leading to variable behaviour in a 
system containing a single receptor type (Pommier et al., 1999). 
An area of concern observed within this experiment however is that of inconsistency in 
amplitude between different sets of experiments using the same treatments. This may be 
partially explained by several disruptive factors affecting housing conditions which were 
apparent. These factors were not within the control of the experimenter. These factors may 
also explain the marked habituation to startle observed with the DMSO group in figure 2.5. 
This profile appears to mimic that of the putative anxiogenic agents.  
With an attempt in equating these findings to the human condition, it may be speculated that 
activation of one subsystem may confer certain behavioural changes indicative of particular 
anxiety disorders, whereas activation of the other may produce changes related to a different 
set of anxiety-like symptoms. This may partly explain the range of different anxiety disorders 
in the clinical condition, although this is highly speculative. 
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CHAPTER THREE – ANIMAL MODELS OF UNCONDITIONED FEAR:  
ELEVATED PLUS-MAZE 
Introduction 
The elevated plus-maze test of anxiety is derived from the work of Montgomery (1955) on the 
relation between fear and exploratory drives in rats, the basic premise of which was that 
environmental novelty evokes both fear and curiosity, thereby creating a typical approach-
avoid conflict (Rodgers and Cole 1994). Montgomery (1955), found that rats consistently 
showed higher levels of exploration of enclosed alleys than in open alleys when faced with a 
choice of alley type in an elevated Y-maze. These data were interpreted as indicating that open 
arms engender a higher level of fear than enclosed arms, leading to increased avoidance. The 
open areas might be associated subjectively with a greater risk of predation whilst the enclosed 
environments would confer a secure subjective experience. 
This observation was further developed by Handley and Mithani (1984) as a potential basis  
for an animal model of anxiety. Their model was essentially an X-maze elevated 70 cm from 
ground level with two enclosed and two open arms (both opposite each other). A range of 
benzodiazepine agonists increased the ratio of open over total arm entries whereas several 
inverse agonists decreased this ratio significantly, conferring a predictive validity over a ten-
minute trial period. From this evidence they proposed that the X-maze might provide a valid 
model of 'fear-motivated' behaviour in rodents. This study was followed by a more extensive 
investigation by Pellow et al., (1985) which examined behavioural and physiological changes 
in addition to pharmacological effects. Both studies used the same rat strain and mazes of 
similar dimensions with procedural variation. Pellow et al., used a 5-minute exposure to a 
hole-board apparatus followed by a 5-minute period on the elevated plus-maze. In addition, 
Pellow et al., instituted an open over total time measure as an index of anxiety. A cross-species 
sensitivity to the elevated plus-maze as a measure of anxiety was subsequently confirmed by 
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Lister (1987) using NIH Swiss mice. Lister adapted the maze with an appropriate decrease in 
dimensions. Using the procedural modification utilised by Pellow et al., (1985) with prior 
hole-board exposure and a 5-minute test, Lister observed a similar pharmacological and 
behavioural profile to that described for rats. An important variation conferred within the 
Lister model was in the use of clear Perspex in construction of the closed arm walls. This 
adaptation allowed equalisation of light levels in all four arms which would eliminate the 
rodent specific preference for darkened areas over lighted. Hence, this variation provided a 
more exact model of rodent preference for enclosed over open areas rather than for light level 
differences.   
Avoidance of the open arms of the maze is consistent with the view that these areas evoke a 
stronger fear reaction than the enclosed arms, thereby providing the model with face (and 
possible construct) validity (Treit et al., 1993a). Pellow et al., (1985) observed more fear-
related behaviours; defecation, immobility, and freezing on the open arms of the maze, which 
may provide evidence of face validity. In addition, they observed that inescapable confinement 
upon the open arms produced a significant two-fold increase in plasma corticosterone level 
compared to those confined within the closed arms. This may also provide some evidence of 
the construct validity for the model. 
Rodgers and fellow researchers (Lee and Rodgers, 1991; Rodgers et al., 1992) observed that 
exposure of mice to the elevated plus-maze produces a non-opioid form of 'stress analgesia', an 
effect that is prevented by prior treatment with anxiolytic drugs. This may be an innate 
response to stress whereby, an animal under assault, will subjectively focus on escape, rather 
than pain resulting from injury.  This phenomenon of plus-maze antinociception has been 
independently confirmed for both rats (Taukulis and Goggin, 1990), and mice (Conceicao et 
al., 1992). These studies provide further evidence for face and construct validity within this 
paradigm. 
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Pharmacological validation of the elevated plus-maze 
Benzodiazepine specific receptor ligands: 
Anxiolytic-like activity on the plus-maze has been observed following microinfusion of 
midazolam into several areas of the brain; basolateral amygdala (Green and Vale, 1992), the 
dorsal periaqueductal grey region (Russo et al., 1993) and the septum (Pesold and Treit, 1994; 
Pesold and Treit, 1992; Pesold and Treit, 1996).  
Withdrawal from a benzodiazepine chronic treatment schedule shows an anxiogenic-like 
profile on the maze (Baldwin and File, 1988; File et al., 1987) which can be reversed by the 
benzodiazepine receptor antagonist, flumazenil (which alone exhibits no activity) (File, 1990). 
Non-benzodiazepine GABA receptor specific ligands: 
A range of other compounds exert an influence on the GABA receptor/chloride channel 
complex. Barbiturates, as well as progesterone (Reddy and Kulkarni, 1997) and several 
pregnane-related steroids; alphaxalone (Britton et al., 1991), and pregnanolone (Rodgers and 
Johnson, 1998), in addition to exerting barbiturate-like effects on the GABA receptor/chloride 
channel, also produce anxiolytic effects in this test. As might be predicted, consistent 
anxiolytic-like activity has also been reported for ethanol, which is blocked by benzodiazepine 
receptor antagonists/inverse agonists such as Ro154513 and FG7142 (Lister, 1988). 
Withdrawal from chronic ethanol treatment produces an anxiogenic-like behavioural profile on 
the maze (Baldwin et al., 1991; File et al., 1991; Rassnick et al., 1993) which can be reversed 
by chlordiazepoxide, flumazenil and baclofen (File et al., 1991; File et al., 1992), alpha-helical 
corticotrophin releasing factor (CRF) (Baldwin et al., 1991), buspirone (Lal et al., 1991) and 
mianserin (Lal et al., 1993). Pentylenetetrazol and picrotoxin, which inhibit the functioning of 
the GABA receptor/chloride-channel complex, have consistently been reported to produce 
anxiogenic-like effects (Treit, 1987). Several direct GABAA and GABAB agonists (e.g. 
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muscimol) have also been reported to have anxiolytic effects (Corbett et al., 1991), while the 
GABAB agonist baclofen, is apparently anxiolytic only in handling-naive rats (Andrews and 
File, 1993). Essentially, therefore the elevated plus-maze is bi-directionally sensitive to 
changes in anxiety induced by benzodiazepine receptor ligands. The phenomenon of 
benzodiazepine-withdrawal anxiogenesis further adds to the pharmacological validity of the 
test for agents of this class. 
Adrenoceptor ligands: 
The effects of alpha-adrenoceptor ligands on anxiety in the elevated plus-maze have been 
highly variable. Several α1- and α2-agonists studied have proven quite equivocal regarding 
their effects on the maze. The relatively non-selective α2-antagonist, yohimbine, however has 
consistently produced anxiogenic-like effects in the elevated plus-maze while effects of more 
selective α2-antagonists are much less convincing. ß-adrenoceptor antagonists have also been 
inconsistent in effect (for review see Rodgers and Cole, 1994). However, it is observed that 
several of these "beta-blockers" exhibit additional affinity for serotonergic receptors. A study 
by Njung'e et al., (1993), alluded to this conclusion where of a range, of non-specific and 
receptor-selective ß-ligands tested, only those antagonists with additional high affinity for 
5HT1A receptors (i.e. pindolol and alprenolol), exert anxiolytic effects in the elevated plus-
maze. The remaining antagonists and a series of agonists were inactive. This evidence appears 
to suggest that, given the reputed relationship of α2-adrenergic function and panic disorder, 
and ß-adrenoceptors in generalised anxiety (Nutt, 1991), predictive (pharmacological) 
validation for these conditions is not satisfied within the plus-maze. 
Serotonergic receptor ligands: 
In the plus-maze, PCPA-induced 5-HT depletion has generally been reported to reduce anxiety  
(Critchley et al., 1992; Moser, 1989; Treit et al., 1993b). In converse, systemic administration 
of the 5-HT precursor, L-5-HTP, is reported to exert anxiogenic-like effects in the maze 
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(Soderpalm et al., 1989). Handley and McBlane (1993) observed that 8-Hydroxy-2-(di-n-
propylamino)tetralin (8-OHDPAT), a putative 5HT1A agonist, produces a contradictory 
behavioural profile at the same dose with anxiolytic effects or anxiogenic-like effects 
depending upon the level of maze lighting (high and low illumination respectively). Similar 
highly variable results have been obtained with buspirone when administered systemically 
(Cole and Rodgers, 1994). Andrews and File (1993) have attributed this pattern of 
inconsistency to anxiogenic-like effects of buspirone produced only in handling habituated rats 
and zaclopride only in those handling naïve. 5HT2 and 5HT3 receptor antagonists have also 
yielded similarly inconsistent results in the plus-maze. Serotonergic reuptake inhibitors are 
also highly inconsistent in their activity on the maze. Pharmacological intervention with 
serotonergic agents appears to depend strongly upon endogenous anxiety levels and varies 
between genetic strain, housing conditions, handling experience and the specific conditions 
under which the test is conducted (Rodgers and Cole, 1994).  
Cholecystokinin receptor ligands: 
Kharro et al., (1989) were the first to report that systemic administration of the cholecystokinin 
(CCK) agonists, caerulein (non-selective) and pentagastrin (CCK2 selective) decreased the 
exploratory activity of mice in the elevated plus-maze. Harro et al., (1990) went on to 
demonstrate that this anxiogenic-like action of caerulein was attenuated by acute pre-treatment 
with the cholecystokinin antagonist proglumide at high doses, but not with diazepam. 
Furthermore, proglumide was observed to increase exploratory activity of rats in the plus-
maze. Mannisto et al., (1994) observed that the "anxiogenic" effect of caerulein was 
antagonised by the CCK2 specific antagonist, L-365260, but was increased by the 
cholecystokinin non-selective antagonist devazepide (at high doses). L-365260 and devazepide 
at these doses, alone were unable to modify behaviour. It is of note however that co-
administration of caerulein with devazepide also inhibited behavioural indices within the open 
field test, thus indicating an inhibitory effect upon locomotor activity. Caerulein alone 
THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS OF CHOLECYSTOKININ 
 67
exhibited no modification of activity in this open field test.  
Several studies have demonstrated that peripheral administration of the cholecystokinin 
tetrapeptide, CCK-4 decreased exploratory activity in an elevated plus-maze, (Harro and 
Vasar, 1991a; Hadjiivanova et al., 1995). This action was attenuated with cholecystokinin 
receptor antagonists; proglumide, lorglumide, L-365260 and devazepide (Harro and Vasar 
1991a). Rex et al., (1994) confirmed that a peptidase resistant form, BOC-CCK-4 also 
modified behavioural indices within the plus-maze, indicative of anxiety.  
While Rex et al., (1994) found CCK-8s to be without effect within the dose range tested, Vasar 
et al., (1994) observed that CCK-8s, at 2.5-10 µg.kg-1; via the subcutaneous (s.c.) route, 
decreased the exploratory activity of mice in an elevated plus-maze. Interestingly though, L-
365260, (1-100 µg.kg-1; i.p.), proglumide, (0.1-1 µg.kg-1, i.p.), and devazepide, at a high dose, 
(100 µg.kg-1) actually potentiated the anti-exploratory effect of CCK-8s (2.5 µg.kg-1).  
Johnson and Rodgers (1996) in contrast observed that CCK-4 (12.5-100 µg.kg-1) failed to 
produce any significant behavioural effects in the murine plus-maze, while CCK-8s induced 
signs of behavioural inhibition at 100 µg.kg-1 without altering anxiety-related indices.  
Structural modification of the CCK-8 peptide has yielded several highly selective CCK2 
agonists exhibiting good bioavailability and degradative resistance. Following intravenous 
(i.v.) injection of one such analogue BC-264, in tritiated form, the ligand was found in its 
intact form in mouse brain tissue. Interestingly, BC-264 systemically administered increased 
the anxiety-like responses of the "anxious" rat and decreased these responses in "non anxious" 
animals in the elevated plus-maze (Dauge et al., 1992)). In a study by Derrien et al., (1994) 
while the nonselective cholecystokinin agonist BDNL and selective CCK2 agonist BC-197 
induced anxiogenic-like effects in the plus-maze, BC-264, however, had no observed activity. 
The effects of BDNL were not modified by L-365260, but were suppressed by CI-988 and by 
high doses of L-364718 (a selective CCK1 antagonist). BC-197 induced effects were also 
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blocked by CI-988. BC-264 produced anxiogenic-like dose dependent effects when 
administered with L-365260 (200 µg.kg-1) and opposing effects with CI-988 (2 µg.kg-1). 
Binding competition with [3H]pBC-264 using guinea pig, mouse, and rat brain membranes 
adhered significantly to a two-site model than to a one-site model with competition from BC-
197 but not with BC-264 (Derrien et al., 1994). This, examined further in chapter six, indicates 
that where BC-197 exhibits differing affinities for two distinct receptor sites, BC-264 exhibits 
a very similar affinity for these sites (which is not revealed by saturation analysis). Structural 
modification of CCK-4 yielded another highly selective CCK2 receptor ligand, JMV-320 
which also decreased exploratory activity in the elevated plus-maze but not in the open field 
test, indicating an anxiety-like behaviour within the plus-maze (Hadjiivanova et al., 1995). 
Systemic Administration of Cholecystokinin Antagonists: 
A study first utilising newly synthesised peptoidal based CCK2 specific antagonists, CI-988 
and PD-135158 demonstrated that they produced potent anxiolytic effects in the mouse 
black/white box test, the rat elevated plus-maze test and the rat social interaction test after 
systemic administration. In addition these antagonists were marked by an absence of sedation 
and long-term abuse potential. Furthermore, both attenuated withdrawal anxiety from a variety 
of abused drugs (Hughes et al., 1990; Costall et al., 1991). CCK2 selective antagonists PD-
135666 (CCK2 selectivity 260:1) and PD-141479 (30:1) and the unselective CCK1 and CCK2 
receptor antagonist PD-142898 (1.1:1) also produced anxiolytic effects (Singh et al., 1995). 
Administration of synthetic antagonists, PD-135158 (cholecystokinin non-specific) or CI-988 
(1mg.kg-1 s.c.) attenuated heightened anxiety-like behaviour in the murine plus-maze resulting 
from chronic ethanol administration. CI-988 and L-365260 also produced anxiolytic-like 
effects alone (Wilson and Little, 1998).  
The CCK2 specific antagonist, L-365260 also produced an increase of indices within the plus-
maze, indicative of anxiolysis. Both the non-CCK2 antagonists, 3S-(-) enantiomer of L-365260 
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and devazepide failed to modify exploratory behaviour, suggesting that CCK2 receptor 
activation underlies this behaviour (Rataud et al., 1991) 
A pyrazolidinone related CCK2 antagonist LY-288513 (3, 10 mg.kg-1, IP; 10, 30 mg.kg-1, PO) 
produced an anxiolytic-like action in mice with a magnitude of effect similar to that of 
diazepam, except without affecting muscle tone, neuromuscular coordination, or sensorimotor 
reactivity (Helton et al., 1996). Novel quinazolinone and arylurea derived CCK2 antagonists 
are also reported as orally active in the plus-maze (Padia et al., 1998). 
Revel et al., (1998) demonstrated that CR-2945, an antranilic acid derived cholecystokinin 
antagonist showing a very high selectivity for CCK2 receptors (9000:1) over CCK1, also 
showed significant dose-dependent anxiolytic-like effects in four rodent tests of anxiety 
including the mouse black/white box, rat elevated plus- and zero- maze, and punished licking. 
Within this study commonly used benzodiazepine derived CCK2 antagonists PD-135158 and 
L-365260 were inactive in the elevated plus-maze after oral administration. The magnitude of 
the activity of CR-2945 was comparable to that of diazepam, but without sedation and ataxia. 
Furthermore, a chronic treatment with CR-2945 (seven days) did not induce tolerance or 
withdrawal anxiety in rats. 
In contrast to these positive findings, Johnson and Rodgers (1996) observed that 
cholecystokinin receptor antagonists; devazepide, L-365260 and PD-135158 within the range 
1.0 µg.kg-1-1.0mg.kg-1, were without significant effect on the murine plus-maze. Dawson et 
al., (1995) also noted a lack of effect of CCK2 antagonists L-740093 (0.1-1.0mg.kg-1), L-
365260 (0.00001-10.0mg.kg-1), and CI-988 (0.01-1.0mg.kg-1) within the plus-maze in rats. 
Griebel et al., (1997) again confirmed a lack of activity of CCK2 antagonists PD-135158 
(0.001-1.0mg.kg-1) and LY-288513 (1-3mg.kg-1) within the plus-maze.  
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Central Administration of Cholecystokinin Antagonists: 
Holy and Wisniewski (1998) observed that intracerebroventricularly administered CCK-8 and 
CCK-4 induced an anxiogenic-like effect in the plus-maze. Intracerebroventricular 
administrations of caerulein or pentagastrin increased dose dependently the level of anxiety on 
the plus-maze. CI-988 dose dependently antagonised an anxiogenic-like response to 
pentagastrin but not that induced by pentylenetetrazol when administered systemically (Singh 
et al., 1991). Intracerebroventricularly infused CCK-antisense oligodeoxynucleotide into rats 
(over 3 days) was observed to significantly decrease anxiety-like behaviour in rats within the 
plus-maze (Cohen et al., 1998). 
Intra-amygdaloidal administration with 20ng of Boc-CCK-4 and 1ng of CCK-8s failed to 
influence anxiety-related behaviour within the plus-maze according to Huston et al., (1998). 
However, Belcheva et al., (1994) observed that bilateral microinjections of CCK-8 into the 
amygdala confirmed the anxiogenic-like effect of CCK-8 on the plus-maze. 
Meanwhile, Dauge et al., (1989b) observed that administration of CCK-8s into the 
posteromedial nucleus accumbens produced a decrease in exploration within the elevated plus-
maze which was reversed by systemic administration of the selective CCK1 antagonist L-
364718. This was not observed after administration of CCK-8us in this accumbal region. 
Administration into the anterior nucleus accumbens however also had no effect. Ladurelle et 
al., (1995) went on to show that with intra-accumbal administration, an anxiogenic-like effect 
of CCK-8s was observed in the elevated plus-maze, but only in rats previously submitted to a 
novel environment (four-hole box). 
Benzodiazepine Interactions: 
With regard to an association between the benzodiazepine and cholecystokinin systems there 
are several important pieces of evidence connecting them. It has been demonstrated previously 
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that acute administration of benzodiazepine anxiolytic agents at low doses antagonise CCK-8 
induced activation of hippocampal pyramidal neurones (Bradwejn and De Montigny, 1985) 
and that activation of the GABA receptor-chloride channel complex appears to inhibit the 
release of cholecystokinin from the rat cerebral cortex (Yaksh et al., 1987) 
Despite some conflicting results, it is generally concluded that with in-vitro receptor binding 
studies of brain homogenates the number of benzodiazepine binding sites and the affinity of 
these does not change with long-term benzodiazepine agonist treatment (Heninger and 
Gallager 1988). However, Harro et al., (1990b), observed that an up-regulation of sulphated 
[3H]CCK-8 receptor binding sites is evident after chronic diazepam administration for 2 
weeks. A single acute anxiolytic dose of diazepam however did not produce any change in 
binding of either sulphated [3H]CCK-8 or [3H]flunitrazepam. 
The benzodiazepine inverse agonist, FG-7142 with acute administration increased 
cholecystokinin mRNA levels in specific regions of the amygdala and the hippocampus. The 
benzodiazepine antagonist, flumazenil, which was inactive when given alone, significantly 
antagonised the anxiogenic-like activity of CCK-8us and the anxiolytic-like effects of 
devazepide (high dose) and L-365260 (Chopin and Briley 1993). This indicates a definite role 
of the GABA receptor in gating the anxiety-like effects of cholecystokinin.  
Harro et al., (1990a) observed that rats separated into subgroups with high and low exploratory 
activity on the elevated plus-maze differed in binding to benzodiazepine and cholecystokinin 
receptors. It was established that the anxious (low exploration) group exhibited a significantly 
decreased number of benzodiazepine receptors in frontal cortex and hippocampus and a 
decrease of CCK-8 specific receptors in the hippocampus. Non-anxious animals had a 
significantly lower number of CCK-8 specific receptors in frontal cortex. Caerulein and 
pentagastrin administered intraperitoneally at plus-maze "anxiogenic" doses decreased the 
number of benzodiazepine binding sites in rat frontal cortex. Acute treatment of rats with FG-
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7142, an anxiogenic-like benzodiazepine receptor inverse agonist, did not influence 
upregulation of CCK-8 specific receptor binding in the frontal cortex (Harro et al., 1990a) but 
did increase cholecystokinin mRNA levels in the basolateral amygdala and the CA3 pyramidal 
cell layer of the hippocampus (Brett and Pratt, 1995). This demonstrates the high region 
specificity underlying anxiety-like behaviour. Koks et al., (1997) showed that under this same 
dichotomy, "anxious" rats showed a significantly lower affinity (KD) of 5HT2A receptors in the 
frontal cortex compared to control and "non anxious" rats. No differences in density (BMAX) 
were found. An increase in cholecystokinin receptor density in the hippocampus was also 
observed in the "anxious" rats.  Harro et al., (1990b) observed that rats undergoing diazepam 
withdrawal, exhibited an increase in anxiety-like behaviour on the plus-maze, yet showed no 
changes in [3H]flunitrazepam binding. However the apparent number of sulphated [3H]CCK-8 
binding sites was significantly increased in the primary olfactory cortex, frontal cortex and 
hippocampus. Acute diazepam treatment had no influence on binding. 
Methodological Disparities: 
Detailed assessment of plus-maze literature indicates that inconsistencies observed in 
pharmacological studies cannot be ascribed to species differences despite major strain 
differences in basal levels of plus-maze anxiety (Costall et al., 1989; Mangiafico et al., 1989; 
Pare, 1992; Pellow et al., 1985) and mice (Miyamoto et al., 1992; Rodgers and Cole, 1993a; 
Rodgers and Cole, 1993b; Trullas and Skolnick, 1993). Anxiety indices are also reported to 
increase with age (Frussa-Filho et al., 1991).  
An interesting recent study may have provided additional indicators for the marked differences 
between findings of different groups with apparently similar methodology. Koks et al., (2000) 
observed that caerulein (5 µg.kg-1, s.c.) produced the most robust action in animals brought 
immediately from the experimental room prior to the experiment, and kept in isolation after 
caerulein administration. Caerulein failed to modify exploratory activity in rats both familiar 
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with the experimental room, and kept in home-cages after injections. The action of caerulein in 
these "stressed" rats was attenuated by L-365260 (100 µg.kg-1, i.p.). Furthermore marked 
seasonal fluctuations were observed to occur in the exploratory activity of rats, with activity 
greatly decreased in July compared to November. Moreover rats displaying the inhibited 
"summer" activity had an increased density of cholecystokinin and 5-HT2 receptors in the 
frontal cortex and increased density of cholecystokinin receptors in the hippocampus.  
Furthermore, it has also been observed that rats tested ante meridiem (08-12.00) exhibit greater 
exploration than those tested post meridiem (14-17.00) (Griebel et al., 1993).  
Vasar et al., (1993a) observed that isolation of male rats significantly reduced their exploratory 
activity in the elevated plus-maze compared with those group housed. Caerulein at a high dose 
significantly decreased the exploratory behaviour of rats housed in groups, but not in the 
isolated rats. This was perhaps due in part to floor effects produced by an isolation-induced 
decrease in indices within the vehicle group. This was further examined in the following study. 
Interestingly, low doses of caerulein increased exploratory indices of isolated rats in the plus-
maze. Concurrently, social isolation of the rats increased the number of [3H]pCCK-8 binding 
sites in the frontal cortex, but not in the other forebrain structures (the mesolimbic area, 
striatum and hippocampus), without any changes in the density of benzodiazepine receptors 
observed. In other studies it has, quite conversely, been observed that housing isolation either 
exhibits no effect (Frussa-Filho et al., 1991) or is anxiogenic (Janowska et al., 1991). 
Furthermore, isolated housing for periods of greater than seven days is observed to decrease 
plus-maze anxiety of mice (Hilakivi et al., 1989; Rodgers and Cole, 1993b). In addition, 
behavioural profiles are not predictive of dominant or subordinate social status in male mice 
(Hilakivi-Clarke and Lister, 1992). 
While the effects of prior handling have not been studied extensively, this procedure has been 
reported to either increase (Andrews and File, 1993) or have no effect upon (Brett and Pratt, 
1990) basal levels of open arm exploration in rats. Irrespective of effects on basal anxiety 
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however, handling has been found to significantly alter responses to specific drugs, including 
diazepam, cocaine, zacopride and buspirone (Andrews and File, 1993; Brett and Pratt, 1990; 
File and Andrews, 1991; Rogerio and Takahashi, 1992). Hole board exposure prior to plus-
maze testing also appears to reduce basal anxiety levels in both rats (Pellow et al., 1985) and 
mice (Lister, 1987; Rodgers and Cole, 1993a). Similar effects of prior novelty exposure have 
also been reported in rats (DaCunha et al., 1992). A range of stressors have been observed as 
anxiogenic on the plus-maze, including saline injection (Adamec et al., 1991), immobilization 
(Albonetti and Farabollini, 1992; Handley and McBlane, 1993), electric shock (Steenbergen et 
al., 1990), social defeat (Heinrichs et al., 1992; Rodgers and Cole, 1993b), cat odour 
(Zangrossi and File, 1992a; Zangrossi and File, 1992b) and cat exposure (Adamec and 
Shallow, 1993). 
The influence of the level of illumination on plus-maze performance is equivocal, with groups 
either reporting no effect (Falter et al., 1992; Handley and McBlane, 1993; Pellow et al., 1985) 
or reductions in open arm exploration (Benjamin et al., 1990; Lee and Rodgers, 1990; Morato 
and Castrechini, 1989). Studies examining the effects of repeated exposure to the plus-maze 
are examined later in this thesis.  
Lister (1987) observed that measures of time spent and entries onto the open arms were 
heavily dependent upon anxiety level while total arm entries appeared to be measures of both 
locomotor activity and anxiety. Concurrent assessment of additional behavioural measures 
may thus be necessary in order to assist interpretation.  However, many of these pre-testing 
regimes modify behaviour within the highly sensitive plus-maze, while post-trial assessment 
within these models is again influenced by the anxiogenic nature of plus-maze exposure. 
Therefore, the hope that, concurrent testing might aid interpretation of plus-maze activities is 
perhaps an erroneous expectation.   
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The effects of stressors upon plus-maze behaviour show, not only decreased open arm activity, 
but also display depressed levels of general activity and rearing in the maze (Rodgers and 
Cole, 1993a). Prior stress also increases risk assessment measures. During assessment of a 
range of anxiolytic compounds, Cole and Rodgers (1994), observed that risk assessment 
measures are generally more sensitive to drug action than open arm time and entries.  
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Materials and Methods 
Animals: 
Male rats of the Sprague Dawley strain (Laboratory Animal Centre, National University of 
Singapore, Singapore), 250-320g were housed in either groups of five to seven or singularly, 
and maintained with free access to food and water ad libitum, in an animal room for one week 
(or ten days in the case of isolation experiments) prior to experimentation. Room lights were 
on from 07:00 to 19:00 hours.  Animals were brought into the brightly lit, test room 
immediately prior to plus-maze testing and handled only at that time for weighing and 
injection procedures. Operator handling was near identical throughout the sample. Animals 
were randomly assigned treatment groups using a simple computer program random number 
sequence generator (Random Number Generator for Q-Basic by Colin Greengrass, 1998). This 
program (see Appendix C for listing) generated random whole numbers within a range 
corresponding to an assigned treatment group.  
Isolation Protocol  
Isolation was carried out in opaque cages with animals randomly assigned from the initial 
batch. Testing was carried out under a regime in which each isolated sample was isolated for 
precisely 10 days. Initially upon delivery of 24 rats, 20 were group housed (five cages of 4 per 
cage), and four were housed in isolation. On the second day, four animals inhabiting one group 
housing cage were separated for isolation housing, with a remaining 16 group housed. On the 
third day, another group-housed sample was isolated leaving 12 rats group housed and 12 
isolated. On day ten, the first batch of isolated animals were tested on the plus-maze. Upon 
subsequent days those animals that had been isolated sequentially were tested in that order, 
thus conferring isolation for a fixed period. Cages were identical in material and dimensions 
for both group-housed and isolated animals. Food and water was provided ad libitum.   
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Drugs and Administration 
Cholecystokinin peptide agonists: CCK-4 (Trp-Met-Asp-Phe-NH2) and CCK-8us (Asp-Tyr-
Met-Gly-Trp-Met-Asp-Phe-NH2; Biotechnology Centre, National University of Singapore); 
CCK-8s (Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2; American Peptide Company and 
Princeton Biomolecules) ; the cholecystokinin peptoidal antagonist CI-988 ([R-(R*,R*)]-4-[[2-
[[3-(1H-Indol-3-yl)-2-methyl-1-oxo-2-[[(tricyclo[3.3.1.1.3,7]dec-2-yloxy)carbonyl]-
amino]propyl]-amino]-1-phenylethyl]amino]-4-oxo-butanoate-1-deoxy-1-(methylamino)-D-
glucitol; Research Biochemicals Inter-national (RBI)), the pyrazolidine based CCK2 
antagonist, LY-288513 (trans-N-(4-bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidine-
carboxamide; generous gift from Eli Lilly and company) were dissolved in dimethylsulphoxide 
(DMSO; Merck) with either chlordiazepoxide hydrochloride (7-Chloro-2-(methylamino)-5-
phenyl-3H-1,4-benzodiazepine 4-oxide; A generous gift from Roche) at 1.5mg/ml or in DMSO 
alone. In validation studies FG-7142 (N-methyl-D-carboline-3-carboxamide; RBI) was also 
utilised under the same protocol. The drugs or vehicle were administered by intraperitoneal 
injection in a volume of 1ml per kg body weight. Two separate injections were given to each 
animal. Cholecystokinin peptide was stored under desiccation at -70oC. Cholecystokinin 
peptide solutions were prepared freshly each day approximately two hours prior to testing.  
Powdered peptide was dissolved in DMSO and specific concentrations prepared through serial 
dilution, with thorough vortex mixing at each stage. 
Behavioural Procedures 
Elevated Plus-maze: Experiments were similarly conducted to those described previously 
(Pellow et al., 1985; Lister, 1987) with minor modifications. The plus-maze consisted of two 
open arms (50 x 10cm) with a 1cm high surrounding wall and two enclosed arms (50 x 10cm) 
with a 50cm high surrounding wall. The arms extended from a central platform (10 x 10cm) 
and were arranged such that the two open arms were opposite each other as were the closed 
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arms.  The floor of the open arms, the central platform, and the closed arms was made of black 
Perspex. The surrounding walls of the arms were made of clear Perspex. The maze was 
elevated 50cm from the floor on a wooden platform. The test room was maintained with 
controlled light levels and temperature with white noise delivered at 70dB. The maze 
platforms and walls were thoroughly cleaned with 70% ethanol between sessions and allowed 
to dry. At the beginning of the experiments, naïve rats were placed on the central platform 
facing one of the open arms. The total number of visits to the open arms, the total number of 
visits to the closed arms, the cumulative time spent in the open arms and the cumulative time 
spent in the closed arms were subsequently measured for a 5 minute period using manual 
operation of a counter/timer unit (see appendix B.1). An arm visit was recorded when a rat had 
all four paws on one arm. These sessions were videotaped. Behavioural experiments were 
performed between 14:00-17:00hours. Animals were used only once. Drugs were administered 
intraperitonally 30 minutes prior to testing. 
Locomotor Activity: Open field motor activity was assessed for some animals immediately 
following plus-maze testing. The apparatus consisted of a clear Plexiglas chamber of 33cm 
width by 42cm length and walls 20cm in height. The top of the chamber was covered during 
testing with a steel lid with air holes. The chamber was placed on a steel surface. The test room 
was maintained with controlled light levels and temperature with white noise delivered at 
70dB. The chamber was thoroughly cleaned with 70% ethanol between sessions and allowed 
to dry. Locomotor activity was measured using an Opto-varimex mini activity monitoring 
system (Columbus Instruments, USA). An apparatus naïve animal was placed in the chamber 
and allowed a two-minute acclimation period within the chamber before testing. The total 
number and the ambulatory beam interruptions were subsequently measured for 5 minutes. 
Ambulatory locomotor activity is a measure by which repetitive interruptions of the same 
beam are ignored. Approximation of values for grooming/rearing activity is achieved by 
subtraction of total from ambulatory counts, which represents activity without ambulation.   
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Statistics 
Statistical analysis was performed using statistical software (SPSS V9.0, SPSS inc. USA). The 
data were subjected to one-way analysis of variance (ANOVA), and Bonferroni post hoc 
analysis. Probability (p <0.05) was considered statistically significant. Data are presented as 
drug group means with standard error of the mean (SEM). 
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Results and Data 
Figure 3.1.1: Administration of chlordiazepoxide, in saline at 3.0 mg.kg-1 produced a 
statistically significant increase in time spent in the open arms compared to a saline control, 
within the elevated plus-maze; chlordiazepoxide; 3.0mg.kg-1, (F3,32=49.66, p<0.001) at the 
expense of significantly lower time spent in the closed arms (F3,32=49.66, p<0.001). The 
established anxiogenic agent FG-7142 (5.0mg.kg-1) in saline, was unable to significantly alter 
time spent in the open arms. FG-7142 did however produce a significant decrease in time upon 
the central platform (F3, 32=6.63, p<0.01) and a significant increase in time spent within the 
closed arm (F3,32=38.35). 
Figure 3.1.2: Correspondingly, numbers of open arm entries were also significantly increased 
(F3,32=29.56, p<0.001). Furthermore, an increase in the total number of entries into both arms 
was observed (F3,32=13.64, p<0.01). Despite an inability to alter the number of individual 
closed or open arm entry counts, the number of total arm entries was significantly decreased in 
FG-7142 treated rats (F3,32=13.64, p<0.01).   
Figure 3.2.1: Chlordiazepoxide (3.0mg.kg-1) in DMSO increased time spent in open arms 
(F3,35=28.46, p<0.001) offset by a decrease in closed arm time (F3,35=24.20, p<0.01). Despite 
FG-7142 failing to significantly alter time spent in the open arms, time upon the central 
platform was significantly decreased (F3, 35=5.58, p<0.01) and time spent within the closed arm 
was increased (F3,35=24.2, p<0.01). FG-7142 (5.0mg.kg-1) in addition prevented the increase in 
open arm time observed with chlordiazepoxide (3.0mg.kg-1) with co-administration (statistical 
significance compared to chlordiazepoxide alone (F3,35=28.46, p<0.001). 
Figure 3.2.2: Open arm entries were also significantly elevated F3, 35=28.17, p<0.001) in the 
Chlordiazepoxide (3.0mg.kg-1) in DMSO group. FG-7142 also produced a significant decrease 
in open arm (F3,35=28.17, p<0.05); closed arm (F3,35=9.80, p<0.001); and total entries 
(F3,35=18.97, p<0.001) similarly to that observed with FG-7142 in saline.  FG-7142 (5.0mg.kg-
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1) in combination with chlordiazepoxide (3.0mg.kg-1) significantly decreased open arm entries 
(when compared to chlordiazepoxide alone (F3,35=28.17, p<0.001). 
Figure 3.2.3: With subsequent testing of spontaneous open field locomotor activity, it was 
observed that both chlordiazepoxide and FG-7142 inhibited activity significantly: for 
ambulatory activity, chlordiazepoxide (F3,35=5.28, p<0.05), FG-7142 (F3,35=5.28, p<0.05); for 
non-ambulatory activity, FG-7142 (F3,35=3.69, p<0.05); for total locomotor activity, 
chlordiazepoxide (F3,35=5.68, p<0.05), FG-7142 (F3,35=5.68, p<0.05). A combination of 
chlordiazepoxide (3.0mg.kg-1) and FG-7142 (5.0mg.kg-1) did not alter locomotor activity.   
Cholecystokinin Peptide Forms 
The effects of cholecystokinin forms upon reversal of increased open arm time and entries 
induced by chlordiazepoxide (3.0mg.kg-1) were examined.  
Figure 3.3.1: Dose response data for the cholecystokinin tetrapeptide, CCK-4, in combination 
with chlordiazepoxide (3.0mg.kg-1) showed that only a dose of 0.025mg.kg-1 was able to 
significantly decrease percentage time spent in the open arms (F5,43=7.54, p<0.001) compared 
to chlordiazepoxide alone. A resultant increase in closed arm time was observed in 
counterbalance (F5,43=4.31, p<0.01). No other significant differences were observed although 
there appears to be a trend towards an inverse bell shaped dose response curve with regard to 
time spent on open arms and vice versa for time spent on the closed arms. 
Figure 3.3.2: Examination of open arm entry data yielded an interesting correlation whereby 
number of open arm entries appeared to exhibit two separate dose response troughs. CCK-4 
decreased the number of open arm entries only at the dose 0.025mg.kg-1 (F5, 43=3.41, p<0.05), 
corresponding to that of open arm time.  The total number of arm entries however was 
significantly decreased at both 0.025mg.kg-1 (F5,43=3.89, p<0.05) and 0.075mg.kg-1 (F5,43=3.89, 
p<0.05), without any significant changes at the intermediate dose 0.05mg.kg-1.  
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Figure 3.4.1: An inverse bell shaped dose response curve was observed for data of the effects 
of CCK-8us on (%) open arm time within a dose range of 0.005 to 0.1mg.kg-1. CCK-8us, only 
at 0.01mg.kg-1, significantly reversed the effects of chlordiazepoxide (3.0mg.kg-1) upon (%) 
open arm time spent (F4,36=6.69, p<0.001) while closed arm time was increased at this dose 
(F4,36=4.83, p<0.01).  
Figure 3.4.2: CCK-8us demonstrated a significant decrease in open arm entries only at a dose 
of 0.01mg.kg-1 (F4,36=4.23, p<0.01). 
Figure 3.5.1: Examination of a CCK-8s dose response relationship yielded an inverse bell 
shaped dose response curve. Within a dose range of 0.0003 to 0.01mg.kg-1, CCK-8s reversed 
the effects of chlordiazepoxide only at doses 0.001mg.kg-1 (F6,47=5.58, p<0.05) and 
0.002mg.kg-1  (F6,47=5.58, p<0.01) with significant decreases in open arm time. In 
compensation, at these doses closed arm time was increased; 0.001mg.kg-1 (F6,47=8.19, p<0.05) 
and 0.002mg.kg-1  (F6,47=8.19, p<0.001).  
Figure 3.5.2: Data for effect of CCK-8s on number of arm entries showed a similar 
distribution to that of CCK-4. At a dose of 0.0005mg.kg-1 the number of open arm entries 
(F6,47=6.86, p<0.05), closed arm entries (F6,47=5.94, p<0.01), and the resultant total number 
(F6,47=8.31, p<0.001) were significantly inhibited. This also occurred at the dose 0.002mg.kg-1, 
with significant inhibition of number of open arm entries (F6,47=6.86, p<0.05), closed arm 
entries (F6,47=5.94, p<0.05), and the resultant total number (F6,47=8.31, p<0.01). Yet again the 
intermediate dose of 0.001 did not show a significant decrease in number, although did 
narrowly miss significance for open arm entries (F5,43=3.89, p=0.064).  
Figure 3.6.1: A combination of cholecystokinin forms at both half and maximally effective 
doses, with regard to attenuation of chlordiazepoxide effects upon time spent in the open arms, 
yielded quite unexpected data. In comparison with the chlordiazepoxide group, data for 
cholecystokinin forms alone were in conformity with earlier dose response studies. A dose of 
THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS OF CHOLECYSTOKININ 
 83
0.0125mg.kg-1 failed to evoke a response, while a higher dose of 0.025mg.kg-1 significantly 
inhibited the activity of chlordiazepoxide in increasing open arm time (F15,114=15.81, p<0.01). 
CCK-8us also acting in conformity with the earlier dose response study showed no significant 
effects at 0.005mg.kg-1 and a significant inhibition of chlordiazepoxide function at 0.01mg.kg-1 
(F15,114=15.81, p<0.001). CCK-8s tested at three doses produced significant inhibition at doses 
0.001mg.kg-1 (F15,114=15.81, p<0.001) and 0.002mg.kg-1 (F15,114=15.81, p<0.001) and not at 
0.0005mg.kg-1. Interestingly the maximal dose of CCK-8us (0.01mg.kg-1) also induced a 
significant increase in time spent on the central platform (F15,114=3.05, p<0.05). Interestingly, a 
combination of CCK-4 and CCK-8 (both forms) at either half or at their maximally effective 
doses failed to elicit inhibition of chlordiazepoxide activity.  A combination of CCK-8us and 
CCK-8s at these doses maintained the same inhibition of chlordiazepoxide activity, compared 
to chlordiazepoxide alone, chlordiazepoxide (3.0) with CCK-8us (0.005) and CCK-8s (0.0005; 
F15,114=15.81, p<0.001); chlordiazepoxide (3.0) with CCK-8us (0.005) and CCK-8s (0.001; 
F15,114=15.81, p<0.01); chlordiazepoxide (3.0) with CCK-8us (0.010) and CCK-8s (0.002; 
F15,114=15.81, p<0.001). With the exception of CCK-8us at 0.01mg.kg-1, most decreases in 
open arm time were compensated by increases in closed arm time or were absorbed by both 
closed arm and central platform time increases.  
Figure 3.6.2: Numbers of arm entries were decreased in the CCK-8s group only at  the dose 
0.002mg.kg-1 (F15,114=6.83, p<0.05) and in the CCK-8us (0.01) / CCK-8s (0.002) combined 
group (F15,114=6.83, p<0.001). In the combined group this significant decrease in arm entries 
was accompanied by a significant decrease in total arm entries (F15,114=2.83, p<0.05).  
Figure 3.6.3: An identical treatment protocol, tested within an open field locomotor activity 
model, failed to demonstrate any significant differences between combination groups. 
Furthermore, a broad standard error was observed within most groups. Trends observed may 
imply an inhibition of locomotor activity in maximal dose groups for CCK-8us and CCK-8s.  
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Figure 3.7.1: A dose response study of the peptoidal CCK2 antagonist, CI-988 (0.002 to 
1.0mg.kg-1) did not yield time data with significant differences.  
Figure 3.7.2: A dose response study of the peptoidal CCK2 antagonist, CI-988 (0.002 to 
1.0mg.kg-1) did not yield entry data with significant differences.  
Figure 3.7.3: A dose response study of the peptoidal CCK2 antagonist, CI-988 (0.002 to 
1.0mg.kg-1) co-administered with chlordiazepoxide (3.0mg.kg-1) yielded data analogous to that 
of the aforementioned cholecystokinin agonists, in that an inverse bell shaped dose response 
curve was observed for open arm time data. A dose of 0.02mg.kg-1 produced a significant 
decrease in chlordiazepoxide induced open arm time (F9,85=9.37, p<0.05).  
Figure 3.7.4: This phenomenon was also observed in a significant decrease in number of open 
arm entries (F9,85=4.77, p<0.001) and in total arm entries (F9,85=3.72, p<0.01). Interestingly 
once again this yielded an interesting correlation whereby the total number of entries appeared 
to exhibit two separate dose response troughs. At the highest dose tested the total number of 
entries was again significantly inhibited (F9,85=3.72, p<0.01) with the intermediate dose of 
0.2mg.kg-1 without effect. Higher doses were tested due to CI-988 small sample size. Dose 
response studies of CI-988 with DMSO (vehicle) in the absence of chlordiazepoxide showed 
no significant effects on any indices.  
Figure 3.8.1: Dose response studies of the pyrazolidinone related CCK2 antagonist, LY-
288513, in DMSO (vehicle) demonstrated a broadly dose dependent increase in time spent 
within the open arms (figure 3.8.1.). LY-288513 at doses, 0.001mg.kg-1 (F8,63=9.87, p<0.05); 
0.1mg.kg-1 (F8,63=9.87, p<0.01); 1.0mg.kg-1 (F8,63=9.87, p<0.01); and 10mg.kg-1 (F8,63=9.87, 
p<0.001) significantly increased time spent within open arms with a steady increase in effect 
with increasing dose. Time spent within the central platform was unaffected while time spent 
upon the closed arms was only significantly decreased at the highest dose tested, 10mg/.kg-1 
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(F8,63=5.44, p<0.001). 
Figure 3.8.2: A profile describing LY-288513, in DMSO (vehicle) effects upon arm entries 
differed only slightly from that of measures of time spent. Total and closed arm entries were 
unaffected across the dose range while doses, 0.1mg.kg-1 (F8,63=6.17, p<0.01) and 10mg.kg-1 
(F8,63=6.17, p<0.001) significantly increased open arm entries. The intermediate, 1mg.kg-1 dose 
was seemingly unaffected.  
Studies of cholecystokinin peptide antagonism by CI-988 and LY-288513 showed a general 
attenuation of effects. A co-administration of chlordiazepoxide and each cholecystokinin form 
showed near identical data to that of previous studies with a significant decrease in time spent 
within the open arm; CCK-4 at 0.0025mg.kg-1 (F8,83=23.36, p<0.001); CCK-8us (F8,83=23.36, 
p<0.001); and CCK-8s (F8,83=23.36, p<0.001) compared to chlordiazepoxide alone. As 
previously shown a combination of chlordiazepoxide and CI-988 (1.0mg.kg-1) shows no 
differences from chlordiazepoxide alone.  
Figure 3.9.1: Addition of CI-988 to both the CCK-4/chlordiazepoxide and CCK-
8s/chlordiazepoxide combination, restores chlordiazepoxide activity. Perhaps a relatively 
extraneous observation is that CI-988 co-administered with CCK-8us/chlordiazepoxide not 
significantly attenuating CCK-8us decreased open arm time, compared to chlordiazepoxide 
alone. With this comparison, CI-988 with CCK-8us/chlordiazepoxide maintains a significant 
difference compared to an unusually high open arm time measure in the chlordiazepoxide 
group (mean 61.37). However, at least partial attenuation of the CCK-8us effect is observed 
where, compared to the CCK-8us/chlordiazepoxide group, CI-988 with CCK-
8us/chlordiazepoxide shows significantly increased open arm time (F8,83=23.36, p<0.05).   
Figure 3.9.2: Measures for number of entries follows a similar pattern to that of time spent 
within each sector, with both CCK-4 (F8,83=11.59, p=0.065) and CCK-8us (F8,83=11.59, 
p=0.057) narrowly missing significance differences from chlordiazepoxide in open arm 
THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS OF CHOLECYSTOKININ 
 86
entries, and CCK-8s achieving significant inhibition (F8,83=11.59, p=0.01). Similarly to time 
spent measures, a combination of CI-988 with either, CCK-4/chlordiazepoxide and CCK-
8s/chlordiazepoxide causes a loss of significant effect of cholecystokinin forms. In addition the 
number of open arm entries for the CCK-4/chlordiazepoxide with CI-988 group is significantly 
greater than that of CCK-4/chlordiazepoxide (F8,83=11.59, p<0.01) and likewise for CCK-
8s/chlordiazepoxide with CI-988 compared to CCK-8s/chlordiazepoxide (F8,83=11.59, 
p<0.001). 
Figure 3.10.1: Antagonism of cholecystokinin effects by LY-288513 showed significant 
attenuation with co-administration. Firstly, significant differences from the chlordiazepoxide 
treatment group were observed for CCK-4 at 0.025mg.kg-1 (F8,63=6.84, p<0.05); CCK-8us 
(F8,63=6.84, p<0.01); and CCK-8s (F8,63=6.84, p<0.001). This effect was largely at the expense 
of time spent in the closed arms. LY-288513 in combination with chlordiazepoxide at 
1.0mg.kg-1 showed no significant differences from chlordiazepoxide alone. The effects of 
cholecystokinin forms on open arm time were attenuated by LY-288513 (1.0mg.kg-1); with 
LY-288513/CCK-4/chlordiazepoxide significantly greater than CCK-4/chlordiazepoxide 
(F8,63=6.84, p<0.05); and with LY-288513/CCK-8us/chlordiazepoxide significantly greater 
than CCK-8us/chlordiazepoxide (F8,63=6.84, p<0.01). Differences between LY-288513/CCK-
8s/chlordiazepoxide and CCK-8s/chlordiazepoxide missed significance but demonstrated a 
trend towards attenuation (F8,63=6.84, p=0.077). LY-288513 at 10.0mg.kg-1 co-administered 
with chlordiazepoxide also showed no significant changes in time spent within each sector on 
the maze.  
Figure 3.10.2: Measures for number of arm entries showed no clear distribution, including a 
lack of effect in CCK-4/chlordiazepoxide and CCK-8us/chlordiazepoxide groups. CCK-
8s/chlordiazepoxide treated rats did however show a significant decrease in number of open 
arm entries  (F8,63=41.59 p<0.05). LY-288513 at 10mg.kg-1 in combination with 
chlordiazepoxide, resulted in marked inhibition in number of entries on the plus-maze; open 
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arm entries (F8,63=3.87, p<0.01); closed arm entries (F8,63=3.33, p=0.079) and total arm entries 
(F8,63=2.68, p<0.05).  
Figure 3.11.1: Antagonism of the effects of FG-7142 by CI-988 was studied with no 
differences between FG-7412 and FG-7142/CI-988 groups observed. Data was found to be 
indistinguishable between groups. Both FG-7412 and FG-7142/CI-988 groups showed 
significant inhibition of time spent within the open arms (F2,18=7.03, p<0.05 for both) and on 
the central platforms (F2,18=12.57, p<0.01 FG-7412; p<0.001 FG-7412/CI-988) and a 
significant increase in time spent in the closed arms (F2,18=32.48, p<0.001 for both).  
Figure 3.11.2: In addition, measures for number of entries were also significantly inhibited in 
both groups compared to the vehicle group, but no differences were observed between FG-
7142 and FG-7142/CI-988 groups.  
Figure 3.12.1: Further study of locomotor activity within the open field for these rats, 
subsequent to plus-maze testing, showed that in both groups activity is significantly inhibited. 
Ambulatory activity is significantly inhibited by FG-7142 (F2,18=10.73, p<0.05) and in total 
activity (F2,18=12.02, p<0.05) whereas FG-7142/CI-988 inhibits activity in all three measures: 
ambulatory (F2,18=10.73, p<0.001);  non-ambulatory (F2,18=10.06, p<0.001);  and total activity 
(F2,18=12.02, p<0.001). 
Social Isolation 
The effects of social isolation on plus-maze behaviour and psychopharmacology was 
examined.  
Figure 3.13.1: Group housed, chlordiazepoxide treated animals (3.0mg.kg-1) exhibited a 
significant increase in time spent in the open arm (F5,42=6.65, p<0.001) offset with a similar 
increase in closed arm time (F5,42=4.35, p<0.01). This phenomenon was not observed however 
in socially isolated rats. A similar finding was observed with LY-288513 (10.0mg.kg-1) in that 
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group housed rats demonstrated a significant increase in time spent on the open arms 
(F5,42=6.65, p<0.01) with socially isolated animals showing no significant differences from the 
vehicle group housed animals.  
Figure 3.13.2: A similar relationship is observed for measures of arm entries with group-
housed chlordiazepoxide treated animals exhibiting significantly increased numbers of open 
arm entries (F5,42=10.39, p<0.001). Socially isolated chlordiazepoxide treated animals did not 
show any differences from the vehicle group housed animals. No significant differences were 
observed in either LY-288513 groups with regard to numbers of arm entries.  
Figure 3.14.1: No significant differences were observed between chlordiazepoxide treated rats 
with either group housing or social isolation protocols. All remaining treatment groups showed 
significant decreases in time spent in the open arms; group housed CCK-4 at 0.025mg.kg-1  
(F7,56=23.08, p<0.001); socially isolated CCK-4 at 0.025mg.kg-1  (F7,56=23.08, p<0.001); group 
housed CCK-8us at 0.01mg.kg-1 (F7,56=23.08, p<0.001); socially isolated CCK-8us at 
0.01mg.kg-1  (F7,56=23.08, p<0.001); group housed CCK-8s at 0.002mg.kg-1  (F7,56=23.08, 
p<0.001); socially isolated CCK-8s at 0.002mg.kg-1  (F7,56=23.08, p<0.001) compared to group 
housed chlordiazepoxide treated rats. This decrease in open arm time was offset by an increase 
in time spent in the closed arms in all groups; group housed CCK-4 at 0.025mg.kg-1  
(F7,56=14.19, p<0.001); socially isolated CCK-4 at 0.025mg.kg-1  (F7,56=14.19, p<0.001); group 
housed CCK-8us at 0.01mg.kg-1  (F7,56=14.19, p<0.001); socially isolated CCK-8us at 
0.01mg.kg-1  (F7,56=14.19, p<0.001); group housed CCK-8s at 0.002mg.kg-1  (F7,56=14.19, 
p<0.001); socially isolated CCK-8s at 0.002mg.kg-1  (F7,56=14.19, p<0.001) compared to group 
housed chlordiazepoxide treated rats. In comparison with the chlordiazepoxide treated socially 
isolated group, the remaining isolated groups measures were significantly inhibited; socially 
isolated CCK-4 at 0.025mg.kg-1 (F7,56=23.08, p<0.001); socially isolated CCK-8us at 
0.01mg.kg-1  (F7,56=23.08, p<0.001); and socially isolated CCK-8s at 0.002mg.kg-1 
(F7,56=23.08, p<0.001). This decrease in open arm time compared to chlordiazepoxide treated 
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socially isolated animals, was counterbalanced by the increase in time spent in the closed arms 
in these groups; socially isolated CCK-4 at 0.025mg.kg-1 (F7,56=14.19, p<0.001); socially 
isolated CCK-8us at 0.01mg.kg-1  (F7,56=14.19, p<0.001); socially isolated CCK-8s at 
0.002mg.kg-1 (F7,56=14.19, p<0.001).  
Figure 3.14.2: Analysis of numbers of arm entries yielded similar data with the exception that 
the CCK-8us treated, group housed, rats that failed to achieve a significant decrease in number 
of open arm entries. Other groups all achieved a corresponding significant decrease in open 
arm entries; group housed CCK-4 at 0.025mg.kg-1  (F7,56=12.96, p<0.001); socially isolated 
CCK-4 at 0.025mg.kg-1  (F7,56=12.96, p<0.001); socially isolated CCK-8us at 0.01mg.kg-1  
(F7,56=12.96, p<0.001); group housed CCK-8s at 0.002mg.kg-1  (F7,56=12.96, p<0.001); socially 
isolated CCK-8s at 0.002mg.kg-1  (F7,56=12.96, p<0.001) compared to group housed 
chlordiazepoxide treated rats. In comparison with socially isolated chlordiazepoxide treated 
rats, socially isolated CCK-4 at 0.025mg.kg-1  (F7,56=12.96, p<0.001); socially isolated CCK-
8us at 0.01mg.kg-1  (F7,56=12.96, p<0.001); and socially isolated CCK-8s at 0.002mg.kg-1  
(F7,56=12.96, p<0.001) significantly inhibited numbers of open arm entries. Within these 
treatment groups no differences in number of closed arm entries nor in total number of entries 
were observed. 
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FIG. 3.1.1: Effects in rats of drugs with known anxiolytic (chlordiazepoxide) and anxiogenic (FG-7142) 
properties, and dimethylsulphoxide (DMSO) versus a saline vehicle on time spent in specific areas of 
the maze (as a percentage of the total trial time) on the elevated plus-maze (results presented as mean  
with SEM); light grey bars show % time spent on open arms, grey bars show % time spent on central 
platform, dark grey bars show % time spent on closed arms. Significant differences from the saline 
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FIG. 3.1.2: Effects in rats of drugs with known anxiolytic (chlordiazepoxide) and anxiogenic (FG-7142) 
properties, and dimethylsulphoxide (DMSO) versus a saline vehicle on entries onto the open and closed 
arms of the elevated plus-maze presented collectively as total entries (results presented as mean with 
SEM); light grey bars show number of entries onto open arms, dark grey bars number of entries onto 
closed arms, combined light grey and grey bars show number of total entries. Significant differences 
from the saline (vehicle) group are shown for open and closed arm entries within each bar and for total 
entries atop each bar; *p<0.05, **p<0.01, ***p<0.001 (Bonferroni post hoc analysis after significant 
one-way ANOVA). 
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FIG. 3.2.1: Effects in rats of drugs with known anxiolytic (chlordiazepoxide) and anxiogenic (FG-7142) 
properties and a combination of both, versus a dimethylsulphoxide (DMSO) vehicle on time spent in 
specific areas of the maze (as a percentage of the total trial time) on the elevated plus-maze (results 
presented as mean with SEM). Light grey bars show % time spent on open arms, grey bars show % time 
spent on central platform, dark grey bars show % time spent on closed arms. Significant differences 
from the DMSO (vehicle) group; **p<0.01, ***p<0.001, and from the chlordiazepoxide group are 
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FIG. 3.2.2: Effects in rats of drugs with known anxiolytic (chlordiazepoxide) and anxiogenic (FG-7142) 
properties and a combination of both, versus a dimethylsulphoxide (DMSO) vehicle on entries onto the 
open and closed arms of the elevated plus-maze presented collectively as total entries (results presented 
as mean with SEM). Light grey bars show number of entries onto open arms, dark grey bars number of 
entries onto closed arms, combined light grey and grey bars show number of total entries. Significant 
differences from the DMSO (vehicle) group (*p<0.05, ***p<0.001) and from the chlordiazepoxide 
group; ¤¤¤p<0.001 are shown for open and closed arm entries within each bar and for total entries atop 
each bar (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG. 3.2.3: Effects in rats of drugs with known anxiolytic (chlordiazepoxide) and anxiogenic (FG-7142) 
properties and a combination of both, versus a dimethylsulphoxide (DMSO) vehicle on locomotor 
activity within an open field chamber. Data presented are total, ambulatory and non-ambulatory beam 
interruptions (results presented as mean with SEM). Light grey bars show ambulatory locomotor 
activity, dark grey bars show non-ambulatory activity, totalling light grey and grey bars show number of 
total beam interruptions. Significant differences from the DMSO (vehicle) group are shown for beam 
interruption counts within each bar and for total entries atop the combined bar; *p<0.05, (Bonferroni 
post hoc analysis after significant one-way ANOVA). 
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FIG. 3.3.1: Effects in rats of a range of doses (in mg kg-1) of cholecystokinin isoform; CCK-4 in 
combination with chlordiazepoxide versus the effect of chlordiazepoxide alone on time spent in specific 
areas of the maze (as a percentage of the total trial time) on the elevated plus-maze (results presented as 
mean with SEM).  Light grey bars show % time spent on open arms, grey bars show % time spent on 
central platform, dark grey bars show % time spent on closed arms. Significant differences from the 
chlordiazepoxide group are shown; **p<0.01, ***p<0.001 (Bonferroni post hoc analysis after 
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FIG. 3.3.2: Effects in rats of a range of doses (in mg kg-1) of cholecystokinin isoform; CCK-4 in 
combination with chlordiazepoxide versus the effect of chlordiazepoxide alone on entries onto the open 
and closed arms of the elevated plus-maze presented collectively as total entries (results presented as 
mean with SEM). Light grey bars show number of entries onto open arms, dark grey bars number of 
entries onto closed arms, combined light grey and grey bars show number of total entries. Significant 
differences from the chlordiazepoxide group are shown for open and closed arm entries within each bar 
and for total entries atop each bar; *p<0.05 (Bonferroni post hoc analysis after significant one-way 
ANOVA). 
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FIG. 3.4.1: Effects in rats of a range of doses (in mg kg-1) of cholecystokinin isoform; CCK-8us in 
combination with chlordiazepoxide versus the effect of chlordiazepoxide alone on time spent in specific 
areas of the maze (as a percentage of the total trial time) on the elevated plus-maze (results presented as 
mean with SEM). Light grey bars show % time spent on open arms, grey bars show % time spent on 
central platform, dark grey bars show % time spent on closed arms. Significant differences from the 
chlordiazepoxide group are shown; **p<0.01, ***p<0.001 (Bonferroni post hoc analysis after 
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FIG. 3.4.2: Effects in rats of a range of doses (in mg kg-1) of cholecystokinin isoform; CCK-8us in 
combination with chlordiazepoxide versus the effect of chlordiazepoxide alone on entries onto the open 
and closed arms of the elevated plus-maze presented collectively as total entries (results presented as 
mean with SEM). Light grey bars show number of entries onto open arms, dark grey  bars number of 
entries onto closed arms, combined light grey and  grey bars show number of total entries. Significant 
differences from the chlordiazepoxide group are shown for open and closed arm entries within each bar 
and for total entries atop each bar; **p<0.01, ‡ signifies narrowly missed statistical significance, 
(Bonferroni post hoc analysis after significant one-way ANOVA). 
 94















1 0 0 %
C D P  (3 .0 ) C D P  (3 .0 )  +
C C K -8 s
(0 .0 0 0 3 )
C D P  (3 .0 )  +
C C K -8 s
(0 .0 0 0 5 )
C D P  (3 .0 )  +
C C K -8 s
(0 .0 0 1 )
C D P  (3 .0 )  +
C C K -8 s
(0 .0 0 2 )
C D P  (3 .0 )  +
C C K -8 s
C D P  (3 .0 )  +
C C K -8 s








FIG. 3.5.2: Effects in rats of a range of doses (in mg kg-1) of cholecystokinin isoform; CCK-8s in 
combination with chlordiazepoxide versus the effect of chlordiazepoxide alone on entries onto the open 
and closed arms of the elevated plus-maze presented collectively as total entries (results presented as 
mean with SEM). Light grey bars show number of entries onto open arms, dark grey bars number of 
entries onto closed arms, combined light grey and grey bars show number of total entries. Significant 
differences from the chlordiazepoxide group are shown for open and closed arm entries within each bar 
and for total entries atop each bar; *p<0.05, **p<0.01, ***p<0.001, ‡ signifies narrowly missed 
statistical significance, (Bonferroni post hoc analysis after significant one-way ANOVA). 
D r
FIG. 3.5.1: Effects in rats of a range of doses (in mg kg-1) of cholecystokinin isoform; CCK-8s in 
combination with chlordiazepoxide versus the effect of chlordiazepoxide alone on time spent in specific 
areas of the maze (as a percentage of the total trial time) on the elevated plus-maze (results presented as 
mean with SEM). Light grey bars show % time spent on open arms, grey bars show % time spent on 
central platform, dark grey bars show % time spent on closed arms. Significant differences from the 
chlordiazepoxide group are shown; *p<0.05, **p<0.01, ***p<0.001 (Bonferroni post hoc analysis after 
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FIG. 3.6.1: Effects in rats of a range of doses (in mg kg-1) of cholecystokinin forms; CCK-4, CCK-8us and CCK-8s in combination at maximal effective and half maximal 
effective doses, with chlordiazepoxide versus the effect of chlordiazepoxide alone on time spent in specific areas of the maze (as a percentage of the total trial time) on the 
elevated plus-maze (results presented as mean with SEM). Light grey bars show % time spent on open arms, grey bars show % time spent on central platform, dark grey bars 
show % time spent on closed arms. Significant differences from the chlordiazepoxide group are shown; *p<0.05, **p<0.01, ***p<0.001, ‡ signifies narrowly missed 
statistical significance, (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG. 3.6.2: Effects in rats of a range of doses (in mg kg-1) of cholecystokinin forms; CCK-4, CCK-8us and CCK-8s in combination at maximal effective and half maximal 
effective doses, with chlordiazepoxide versus the effect of chlordiazepoxide alone on entries onto the open and closed arms of the elevated plus-maze presented collectively as 
total entries (results presented as mean with SEM). Light grey bars show number of entries onto open arms, dark grey bars number of entries onto closed arms, combined light 
grey and grey bars show number of total entries. Significant differences from the chlordiazepoxide group are shown for open and closed arm entries within each bar and for 
total entries atop each bar; *p<0.05, **p<0.01, ***p<0.001;  ‡ signifies narrowly missed statistical significance, (Bonferroni post hoc analysis after significant one-way 
ANOVA). The symbol ‡ represents close adherence to p=0.05. 
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FIG. 3.6.3: Effects in rats of a range of doses (in mg kg-1) of cholecystokinin forms; CCK-4, CCK-8us and CCK-8s in combination at maximal effective and half maximal 
effective doses, with chlordiazepoxide versus the effect of chlordiazepoxide alone on locomotor activity within an open field chamber. Data presented are total, ambulatory 
and non-ambulatory beam interruptions (results presented as mean with SEM). Light grey bars show ambulatory locomotor activity, dark grey bars show non-ambulatory 
activity, totalling light grey and grey bars shows number of total number of beam interruptions. Significant differences from the DMSO group were not observed (Bonferroni 
post hoc analysis after significant one-way ANOVA). 
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FIG. 3.7.1: Effects in rats of a range of doses (in mg kg-1) of cholecystokinin-2 (CCK2); antagonist CI-
988 versus the effect of DMSO (vehicle) on time spent in specific areas of the maze (as a percentage of 
the total trial time) on the elevated plus-maze (results presented as mean with SEM). Light grey bars 
show % time spent on open arms, grey bars show % time spent on central platform, dark grey bars show 
% time spent on closed arms. Significant differences from the DMSO group were not observed 
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FIG. 3.7.2: Effects in rats of a range of doses (in mg kg-1) of cholecystokinin-2 (CCK2); antagonist CI-
988 versus the effect of DMSO (vehicle) on entries onto the open and closed arms of the elevated plus-
maze presented collectively as total entries (results presented as mean with SEM). Light grey bars show 
number of entries onto open arms, dark grey bars number of entries onto closed arms, combined light 
grey and  grey bars show number of total entries. Significant differences from the DMSO group were 
not observed (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG. 3.7.3: Effects in rats of a range of doses (in mg kg-1) of cholecystokinin-2 (CCK2) receptor 
antagonist CI-988 in combination with chlordiazepoxide (3.0mg.kg-1) versus the effect of 
chlordiazepoxide alone on time spent in specific areas of the maze (as a percentage of the total trial 
time) on the elevated plus-maze (results presented as mean with SEM). Light grey bars show % time 
spent on open arms, grey bars show % time spent on central platform, dark grey bars show % time spent 
on closed arms. Significant differences from the chlordiazepoxide group are shown; *p<0.05, 















CDP (3.0) CDP (3.0) +  C I-
988 (0.002)
CDP (3.0) +  C I-
988 (0.02)
CDP (3.0) +  C I-
988 (0.2)













FIG. 3.7.4. Effects in rats of a range of doses (in mg kg-1) of cholecystokinin-2 (CCK2); antagonist CI-
988 in combination with chlordiazepoxide (3.0mg.kg-1) versus the effect of chlordiazepoxide on entries 
onto the open and closed arms of the elevated plus-maze presented collectively as total entries (results 
presented as mean with SEM). Light grey bars show number of entries onto open arms, dark grey bars 
number of entries onto closed arms, combined light grey and grey bars show number of total entries. 
Significant differences from the chlordiazepoxide group are shown for open and closed arm entries 
within each bar and for total entries atop each bar; *p<0.05, **p<0.01, ***p<0.001 (Bonferroni post hoc 
analysis after significant one-way ANOVA). 
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FIG. 3.8.1: Effects in rats of a range of doses (in mg kg-1) of cholecystokinin-2 (CCK2); antagonist LY-
288513 in versus the effect of DMSO (vehicle) on time spent in specific areas of the maze (as a 
percentage of the total trial time) on the elevated plus-maze (results presented as mean with SEM). Light 
grey bars show % time spent on open arms, grey bars show % time spent on central platform, dark grey 
bars show % time spent on closed arms. Significant differences from the DMSO group are shown; 


























FIG. 3.8.2. Effects in rats of a range of doses (in mg kg-1) of cholecystokinin-2 (CCK2); antagonist LY-
288513 in versus the effect of DMSO (vehicle) on entries onto the open and closed arms of the elevated 
plus-maze presented collectively as total entries (results presented as mean with SEM). Light grey bars 
show number of entries onto open arms, dark grey bars number of entries onto closed arms, combined 
light grey and grey bars show number of total entries. Significant differences from the DMSO group are 
shown for open and closed arm entries within each bar and for total entries atop each bar; **p<0.01, 
***p<0.001 (Bonferroni post hoc analysis after significant one-way ANOVA).  
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FIG. 3.9.1: Effects in rats of a dose (1.0 mg kg-1) of cholecystokinin-2 receptor (CCK2) antagonist; CI-988 versus the effect of cholecystokinin forms; CCK-4, CCK-8us and 
CCK-8s in combination at maximal effective doses, with chlordiazepoxide versus the effect of chlordiazepoxide alone on time spent in specific areas of the maze (as a 
percentage of the total trial time) on the elevated plus-maze (results presented as mean with SEM). Light grey bars show % time spent on open arms, grey bars show % time 
spent on central platform, dark grey bars show % time spent on closed arms. Significant differences from the chlordiazepoxide group are shown; *p<0.05, **p<0.01, 
***p<0.001 and from the chlordiazepoxide/CCK-8us group ‡p<0.05 (Bonferroni post hoc analysis after significant one-way ANOVA). 
 102 













D M S O C D P  ( 3 . 0 ) C D P  ( 3 . 0 )  +
C C K - 4
( 0 . 0 2 5 )
C D P  ( 3 . 0 )  +
C C K - 8 u s
( 0 . 0 1 0 )
C D P  ( 3 . 0 )  +
C C K - 8 s
( 0 . 0 0 2 )
C D P  ( 3 . 0 )  +
C I- 9 8 8  ( 1 . 0 )
C D P  ( 3 . 0 )  +
C C K - 4
( 0 . 0 2 5 )  +  C I-
9 8 8  ( 1 . 0 )
C D P  ( 3 . 0 )  +
C C K - 8 u s
( 0 . 0 1 0 )  +  C I-
9 8 8  ( 1 . 0 )
C D P  ( 3 . 0 )  +
C C K - 8 s
( 0 . 0 0 2 )  +  C I-
9 8 8  ( 1 . 0 )






















FIG. 3.9.2: Effects in rats of a dose (1.0 mg kg-1) of cholecystokinin-2 (CCK2); antagonist CI-988 in versus the effect of cholecystokinin forms; CCK-4, CCK-8us and CCK-
8s in combination at maximal effective doses, with chlordiazepoxide; versus the effect of chlordiazepoxide alone on entries onto the open and closed arms of the elevated 
plus-maze; presented collectively as total entries (results presented as mean with SEM).  Grey bars show number of entries onto open arms, dark grey bars number of entries 
onto closed arms, combined light grey and grey bars show number of total entries. Significant differences from the chlordiazepoxide group are shown for open and closed arm 
entries within each bar and for total entries atop each bar; *p<0.05, **p<0.01, ***p<0.001; significant differences from the CCK-4/chlordiazepoxide group; †p<0.05, 
††p<0.01, †††p<0.001; significant differences from the CCK-8us/chlordiazepoxide group; ‡ p<0.05; and significant differences from the CCK-8s/chlordiazepoxide group; 
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FIG. 3.10.1: Effects in rats of a dose (10 mg kg-1) of cholecystokinin-2 (CCK2); antagonist LY-288513 in versus the effect of cholecystokinin forms; CCK-4, CCK-8us and 
CCK-8s in combination at maximal effective doses, with chlordiazepoxide versus the effect of chlordiazepoxide alone on time spent in specific areas of the maze (as a 
percentage of the total trial time) on the elevated plus-maze (results presented as mean with SEM). Light grey bars show % time spent on open arms, grey bars show % time 
spent on central platform, dark grey bars show % time spent on closed arms. Significant differences from the chlordiazepoxide group are shown; *p<0.05, **p<0.01, 
***p<0.001 (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG. 3.10.2: Effects in rats of a dose (10 mg kg-1) of cholecystokinin-2 (CCK2); antagonist LY-288513 versus the effect of cholecystokinin forms; CCK-4, CCK-8us and 
CCK-8s in combination at maximal effective doses, with chlordiazepoxide versus the effect of chlordiazepoxide alone on entries onto the open and closed arms of the 
elevated plus-maze presented collectively as total entries (results presented as mean with SEM). Light grey bars show number of entries onto open arms, dark grey bars 
number of entries onto closed arms, combined light grey and dark grey bars show number of total entries. Significant differences from the chlordiazepoxide group are shown 
for open and closed arm entries within each bar and for total entries atop each bar; *p<0.05, **p<0.01, ***p<0.001; significant differences from the chlordiazepoxide (3.0) / 
LY288513 (1.0) group; ‡ p<0.05; (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG. 3.11.1: Effects in rats of the cholecystokinin-2 (CCK2); antagonist CI-988 (0.02 mg kg-1) in 
combination with FG-7142 (5.0 mg.kg-1) versus DMSO (vehicle) on time spent in specific areas of the 
maze (as a percentage of the total trial time) on the elevated plus-maze (results presented as mean with 
SEM). Light grey bars show % time spent on open arms, grey bars show % time spent on central 
platform, dark grey bars show % time spent on closed arms. Significant differences from the DMSO 
(vehicle) group are shown; *p<0.05, **p<0.01, ***p<0.001 (Bonferroni post hoc analysis after 














D M S O F G -7142 (5 .0 ) FG -7142 (5 .0 ) +  C I-988  (0 .02)











FIG. 3.11.2: Effects in rats of the cholecystokinin-2 (CCK2); antagonist CI-988 (0.02 mg kg-1) in 
combination with FG-7142 (5.0 mg.kg-1) versus DMSO (vehicle) on entries onto the open and closed 
arms of the elevated plus-maze presented collectively as total entries (results presented as mean with 
SEM). Light grey bars show number of entries onto open arms, dark grey bars number of entries onto 
closed arms, combined light grey and grey bars show number of total entries. Significant differences 
from the DMSO (vehicle) group are shown for open and closed arm entries within each bar and for total 
entries atop each bar; **p<0.01, ***p<0.001 (Bonferroni post hoc analysis after significant one-way 
ANOVA). 
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FIG. 3.12.1: Effects in rats of the cholecystokinin-2 (CCK2); antagonist CI-988 (0.02 mg kg-1) in 
combination with FG-7142 (5.0 mg.kg-1) vs. DMSO (vehicle) on locomotor activity within an open field 
chamber. Data presented are total, ambulatory and non-ambulatory beam interruptions (results presented 
as mean with SEM). Light grey bars show ambulatory locomotor activity, dark grey bars show non-
ambulatory activity, totalling light grey and dark grey bars show number of total entries. Significant 
differences from the DMSO group are shown for beam interruption counts within each bar and for total 
counts atop the combined bar; *p<0.05, ***p<0.001 (Bonferroni post hoc analysis after significant one-
way ANOVA. 
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 FIG. 3.13.1:. Effects in rats of chlordiazepoxide (3.0mg.kg-1) and the cholecystokinin-2 (CCK2); 
antagonist LY-288513 (10.0 mg kg-1) versus DMSO (vehicle) between group housed or isolated rats 
upon time spent in specific areas of the maze (as a percentage of the total trial time) on the elevated 
plus-maze (results presented as mean with SEM). Light grey bars show % time spent on open arms, grey 
bars show % time spent on central platform, dark grey bars show % time spent on closed arms. 
Significant differences from the DMSO (group housed) group are shown; *p<0.05, **p<0.01, 
***p<0.001 (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG. 3.13.2: Effects in rats of chlordiazepoxide (3.0mg.kg-1) and LY-288513 (10.0 mg kg-1) versus 
DMSO (vehicle) between group housed or isolated rats upon entries onto the open and closed arms of 
the elevated plus-maze presented collectively as total entries (results presented as mean with SEM). 
Light grey bars show number of entries onto open arms, dark grey bars number of entries onto closed 
arms, combined light grey and dark grey bars show number of total entries. Significant differences from 
the DMSO (group housed) group are shown for open and closed arm entries within each bar and for 
total entries atop each bar; ***p<0.001 (Bonferroni post hoc analysis after significant one-way 
ANOVA). 
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FIG. 3.14.1: Effects in rats of a cholecystokinin forms; CCK-4 (0.025mg.kg-1), CCK-8us (0.01mg.kg-1) and CCK-8s (0.002mg.kg-1) in at maximal effective doses, with 
chlordiazepoxide versus the effect of chlordiazepoxide alone, in either group housed or isolated rats, upon entries onto alone on time spent in specific areas of the maze (as a 
percentage of the total trial time) on the elevated plus-maze (results presented as mean with SEM). Light grey bars show % time spent on open arms, grey bars show % time 
spent on central platform, dark grey bars show % time spent on closed arms. Significant differences from the chlordiazepoxide (group housed) group are shown; *p<0.05, 
**p<0.01, ***p<0.001; Significant differences from the chlordiazepoxide (isolated) group are shown; ¤¤¤p<0.001 (Bonferroni post hoc analysis after significant one-way 
ANOVA). 
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FIG. 3.14.2: Effects in rats of a cholecystokinin forms; CCK-4 (0.025mg.kg-1), CCK-8us (0.01mg.kg-1) and CCK-8s (0.002mg.kg-1) in at maximal effective doses, with 
chlordiazepoxide versus the effect of chlordiazepoxide alone, in either group housed or isolated rats, upon entries onto the open and closed arms of the elevated plus-maze 
presented collectively as total entries (results presented as mean with SEM). Light grey bars show number of entries onto open arms, dark grey bars number of entries onto 
closed arms, combined light grey and grey bars show number of total entries. Significant differences from the chlordiazepoxide group are shown for open and closed arm 
entries within each bar and for total entries atop each bar; *p<0.05, **p<0.01, ***p<0.001; Significant differences from the chlordiazepoxide (isolated) group are shown; 
¤¤¤p<0.001  (Bonferroni post hoc analysis after significant one-way ANOVA). 
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Discussion 
The solvent, dimethylsulphoxide (DMSO) was preferred for service as the vehicle throughout 
these studies due to solubility issues surrounding cholecystokinin peptides in saline.  A general 
uniformity of data between groups using saline and DMSO vehicles, concludes that DMSO 
almost certainly is an appropriate vehicle for use within these experiments. The finding that 
benzodiazepine agonists such as chlordiazepoxide, produce increases in time spent in the open 
arms within the plus-maze is a long established phenomenon (Pellow et al., 1985; Lister, 1987; 
Trullas et al., 1989) and is confirmed in this study. This increase is typically offset by a 
decrease in time spent in the closed arms. It is significant that time spent on the central 
platform is not significantly affected here. Time on the central platform may be seen as a 
decisive period in which an animal evaluates the relative merits of entering each arm. If this 
time period is altered it may be inferred that the drug under test is exerting an effect on 
cognitive processes. Therefore, an increased central platform period, without any change in 
total number of entries, may indicate some impairment in decision-making processes. 
However, compounded with a downward variation in total entry number this may indicate 
inhibited locomotor activity. Rats treated with a benzodiazepine inverse receptor agonist FG-
7142, produced a statistically significant decrease in central platform time which compounded 
with a significant decrease in total arm entries, may remain obscure with regard to 
interpretation using analysis of indices alone. An observed phenomenon within this group 
however implies that a high level of anxiety underlies this behaviour. Animals were observed 
to move quickly into the closed arms shortly after a brief "orientation" period in which 
exploration or central platform based assessment of the open arm occurred. This may imply 
that FG-7142 activates a hypervigilant state that causes a rapid transition from the central 
platform to the closed arms. This state of hypervigilance would support face validity criteria 
given that this is a fundamental symptom within clinical anxiety (Dubovsky 1990). 
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Corresponding increased numbers of open arm entries were also observed for chlordiazepoxide 
compared to the vehicle group. This further supports the reputed anxiolytic effects of 
benzodiazepine agonists implying not only greater time spent within open arms but also 
accompanying increases in open arm entries. Interestingly, chlordiazepoxide produced a 
significant increase in total arm entries. This increase implies either some form of locomotor 
activation or an inhibition of fear within the maze as a whole unit. The latter would be 
apparent whereby a novel environment such as the plus-maze would incorporate anxiety-
promoting elements in both arms. The antithesis of this phenomenon would not extend 
however to putative anxiogenic agents such as FG-7142. This compound while producing 
significant inhibition of arm entries and of time on the central platform, affects behaviour such 
that animals spend a high percentage of time in a single closed arm. A high level of anxiety 
would be proposed to exert similar effects. 
FG7142 however did not produce a significant decrease in time spent in the open arms 
compared to DMSO vehicle but displayed marked significance in increasing closed arm time. 
This lack of significant activity of FG-7142 on open arm time was possibly due to floor effects 
within this model. Unlike previous data (using the saline vehicle) FG-7142 in DMSO produced 
a significant decrease in open arm, closed arm and total entries. This augmentation of effects 
using the DMSO vehicle may be due to greater solubility, thus drugs are able to exert greater 
efficacy. 
As would be expected, FG-7142, a benzodiazepine receptor inverse agonist, prevented the 
increase in open arm indices observed with chlordiazepoxide, indicative of pharmacological 
opposition. Interestingly, both compounds inhibited spontaneous open field locomotor activity 
(figure 3.2.3.). It has previously been observed that chlordiazepoxide increases locomotor 
activity in the open field (Gentsch et al., 1987), which seems to be in contradiction with these 
findings. This phenomenon leads to a possible conclusion that chlordiazepoxide produces 
some sedation at the tested dose. FG-7142 perhaps not surprisingly inhibited locomotor 
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activity. It might be expected of a putative anxiogenic agent, that it would decrease exploration 
within a novel environment. This might also be explained by either increased activation 
(chlordiazepoxide) or decreased activation (FG-7142) of benzodiazepine receptors inhibiting 
locomotor activity via either a hypo-attentive state (chlordiazepoxide) producing sedation or 
via a hyper-attentive state (FG-7142) promoting freezing behaviour.   
A combination of chlordiazepoxide (3.0mg.kg-1) and FG-7142 (5.0mg.kg-1) despite both 
individually inhibiting locomotor activity, produced no difference from that of the vehicle 
group. A combination of both agents would undoubtedly negate the activity of both 
individually given their antagonistic pharmacology, and thus should effectively normalise 
behaviour. It may be noteworthy that measurement of locomotor activity within the first two 
minutes was not carried out. The exploratory phase of chlordiazepoxide treated rats may have 
occurred within this initial period. Therefore, within the measured period, the animal will have 
exhausted an incentive to explore. Interestingly, animals under study appeared to exhibit 
relatively high levels of endogenous anxiety when compared with those in several other 
studies. Consequently, cholecystokinin forms were tested in chlordiazepoxide treated animals 
rather than with nondrugged animals, in order to effectively raise the level of the baseline 
response. This measure was taken to avoid floor effects. However as is shown in this study 
dose dependent effects are an important factor. 
All three forms of cholecystokinin reversed the effect of chlordiazepoxide with an inverse bell-
shaped dose response curve for both time spent and entries into the open arms. This profile has 
been observed for the synthetic agonist BC-197 (Derrien et al., 1994). CCK-4, CCK-8us and 
CCK-8s exerted significant effects at doses, 0.025mg kg-1, 0.005-0.010 mg kg-1, and 0.0005-
0.002 mg kg-1 respectively. At higher doses a reversal of chlordiazepoxide activity was no 
longer observed. This data supports the negative findings of Rex et al., (1997), Rex and Fink 
(1998), and Chopin and Briley (1993) where they failed to observe activity on the plus-maze 
for CCK-8s within the higher dose range 0.01 - 0.1 mg.kg-1. Where these specific doses of 
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cholecystokinin forms counteract the activity of chlordiazepoxide, it may be assumed that this 
is an anxiogenic-like effect on the elevated plus-maze given their reported anxiogenic-like 
activity alone (Rex et al., 1994; Vasar et al., 1994; Koks et al., 1999; Bickerdike et al., 1995; 
Chopin and Briley, 1993).  
Neuropeptide receptor antagonists can be divided into two main classifications, either peptide 
or non-peptide. Non-peptide cholecystokinin antagonists were found to be chemically very 
different to the endogenous peptide cholecystokinin forms (Hill et al., 1992). Until relatively 
recently, the mechanism by which these antagonists exert their effects remained an enigma. 
However, radioligand binding studies combined with mutational analysis of cholecystokinin 
receptors has revealed the existence of distinct binding domains for peptide agonists and non-
peptide antagonists on a single receptor.  These techniques have shown that most peptide 
agonists interact at sites within the extracellular region of the receptor, particularly at the NH2 
terminal strand. Non-peptide antagonists, however, interact at sites within the transmembrane 
region (Beinborn et al., 1993). In a study by Schwartz et al., (1995), it was proposed that 
cholecystokinin receptors, like that of other neuropeptide receptors, follow an allosteric model. 
This model purports that specific ligands exhibit effects that shift a receptor between either an 
active or inactive conformational state. Thus, it was proposed that non-peptide antagonists 
exert their effects by shifting the equilibrium away from the active state. The mechanism by 
which this activation / inactivation is conferred is probably via a coupling / de-coupling, 
respectively of the G protein.  It may still be possible that these "decoupled" receptors exhibit 
efficacy but via another mechanism (other than that conferred by the G-protein) (Weatherford 
et al., 1993; Blaker et al., 2000).  
This mechanism appears to explain the inverted bell-shaped dose-response curve phenomenon 
exhibited by endogenous cholecystokinin forms. As is demonstrated, these agonists produce an 
anxiogenic-like response on the elevated plus-maze over a narrow dose range. A possible 
hypothesis derived from this model is that cholecystokinin peptide agonists are capable of 
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binding both active sites on the single receptor, albeit with differing affinities. At the 
anxiogenic dose, cholecystokinin may bind to the peptide specific site and elicit the response. 
At a higher dose however, cholecystokinin may bind both the peptide specific and the 
purported non-peptide specific site, the latter site with lesser affinity. The activation at the non-
peptide, so-called antagonist site, may shift the receptor to a G protein uncoupled 
conformation, and thus deactivating the receptor, at least with regard to anxiety-like efficacy. 
Brain CCK2 receptors have also been demonstrated, with radioligand binding studies, to exist 
in three different affinity states with regard to CCK-8 forms. Two of these states, exhibiting a 
high or low affinity to CCK-8 were detected. A third state of very low affinity was detected 
using [3H]-L365,260 (radiolabelled non-peptide antagonist). The third state represents a much 
larger percentage of the receptor population than the higher affinity states (Huang et al., 1994).  
This study suggests that non-peptide antagonists bind with a greater affinity to the G protein 
uncoupled conformations (low or very low affinity) and peptide agonists bind with a greater 
affinity to the high affinity form. Peptide agonists may also bind to the G protein uncoupled 
receptor conformation but with a much lower affinity. 
It may be speculated that cholecystokinin binds with high affinity on the G protein coupled 
conformation receptor population and elicits a response at a specific dose. At a higher dose 
however, it may bind both the high and the low affinity receptors, where the low affinity 
receptors exhibit no activity and thus shift an active receptor population to that of an inactive 
population. The increased "activation" of the G protein uncoupled conformation may also have 
an inhibitory effect on the anxiogenic response gated by the active population. Furthermore, it 
may also be proposed that the purported cholecystokinin non-peptide antagonists are actually 
acting as agonists at these low affinity receptor sites.   
An interesting finding in this study was that CCK-8s significantly decreases locomotor activity 
(a measure of total number of entries) on the elevated plus-maze. This phenomenon was not 
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apparent in the CCK-8us and CCK-4 groups. A plausible inference from this observation is 
that CCK1 receptor activation produces this decrease in locomotor activity on the elevated 
plus-maze. CCK-8s exhibits a 500 to 1000 fold greater affinity at the CCK1 receptor compared 
to CCK-8us and CCK-4 (Silvente-Poirot et al., 1993). This phenomenon is again not manifest 
at higher doses, which again may be due to a self-limiting CCK1 receptor mechanism 
analogous to that described earlier for the CCK2 receptor. Undoubtedly this decrease in 
locomotor activity on the maze is the major underlying factor for CCK-8s mediated decreases 
in open arm entries. However it is unlikely that measures for time spent on the open arms are 
altered by this factor. It would appear that CCK-8s exhibits efficacy on the elevated plus-maze, 
which affects both anxiety-like behaviour and locomotor activity, whereas CCK-4 and CCK-
8us only exhibit efficacy on anxiety-like behaviour. Therefore, this phenomenon may be 
dependent upon an equilibration between CCK1 and CCK2 receptors, classically purported to 
underlie anxiety behaviour. This hypothesis may bring into question previous studies that have 
taken the measure of arm entries, and stated categorically that that is a measure of anxiety-like 
behaviour, whilst disregarding locomotor activity as a factor. 
Examination of open arm entry data, for CCK-4 and CCK-8s groups, yielded an interesting 
correlation whereby number of open arm entries appeared to exhibit two separate dose 
response troughs. CCK-4 decreased the total number of arm entries at both 0.025mg.kg-1 and 
0.075mg.kg-1 without any changes at the intermediate dose 0.05mg.kg-1. CCK-8s at 
0.0005mg.kg-1 and 0.002mg.kg-1 decreased the numbers of total, open and closed arm entries, 
with the intermediate dose of 0.001 not showing a significant decrease in numbers. This dose 
response profile however is not observed in CCK-8us treated groups. A hypothesis describing 
this phenomenon is largely conjecture, given the novel finding. It might be viable, however 
that an increase in anxiety level is induced at a lower dose, while at the higher dose an 
inhibition of locomotor activity might be evident. At the intermediate dose however, anxiety 
level may diminish while inhibition of locomotor activity may not yet be manifest, thus a loss 
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of any significant decrease in total arm entries or other measures. This however is not 
supported directly by percentage time spent measures, which indicate that a purported anxious 
state is observed at the intermediate dose for CCK-4 but is not observed at either higher or 
lower doses. Regarding CCK-8s, the supposed anxious state occurs at the intermediate and 
higher dose but not at the lower dose. These observations infer that CCK-8s and CCK-4 
possibly act via different mechanisms with regard to these effects. The aforementioned 
hypothesis may be apparent for CCK-4 given a purported anxiety state induced at the lower 
dose and no effects upon time spent at the higher dose. With regard to CCK-8s, this 
relationship may be in reverse whereby at the lower dose locomotor activity is inhibited via an 
anxiety independent factor and at the higher dose, anxiety dependent reduction in activity are 
observed. The intermediate dose of CCK-8s would thus be at a post-independent and pre-
dependent stage. The CCK2 specific antagonist, CI-988 also reverses the effects of 
chlordiazepoxide on the total number of entries, interestingly also adhering to a profile of two 
separate dose response troughs, identical to that of CCK-4 and CCK-8s.  Therefore the active 
elements underlying these phenomena probably are restricted to CCK2 receptors. The observed 
profile for CI-988 is comparable with that of CCK-8s, given that the higher dose is not active 
with regard to open arm time.  The underlying physiological mechanism surrounding these 
phenomena is mostly open solely to conjecture. One possible mechanism is that of a four way 
model of receptor activation. Firstly where a cholecystokinin peptide is at the maximal dose 
(altering open arm time), activation of one receptor subsite occurs, assigned here as the CCK2A 
site. At the specific dose altering entry number, this is negated by activation of both CCK2A 
and CCK2B sites. At the higher entry number specific dose then CCK2B sites are activated to a 
greater degree than CCK2A sites, possibly via activation at the non-peptide site on the CCK2A 
receptor (thus deactivating the CCK2A receptor), hence secondary arm entry effects. At an even 
higher dose, inactive in all measures, the non-peptide site on CCK2B receptors is also activated, 
thus deactivating both sites. A CCK2 antagonist such as CI-988, therefore, may deactivate both 
subtypes selectively. For example CCK2A deactivation occurring at the lower dose and at the 
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higher dose CCK2B is deactivated. This deactivation of both receptor subtypes inhibits 
locomotor activity within the plus-maze model. At the intermediate dose, however, 
deactivation of both subtypes would not be enough to produce locomotor inhibition, which 
would only occur at higher levels.   Given hindsight, this hypothesis should have been tested 
within the open field locomotor activity paradigm. Although tests were performed using doses 
active upon time spent in the open arms, and the preceding dose; higher doses at which total 
entries are inhibited were not tested.   
Dose response studies of CI-988 with DMSO (vehicle) in the absence of chlordiazepoxide 
showed no significant effects on any indices, probably due to floor effects, i.e.: inability to 
force the effect downwards any further from an already low level.    
Nevertheless, no significant differences were recorded during locomotor activity testing. 
Certain trends were observed. However, standard deviation within drug groups was unusually 
high, thus negating possibility of significant analysis. An explanation for this variation cannot 
be easily proposed apart from perhaps differing sensitivities of individual animals to 
cholecystokinin doses determined by their distinct endogenous anxiety levels. 
A combination of cholecystokinin forms at both half and maximally effective doses, with 
regard to attenuation of chlordiazepoxide effects upon time spent in the open arms (figure 
3.6.1.), yielded quite exceptional results. The higher dose inhibited the activity of 
chlordiazepoxide (by decreasing open arm time), whereas the lower dose was either inactive or 
at least only partial in effect. Despite the maximal dose of CCK-8us (0.01mg.kg-1) increasing 
time spent on the central platform in this study, this was not observed in the previous dose 
response study, and thus perhaps can be disregarded. Another interesting phenomena was 
observed here whereby, a combination of CCK-4 and CCK-8 (either form) at either half or at 
their maximally effective doses failed to elicit inhibition of chlordiazepoxide activity.  It might 
be expected that combining two different forms of cholecystokinin peptide at half their 
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maximally active doses would also produce a maximal effect, if they were efficacious via the 
same receptor site. However data to the contrary was observed. Furthermore, a combination of 
CCK-8us and CCK-8s at these doses did maintain the expected inhibition of chlordiazepoxide 
activity. These phenomena may be explained by either of the following hypotheses:  
1. Binding site/ receptor interactions are specific for CCK-4 and CCK-8, at two distinct 
binding sites on either separate or on the same receptor that counteract the action of one 
another. These receptors would exist either centrally or peripherally.  
2. Distinct populations of receptors present at different regions of the central or peripheral 
nervous system (where cholecystokinin forms differ in their bioavailability) due to either 
differential blood brain barrier permeability or other peripheral bioavailability factors. 
It may be proposed that the CCK-4 induced anxiety-like activity is gated at the CCK2 receptor 
and is counteracted by CCK-8s at the CCK1 receptor. However, subsequent studies showed 
that, specific CCK2 antagonists, CI-988 and LY-288513, attenuated a reversal of 
chlordiazepoxide activity, by each cholecystokinin form. This would indicate that solely CCK2 
receptor activation underlies these effects in all cholecystokinin forms tested. This hypothesis 
of CCK2 receptor subpopulations is further supported by evidence from a study by Derrien et 
al., (1994) that a systemically administered, selective CCK2 agonist BC-197 induced 
anxiogenic-like effects in the plus-maze, whereas the CCK2 agonist BC-264 had no observed 
activity. BC-197 induced effects were also blocked by CI-988 but BC-264 produced 
anxiogenic-like dose dependent effects when administered with L-365260. Binding 
competition with [3H]pBC-264 revealed that BC-197 exhibits differing affinities for two 
distinct receptor sites and BC-264 exhibits a very similar affinity for these sites. This implies 
that BC-264 binds to both peptide and non-peptide receptor sites with equal affinity, therefore, 
exhibiting activity via the former and negating this activity via the latter. Addition of L-
365260, binding solely to the non-peptide site will exert no efficacy, and thus confers activity 
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to BC-264 at the peptide site, hence anxiogenesis. BC-197 is probably efficacious only at the 
peptide site and will only be antagonised in effect by CI-988 at the non-peptide site, thus 
negating any activity. 
Numbers of arm entries were modified only in the CCK-8s group at the maximally responding 
dose and in the CCK-8us (0.01) / CCK-8s (0.002) combined group. This differed from profiles 
in the preceding dose response curves, where CCK-4 and CCK-8us both achieved significant 
differences. This loss of significance may be explained by a relatively low number of entries 
by the chlordiazepoxide group in this study (a mean of 9.375 for open entries) compared to 
that within previous CCK-4 and CCK-8us (a mean of 12.69) dose response studies. 
Experimental and housing conditions for both batches were identical.  Differences between 
numbers of open arm entries between batches missed significance with a p-value of 0.98. 
Closed arm entries showed no observed trends whereas numbers of total arm entries between 
batches were significantly different (F1,21=4.80, p<0.05). A cause of this variation cannot be 
easily proposed apart from differences between batches of animals and their specific 
locomotor activity. 
Dose response studies of the CCK2 antagonist, LY-288513, in DMSO (vehicle) demonstrated a 
broadly dose dependent increase in time spent and in number of entries onto the open arms 
without the previously dominant inverse bell shaped dose response profile. This might occur 
where LY-288513 not exhibiting selectivity for either subtype, and thus at a suitable dose 
rebalancing any endogenous imbalance between receptor subtypes. This would thus exert an 
anxiolytic like response. Despite total and closed arm entries remaining unaffected across the 
dose range, doses, 0.1mg.kg-1 and 10mg.kg-1, open arm entries were significantly increased. 
Yet again, however, an intermediate, 1mg.kg-1 dose was without effect. This phenomenon of 
dual peak or trough profiles across a dose response was observed for measures of open or total 
entries in other tested agonists and antagonists.  A possible hypothesis elucidating this 
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phenomenon was proposed earlier.  
Studies of cholecystokinin peptide antagonism by CI-988 and LY-288513 showed a general 
attenuation of effects, whereby co-administration of CI-988 with both the CCK-
4/chlordiazepoxide and CCK-8s/chlordiazepoxide combinations, restores chlordiazepoxide 
activity. Perhaps a relatively extraneous observation is that CI-988 co-administered with CCK-
8us/chlordiazepoxide only partially attenuating CCK-8us decreased open arm time, compared 
to chlordiazepoxide alone. With this comparison, CI-988 with CCK-8us/chlordiazepoxide 
maintains a significant difference compared to an unusually high open arm time measure in the 
chlordiazepoxide group (mean 61.37). However, at least partial attenuation of the CCK-8us 
effect by CI-988 is observed where, compared to the CCK-8us/chlordiazepoxide group, 
showing a significantly increased open arm time (F8,83=23.36, p<0.05).    Measures for number 
of entries follows a similar pattern to that of time spent within each sector thus can be assumed 
to adhere to the same mechanism. 
The effects of cholecystokinin forms on chlordiazepoxide increased open arm time were 
attenuated by LY-288513 (1.0mg.kg-1), with the exception of the CCK-8s combination 
narrowly missing significance. This partial inhibition of CCK-8s effect is interesting given that 
the other CCK2 antagonist tested, CI-988, only partially inhibited CCK-8us. An explanation 
for this effect remains enigmatic. Measures for number of arm entries did not show such a 
clear distribution.  
Interestingly, a chance prior observation was made that a dose of LY-288513 at 10mg.kg-1 in 
combination with chlordiazepoxide, resulted in marked inhibition in number of entries on the 
plus-maze. Furthermore, locomotor activity was visibly observed to be impaired within the 
apparatus, in addition to a clear lack of muscle tone in LY-288513/chlordiazepoxide treated 
rats. A dose of 10mg.kg-1 of LY-288513 with chlordiazepoxide was initially selected for 
antagonism but was shelved after these preliminary findings. These observations strongly 
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imply that chlordiazepoxide and LY-288513 at this higher dose produce sedation in 
combination, much the same as a high dose of chlordiazepoxide alone. Whether, the sedative 
activity of chlordiazepoxide is augmented by LY-288513 or whether LY-288513 produces 
discrete sedative properties alone requires further investigation. Doses of 20mg.kg-1 LY-
288513 suffered from some solubility difficulties, thus preventing study.   
An experiment to determine whether CI-988 was able to inhibit activity of FG-7142 produced 
data which was indistinguishable between groups. The aim of this study was to determine 
whether the anxiogenic activity of FG-7142 was upstream of the cholecystokinin anxiogenic 
system. This was therefore observed to not be the case. This study indicated that FG-7142 
induced anxiogenesis is either independent or downstream from cholecystokinin-induced 
anxiogenesis. It is more likely that the benzodiazepine component is downstream of the 
cholecystokinin component. This would account for attenuation of cholecystokinin anxiogenic 
activity by chlordiazepoxide (in that order) rather than cholecystokinin attenuating 
chlordiazepoxide activity. If cholecystokinin antagonists were to attenuate activity of FG-7142 
this would strongly imply that cholecystokinin components lie upstream of benzodiazepine 
components, which appears to not be the case. 
Further study of locomotor activity within the open field for these rats, subsequent to plus-
maze testing, showed that in both groups, activity is significantly inhibited. There appears to 
be a trend however that the CI-988/FG7142 inhibits locomotor activity to a greater extent than 
FG-7142 alone. CI-988 alone at this dose is observed to significantly inhibit total entry number 
in the plus-maze.     
Social Isolation 
While Vasar et al., (1993a) and Janowska et al., (1991) observed that social isolation of male 
rats significantly reduced their exploratory activity in the elevated plus-maze, compared with 
those group housed, this was not observed in this study. Chlordiazepoxide however was 
THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS OF CHOLECYSTOKININ 
 123
observed to exhibit activity in group-housed but not in socially isolated animals. This implies 
that floor effects may have been observed for nondrugged animals, where the level of anxiety 
cannot be measured at any greater degree within the model. Floor effects can be considered 
whereby a model provides no extension for a possibility of further measurement, that the 
measurement within the model has reached its’ maximal or minimal point, despite not reaching 
a figure close to zero. In this model at a maximal level of anxiety, it is not assumed that this is 
equivalent to an approximation of zero in measurement. LY-288513 was also observed to 
achieve this effect, whereby, in group-housed animals, increasing open arm time, and lacking 
activity in the isolated group. This would indicate that social isolation can affect 
cholecystokinin induced anxiety. The succeeding series of experiments showed that floor 
effects within the model appear to explain previous findings such as in the abovementioned 
study by Vasar et al., (1993a), where caerulein at a high dose significantly decreased the 
exploratory behaviour of rats housed in groups, but not in the isolated rats. A lack of effect was 
determined through analysis with regard to significant differences between caerulein in 
isolated rats and vehicle in isolated rats. This study was undertaken in order to test a 
hypothesis that floor effects, produced by isolation-induced decreases in indices within the 
vehicle group, were responsible for an observed lack of activity. Interestingly, where social 
isolation of the rats increased the number of [3H]pCCK-8 binding sites in the frontal cortex 
(Vasar et al., 1993a) it may merely be attributed to a simple increase in anxiety level and not to 
some more fundamental change in efficacy of cholecystokinin with regard to behavioural 
models. It also cannot be assumed that an increase in receptor binding will prevent any further 
activation, apart from merely shifting the starting point upwards. No changes were observed in 
the density of benzodiazepine receptors. This implies that an increase in anxiety-like behaviour 
might be independent of the benzodiazepine component. This is not given credence however 
by findings in this study where, in the vehicle group, there are no observable differences 
between group-housed and socially isolated animals. In agreement with this finding is another 
by Frussa-Filho et al., (1991) which shows that housing isolation produces no effect. 
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Significant changes between group housed and isolated animals treated with chlordiazepoxide 
and the cholecystokinin antagonist are observed however, which implies that both 
benzodiazepine and cholecystokinin systems provide active components in this behavioural 
observation.  
It may be quite possible that a differing endogenous level of anxiety underlies differences in 
findings within a vehicle group between studies. Where animals exhibit a higher level of 
endogenous anxiety then floor effects may be observed, whereas lowered endogenous anxiety 
levels and those pharmacologically manipulated (by benzodiazepines, for example) are able to 
demonstrate significant differences.  
Housing effects upon cholecystokinin activity were examined using maximally effective doses 
of CCK-4, CCK-8us and CCK-8s, as described in earlier studies (see figures 3.2 to 3.4). All 
remaining treatment groups showed significant decreases in time spent in the open arms 
compared with chlordiazepoxide and specific housing regimes. This finding provides further 
evidence that floor effects were responsible for lack of effects observed by caerulein in the 
aforementioned study. Despite not testing these cholecystokinin forms in the absence of 
chlordiazepoxide, which would provide almost unfailing evidence, were there to be no effects 
observed in isolated animals, this hypothesis of floor effects, would be strongly supported by 
the available data.   
Thus an explanation of the range of differing results using cholecystokinin specific ligands, 
may either be explained by hypotheses described within, or by experimental, strain, or housing 
differences. Given that these hypotheses highlight a far greater subtlety regarding the 
underlying mechanisms, it is also likely that subtle differences in the aforementioned factors 
are also able to alter this cholecystokinin receptor balance. Therefore, a range of studies with 
often quite contradictory findings regarding the same ligand doses and route of administration, 
but differing in their experimental procedures are apparent. 
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CHAPTER FOUR - ANIMAL MODELS OF CONDITIONED FEAR 
Introduction  
Clinically defined phobias are thought to correspond to animal models of the conditioned fear 
paradigm. Classically pairing an electric shock with a light cue and eliciting some form of 
anxious response is a commonly utilised model of such. Relating Pavlovian conditioning to the 
underlying nature of human phobic conditions however may seem rather contrived. Commonly 
reported clinically defined phobias are concentrated within a restricted number of fear-
inducing stimuli (Davey 1995). These stimuli, would ordinarily represent a minor threat, yet in 
phobic conditions produce disproportionately high fear associations. Expectancy bias is an 
estimate of the degree of perceived threat that any stimulus might represent. The level at which 
expectancy bias is influenced by either ontogenetic experiences (conditioned fear) or innate 
alarm signals (unconditioned fear) underlies two major groups of animal model. The shock-
light classical Pavlovian conditioning paradigm, under these criteria may seem quite artificial 
in that an animal will not display an innate fear of electric shock. It may be therefore proposed 
that as Pavlovian fear conditioning is solely characterised by ontogenetic experience, it is not 
representative of a majority of characterised and clinically defined phobia. In the previous 
chapter, the pharmacological nature of the elevated plus-maze was examined. Anxiety-like 
behaviour exhibited upon the maze is believed to be generated by an innate fear response 
elicited by one or more variables within the apparatus itself. However, on subsequent 
exposures to the plus-maze, the pharmacological profile of benzodiazepine anxiolytics, which 
exhibit well defined efficacy on an initial exposure, is inactivated. It may be proposed that 
while the first exposure elicits an innate neophobic-like response, subsequent exposure evokes 
a conditioned fear-like response. This might be confirmed in face validity arguments as having 
consistency with that of human phobic development. Within the process of this conditioning 
procedure, there is an exposure phase leading to an active avoidance phase. Development of 
phobia in humans additionally is believed to exhibit these two phases. This chapter focuses on 
THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS OF CHOLECYSTOKININ 
 126
characterisation and validation of the two trial elevated plus-maze as a putative model of 
phobia and interactions with the cholecystokinin system. In addition, the question of whether 
cholecystokinin possesses activity in a classical fear potentiated startle paradigm is examined. 
The Two Trial Elevated Plus-maze: A Putative Model of Phobia 
A discovery by Lister (1987) that a single prior exposure to the plus-maze renders a mouse 
relatively insensitive to the anxiolytic effects of chlordiazepoxide on further trials, has 
provided scope for a great wealth of research into the area. File (1990) confirmed this 
phenomenon in rats, claiming a similar insensitivity to chlordiazepoxide on trial two. File 
(1990) noted that this phenomenon of "one-trial tolerance" persisted even when the two trials 
were separated by as much as fourteen days, and according to File et al., although disputed by 
other authors, the scores of control animals remain stable over repeated tests. In addition, they 
found that chlordiazepoxide was able to block the development of this phenomenon with a 
very high dose given prior to the initial trial. This however, is almost certainly due to either 
amnestic activity or state induced attentional deficits. This study also showed that 
interestingly, the conditioning phase on trial one was not specific to any individual plus-maze 
apparatus. This phenomenon was observed even when the mazes utilised on both trial one and 
two, were of different materials.  
File (1993) suggested that the phenomenon of chlordiazepoxide inactivity on trial two is due to 
a mechanism by which during the first 5 minutes in the elevated plus-maze, rats are 
conditioned to fear of heights, associated with the plus-maze aversive stimulus, and it is, a 
phobic anxiety state that is measured during the second 5-minute trial. It would thus follow 
that chlordiazepoxide, which like other benzodiazepines is clinically inactive in treatment of 
phobic conditions, will be inactive in this animal model of phobia.  
Broadly in confirmation of this observation, Treit et al., (1993a) demonstrated that although 
diazepam-treated rats avoided the open arms less than vehicle-controls on the first test, this 
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difference faded away across subsequent trials.  
File et al., (1993) observed that attenuation of diazepam activity on trial two occurs only when 
the trials are short (5 minutes); with longer exposure (10 minutes) diazepam retains anxiolytic 
efficacy. File et al., concluded that during a brief (5 minute) trial in the plus-maze, rats acquire 
a specific phobic anxiety (conditioned fear), which is relatively resistant to benzodiazepines. 
With a longer exposure to the plus-maze this form of fear extinguishes. Interestingly though, 
the phenomenon is not seen in unhandled rats, in rats given longer trials in the plus-maze, or 
with those administered an amnestic treatment on trial one (Andrews and File 1993). 
Holmes and Rodgers (1999) demonstrated that, while extending the duration of initial 
exposure to 10 minutes did not prevent the loss of chlordiazepoxide (10mg.kg-1) efficacy in a 
standard-duration second trial, increasing the duration of both trials to ten minutes reinstated 
an anxiolytic profile for the compound.  
File and Zangrossi (1993) examined this two trial phenomenon in other aversive models of 
anxiety, observing that diazepam (5mg.kg-1) increased the number of shocks accepted by rats 
on two successive trials in the punished drinking test. Hence, this phenomenon of tolerance to 
benzodiazepines within the second trial is possibly restricted to the plus-maze and like 
protocols. Furthermore, File and Zangrossi (1993)  observed that chlordiazepoxide also 
retained its ability to counteract anxiogenic effects in the plus-maze induced by prior exposure 
to cat odour, over successive trials. This implies that the specific anxiety component to which 
benzodiazepine tolerance is developed within a two trial paradigm, is exclusively due to fear 
conditioning factors within the plus-maze itself. Furthermore, the anxious response observed 
within the plus-maze with exposure to cat odour is multifaceted, whereby two or more 
components underlie the total anxious response on the successive trials.  File and Zangrossi, in 
addition, observed that chlordiazepoxide (5 and 10 mg.kg-1) was also ineffective against the 
behavioural responses of rats during exposure to cat odour, another possible animal test of 
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phobia. 
These observations again imply that several factors are underlying the observed anxiety 
measures within this paradigm. Hence, the anxiety component, which underlies development 
of chlordiazepoxide tolerance, is fundamental to behaviour during exposure to cat odour, and 
during trial two of the plus-maze. These may be described as an innate phobic and a 
conditioned phobic response respectively. Another type of anxiety-like behaviour is that 
observed in the plus-maze subsequent to cat odour exposure, which is resistant to 
chlordiazepoxide tolerance, and possibly the same as that observed in the initial plus-maze 
exposure of naïve rats. This might be described as a generalised neophobic anxiety. However, 
it was noted by Hogg and File (1994), that laboratory-bred rats can be divided into those 
showing clear innate behavioural responses to the odour of a predator (a cat) and those 
showing no response, these two groups differed neither in their responses to a neutral odour, 
nor in the elevated plus-maze tests of anxiety. Furthermore, within trial two in the plus-maze, 
two clear groups of responders and non-responders could be identified (but not on trial one or 
in the social interaction test). Interestingly however, the distribution of cat odour responders 
did not correspond to the distribution within plus-maze trial two. This suggests that it is 
possible to identify bimodal populations of rats in tests of both innate and acquired simple 
phobias, and that these populations are quite distinct.   
Dawson et al., (1994) re-examined the phenomenon of "one-trial tolerance" in the elevated 
plus-maze and observed that unlike previous experiments, nondrugged pre-exposure to the 
maze resulted in habituation with a consequential reduction in time spent on the open arms. 
Habituation was measured by recording the actual distance travelled by the rats in the maze, 
which was found to be significantly reduced by pre-exposure. Dawson et al., observed that 
chlordiazepoxide administration prior to trial one resulted in an inhibition of "anxiolytic-like" 
effects of chlordiazepoxide, on trial two. Dawson et al., found contrary to previous findings 
that, although the time spent on the open arms was reduced by pre-exposure, chlordiazepoxide 
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significantly increased the time spent on the open arms by rats pre-exposed under a non-
drugged state. The authors inferred that rats do not become tolerant to the effects of 
chlordiazepoxide, but rather the reduced response to chlordiazepoxide after pre-exposure is 
due to habituation of exploratory behaviour. This is perhaps a valid point, given that 
chlordiazepoxide is plainly ineffective in promoting motivation for exploration in addition to 
its inactivity in phobia. This question forms part of the following study and is elaborated 
further here.  
Rodgers et al., (1996) confirmed in mice, some of the findings of Dawson et al., (1994) where 
re-exposure to the maze, produces an increased avoidance of the open arms and a 
corresponding preference for the enclosed sections of the apparatus. Rodgers et al., (1996) 
conducted further ethological analyses of behaviour during trial two and confirmed marked 
differences to that seen on initial exposure. These changes furthermore are independent of the 
duration of trial one (2 vs. 5 minutes). Trial two specific behavioural changes included a 
decrease in entry latencies, open arm entries, time on the open arms and central platform, 
lower levels of exploratory head dipping, and increased entries into and time spent in the 
closed arms. Subsequent time lapse analyses of the behaviour of naïve animals within the 
initial trial showed that behaviour during the first minute is characterized by high levels of risk 
assessment based at the central platform and relatively low, but equal, levels of open- and 
closed-arm exploration. Subsequent exploration showed increasing open arm/central platform 
avoidance, increasing closed-arm preference, and decreasing levels of central platform risk 
assessment and exploratory head-dipping. These analyses appear to reveal a fear conditioning 
process within the initial exposure.  
Within my own studies I can confirm some of these observations (data not shown) whereby 
most open arm exploration occurs within the first period of the trial, and animals spend more 
time in the closed arm in the later period. In addition, Rodgers et al., (1996) demonstrated that 
post-trial administration of the muscarinic antagonist and putative amnestic agent, scopolamine 
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(0.1-1.0 mg.kg-1), failed to significantly alter the behavioural changes seen between trials.  
Holmes and Rodgers (1998) observed upon exposure of mice to the plus-maze for 5 minutes 
for three consecutive days, that a single prior nondrugged exposure to the maze increases 
behavioural indices of anxiety and that these changes are either maintained or further enhanced 
on subsequent trials. Espejo (1997) has confirmed this observation. Furthermore, the 
behavioural profile evident by trial three was largely unchanged when animals were re-
exposed to the maze 10 days later. Detailed time based analyses of behavioural patterns within 
trials demonstrated that open arm avoidance is acquired by the third minute of trial one, and 
that the behavioural profile evident by the end of trial one is markedly different to that seen at 
the beginning of that trial. This late trial behaviour is generally maintained or even accentuated 
on trials 2 and 3 (Holmes and Rodgers 1998). 
The Aversive Nature of the Plus-maze 
File et al., (1992) observed that handling of rats produced insensitivity to chlordiazepoxide in 
the plus-maze. This phenomenon was not seen in unhandled rats. Chlordiazepoxide-induced 
decreases in cortical GABA release were abolished by prior plus-maze experience. 
Hippocampal GABA release in response to chlordiazepoxide was decreased in unhandled and 
increased in handled rats. This would thus imply that the phobic conditioning of the first plus-
maze trial is driven by both animal handling and plus-maze exposure. 
Treit et al., (1993a) attempted to examine the precise nature of the anxiogenic stimuli 
associated with phobic conditioning within the plus-maze. Although it has often been assumed 
that rats avoid the open arms because of their novelty, height, or open field, the anxiogenic role 
of these stimuli in the plus-maze had not previously been methodically examined. The 
experimenters observed that firstly, with rats repeatedly exposed to the elevated plus-maze, 
open-arm avoidance increased on the second trial and showed no evidence of habituation after 
eighteen trials. Furthermore, three 30-minute sessions of confinement to the open arms 
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("flooding") failed to decrease rats' open-arm avoidance. Instead, rats that had received 
flooding avoided the open arms significantly more than control rats during the first test. 
However, in contrast to this observation, Bertoglio and Carobrez (2000) noted that rats 
confined to either open or enclosed arms failed to show an increased avoidance of open arms 
in a subsequent trial. Holmes and Rodgers (1999) observed that trial one confinement to an 
open arm did not compromise chlordiazepoxide efficacy when mice were subsequently 
allowed to freely explore the maze, whereas closed arm confinement during initial exposure 
abolished the drug's anxiolytic action upon retest. The authors suggest that the experientially 
induced loss of benzodiazepine efficacy in the mouse plus-maze depends rather critically upon 
prior discovery and exploration of relatively safe areas of the maze (i.e. closed arms).  
Treit et al., (1993a) further demonstrated that variation of plus-maze height from 50 to 6 cm, 
did not change open-arm activity. Height cues were manipulated further by placing a "floor" 8 
cm beneath one open arm while leaving the floor of the other open arm at 50 cm. Rats did not 
avoid the "low" open arm less than the "high" open arm. It was thus concluded that height of 
the plus-maze was not the anxiogenic factor in the efficacy of this model. 
In a further attempt to elucidate the aversive nature of the plus-maze, Fernandes and File 
(1996) tested rats in a plus-maze, with or without small ledges on the open arms.  
Chlordiazepoxide had significant anxiolytic-like effects on trial 1 only in the maze without 
ledges, and on trial 2 only in the maze with ledges; thus, the presence of ledges differentially 
affected anxiolytic sensitivity on trials 1 and 2. The authors suggest "both types of plus-maze 
may be measuring the same type of anxiety with different sensitivities on trial one (e.g., 
generalised anxiety or fear of open spaces), different types of anxiety on trial 2 (without 
ledges--phobia/fear of heights; with ledges--not known)".  
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Neuropharmacology of the Two Trial Phenomena 
In an attempt to validate this model further, File et al., (1994) demonstrated that rats given one 
or two 5-minute trials in the elevated plus-maze had plasma corticosterone concentrations 
significantly higher than the home cage control group. Furthermore they observed that in rats 
given two plus-maze trials, corticosterone responses were significantly higher in the group 
given 10-minute rather than 5-minute trials, and that chlordiazepoxide habituation was not 
observed in the ten minute trial group. Moreover, previous experience of cat odour (1 week 
earlier) had no effect on the plasma corticosterone level, but did have an anxiogenic-like effect 
that could be detected by a decrease in the percentage of time spent on the open arms of the 
plus-maze. 
Chacur et al., (1999) observed that a receptor autoradiography of rat brains after a single drug-
free experience in the elevated plus-maze (with sacrifice post exposure) revealed that 
radiolabelled flunitrazepam binding was significantly elevated in several amygdaloid and 
hippocampal nuclei. Tritiated muscimol binding in adjacent sections was not significantly 
altered. The authors suggest that benzodiazepine receptors are able to alter binding affinity / 
receptor density very rapidly in response to anxiogenic conditions. Moreover, the findings that 
flunitrazepam binding is increased by maze exposure, is ostensibly the opposite to that which 
might be expected, and additionally, the rapidity with which a change in binding is detected is 
curious. It may be possible that affinity of individual benzodiazepine receptors, and not down-
regulation of receptors, is altered in response to the aversive stimulus. This would both 
increase the efficacy of the endogenous benzodiazepine species and increase observable 
binding affinity. An example of where this might also occur is with the various affinity states 
of the cholecystokinin2 receptor subtype (Huang et al., 1994)  
File and Gonzalez (1996) observed that direct administration of the 5-HT1A receptor agonist 8-
hydroxy-dipropylaminotetralin (8-OH-DPAT) into the Medial Raphe Nuclei had significant 
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anxiolytic effects in all three test situations examined (social interaction, plus-maze trials 1 and 
2). These anxiolytic effects were antagonised by the 5-HT1A receptor antagonist WAY-100635.  
Functional Neuroanatomy of the Two Trial Phenomena 
File et al., (1998) observed that rats that had received reversible bilateral lesions of the 
basolateral amygdala (by lidocaine injection) immediately after trial one responded with an 
anxiolytic response to chlordiazepoxide when tested forty-eight hours later on trial two. Those 
that received vehicle injections after trial 1, showed the usual lack of response to 
chlordiazepoxide on trial 2. The authors consequently propose that "the basolateral amygdala 
plays a crucial role in the consolidation of information that leads to the formation of a 
proposed phobia and subsequent insensitivity to benzodiazepines". 
In addition, rats receiving lidocaine infusions, into the dorsomedial hypothalamus immediately 
before trial 2, responded with an anxiolytic response to chlordiazepoxide. Those injected with 
control infusions into the dorsomedial hypothalamus showed the usual lack of response to 
chlordiazepoxide (5mg.kg-1, intraperitoneal). Since the lidocaine injections were without 
anxiolytic effects, the authors suggest that this region of the hypothalamus regulates the 
functional state of benzodiazepine receptors in other brain regions (File et al., 1999).  
Ouagazzal et al., (1999), examined the effects of a wide dose range of systemically 
administered (-)-nicotine on trials 1 and 2 in the plus-maze. Higher doses of nicotine had 
anxiogenic-like effects on both trials. Infusion of nicotine bilaterally into the dorsal 
hippocampus was without effect on trial one, but a dose of 1 microgram had an anxiolytic 
effect on trial two. In addition, in trial 1, lateral septal administration of nicotine has 
anxiogenic-like effects, while in trial two it has no effect (File et al., 2000). 
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A Motivational Deficit Underlying Two Trial Tolerance 
Pereira et al., (1999) examined whether this phenomenon of "one-trial tolerance" resulted from 
a motivational deficit on trial two. A hypothesis arises that whereas there is a motivational 
conflict on trial one in relation to the open arms (exploration drive versus natural fear of open 
spaces), accordingly, there is no "reason" for an animal to explore on trial two. A motivational 
conflict was introduced in this study on trial two by rendering the enclosed arms of the 
apparatus aversive on trial one. Upon entry into the closed arms, an aversive stimulus (hot air 
puff) was produced until the animal left the arm. On trial two, rats did not receive this aversive 
stimulation (extinction procedure). Chlordiazepoxide significantly increased open arm 
exploration indices on trial two in rats that had been submitted to aversive conditioning, but 
was ineffective in rats which had been exposed to a standard maze conditions on trial one. In 
addition, there was no difference in the open exploration on trial two between saline-treated rat 
groups. Furthermore, the aversive conditioning in trial one did not modify the number of total 
arm entries on trial two. The authors suggest that the anxiolytic effect of chlordiazepoxide in 
the elevated plus-maze depends on the presence of a motivational conflict situation. An 
attempt to elucidate this as an underlying mechanism was made in a study within this chapter. 
Shock Potentiated acoustic Startle 
The fear potentiated startle paradigm was first described by Brown et al., (1951). This 
groundbreaking study demonstrated that the magnitude of the startle reflex in response to an 
acoustic stimulus was potentiated when presented with a shock-paired stimulus. The fear 
conditioning trials provide a light cue serving as a conditioned stimulus thus signalling an 
incoming presentation of a footshock (the unconditioned stimulus). This model is a classic 
example of Pavlovian fear conditioning.  
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Face Validity 
From this and other studies, it is clear that the startle reflex is potentiated during 
experimentally induced anxiety (i.e.: fear-potentiated startle). In satisfying the face validity 
criteria for this model, it is also increased in various phobic anxiety disorders. Clinical studies 
have observed that stimuli previously associated with phobia are able to potentiate startle 
responses.  In a study by Grillon et al., (1993) the eye-blink component of the acoustic startle 
reflex was measured in a paradigm involving the anticipation of electric shocks in normal 
human subjects. The individual anxiety level related to anticipation of the shock was assessed 
using the State-Trait Anxiety Inventory. The magnitude of fear-potentiated startle was 
increased in the high-anxiety group when compared to the low-anxiety group. The time-course 
of startle modulation suggested a longer duration of anticipatory anxiety in the high-fear 
group. Trait anxiety, which was assessed with the trait portion of the STAI, did not relate to 
individual differences in either baseline or fear-potentiated startle (Grillon et al., 1993). 
Difficulties may arise in comparison of this model with phobia in the clinical condition 
specifically with regard to the nature of the aversive stimulus. 
Predictive Validity 
The history of study of the pharmacological nature of fear-potentiated startle has been fraught 
with questionable methodology and validity. In one of the earlier studies of the pharmacology 
of fear potentiated acoustic startle, Davis (1979) found that diazepam produced a dose-
dependent decrease of the potentiated startle effect (with a shock paired light stimulus). The 
effect was thought to be selective since the same doses did not depress baseline startle 
amplitude measured in non-conditioned apparatus naïve animals. In order to rule out whether 
diazepam exhibited state-dependent effects of learning during the acquisition trials, rats were 
trained under diazepam and were found to exhibit the same dose-dependent decrease in startle 
amplitude in the retention trial as those trained with saline. Therefore, Davis proposed that "the 
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primary effect of diazepam was to block expression of, rather than acquisition of fear, as 
measured by potentiated startle". State dependent effects on learning may arise from possible 
attentional deficits produced by any pharmacological intervention. These data however, fail to 
show whether or not diazepam is acting upon amnestic mechanisms and thus causing 
inhibition of memory eduction or whether exhibiting an anti-anxiety effect. The control study 
of state dependence failed to rule this out, whereby any alteration of the acquisition phase of 
the conditioning trials would be determined but possible effects on memory recall would be 
masked. Hence, studies utilising pharmacological manipulation of this model at the retention 
trial will undoubtedly remain somewhat equivocal in their conclusions.  
Using this perhaps flawed methodology it has been shown that a range of anxiolytic agents 
such as diazepam, midazolam, and flurazepam are able to produce dose dependant decreases in 
the level of fear potentiated startle (Davis, 1979; Hijzen and Slangen, 1989). Benzodiazepines 
have also been shown to exhibit an "anxiolytic" effect in inhibition of the potentiated startle 
amplitude without affecting the basal startle level of the acquisition session (Davis, 1993). In a 
study by Berg and Davis (1984) it was demonstrated that this inhibitory effect of diazepam on 
potentiated startle was attenuated by flumazenil, a benzodiazepine receptor antagonist, when 
startle was electrically initiated at the brainstem. Another study by Hijzen and Slangen (1989) 
using a benzodiazepine receptor inverse agonist showed an enhancement of the potentiated 
startle response.  
Following cocaine withdrawal, humans commonly experience an abstinence syndrome 
accompanied with high levels of anxiety. Chronic cocaine administration in rats produces 
lasting increases in conditioned fear, measured by fear-potentiated startle. Repeated cocaine 
pre-exposure can effect acoustic startle differently depending on whether fear conditioning 
occurred and whether cocaine was administered in the testing chamber (Gordon and Rosen 
1999). 
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Construct Validity 
A series of studies have indicated that the amygdaloid complex is necessary for acquisition and 
expression of conditioned fear and that an efferent amygdalofugal pathway to the primary 
startle circuit, at the level of the caudal pontine reticular formation, mediates the expression of 
conditioned fear (Fendt et al., 1996a). Pre- and post-training lesions of the midbrain central 
grey (CG) totally blocked the potentiation of the acoustic startle amplitude. This was not 
observed in sham-lesioned rats, indicating that CG lesions affect the expression of conditioned 
fear. Baseline startle amplitude was not influenced by CG lesions (Fendt et al., 1996b). 
Plus-Maze Exposure and Potentiation of Acoustic Startle 
It has been observed that significant negative correlations were observed among inbred mouse 
strains between the percent time spent in the open arms of the elevated maze and amplitude of 
an acoustic startle response (Trullas and Skolnick 1993).  Adamec et al., (1999a & 1999b) 
have shown that increases in anxiety-like behaviour in rats on the elevated plus-maze and in 
the acoustic startle paradigm, are produced by a single 5-min exposure to a cat and last for 3 
weeks afterwards. However, despite the aversive environment of the elevated plus-maze 
producing fear and apprehensive behaviour in rodents, the effects of plus-maze exposure on 
anxiety levels measured in other models of anxiety has been seldom, if at all, studied. My own 
study has shown that plus-maze exposure has indeed an effect on acoustic startle.  
Cholecystokinin and Fear Potentiated Startle 
To date only one study has explored the effects of cholecystokinin ligands upon fear 
potentiated startle. Josselyn et al., (1995) observed that pre-treatment with the CCK2 
antagonist L-365260 (0.1 -10.0 mg.kg-1, I.P.) did not affect baseline acoustic startle 
amplitudes, but dose-dependently decreased fear-potentiated startle. The present findings are 
consistent with the effects of CCK2 antagonists in other tests measuring anxiety in animals. 
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Materials and Methods 
Animals 
Male Sprague Dawley rats (Laboratory Animal Centre, National University of Singapore, 
Singapore), weighing 250-320g were housed in groups of five to seven and maintained with 
free access to food and water ad libitum, in an animal room for one week prior to 
experimentation. Room lights were on from 07:00 to 19.00 hours. The test room and housing 
block were maintained at a standard temperature throughout the experiments.   Animals were 
randomly assigned treatment groups using a simple computer program random number 
sequence generator (Random Number Generator V.1.0 by Colin Greengrass, 1998). Usage of 
this number listing is described in chapter two methodology. 
Test Room Conditions 
Animals were tested in each apparatus within a particular test room with constants of 
temperature at 25OC, lighting intensity and background white noise generation (at 70dB).  
Drugs 
A Cholecystokinin peptide antagonist, LY-288513 ([trans-N-(4-bromophenyl)-3-oxo-4, 5-
diphenyl-1-pyrazolidinecarboxamide]) at 10.0 mg/ml (kindly donated by Eli Lilly and 
Company, USA), chlordiazepoxide hydrochloride at 3.0mg/ml (A generous gift from Roche) 
and/or scopolamine hydrobromide at 0.15 mg/ml (Sigma, USA) were dissolved in 
dimethylsulphoxide (DMSO; Merck). Cholecystokinin peptide agonists, CCK-4 (Trp-Met-
Asp-Phe-NH2); CCK-8us (Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2; Biotechnology Centre, 
National University of Singapore) CCK-8s (Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2; 
American Peptide Company and Princeton Biomolecules) were dissolved in DMSO. The drugs 
or vehicle were administered by intraperitoneal injection in a volume of 1ml per kg body 
weight. Drugs were administered 30 minutes prior to testing. Cholecystokinin peptide was 
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stored under desiccation at -70oC. Cholecystokinin peptide solutions were prepared freshly 
each day approximately two hours prior to testing.  Powdered peptide was dissolved in DMSO 




With the exception of the plus-maze multiple exposure experiments, the protocol is identical to 
that described in chapter three, for one trial testing. 
Acoustic Startle Apparatus: 
A computer controlled auditory startle chamber was used (SR-LAB, San Diego Instruments 
Inc.). Further details of this apparatus are described in chapter two; methods and materials. 
Motion data was recorded via an interface assembly to an IBM computer with relevant 
software (San Diego Instruments, PSR2 Software program). Light levels within the chamber 
remained constant throughout the acquisition and retention procedures. The chamber was 
thoroughly cleaned with 70% ethanol between sessions and allowed to dry. The interval 
between the acoustic stimulus and peak amplitude of each startle reflex movement, and the 
peak amplitude itself were recorded. Behavioural experiments were performed between 14:00-
18:00hours. 
Shuttle Box Shock Chamber: 
A single compartment of a computer-controlled two-compartment shuttlebox (San Diego 
Instruments, Inc.) was used as a shock chamber. The Gemini II shuttle box is a two 
compartment acrylic chamber of dimensions: 53cm (width) x 53cm (height) x 32cm (depth) 
with a steel grid floor and a steel, computer controlled, sliding door between compartments. 
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Animals were placed in a lighted compartment (40-W bulb) with the main door closed. The 
scrambled sine-wave electric shock was delivered through the steel grid floor. The shock 
intensity is adjusted manually and calculated by the following formula: y = mx + b; where y = 
shock intensity (mV); m = slope (0.004); x = animal weight (g); and b = y-axis intercept (- 0.4) 
Experimental Procedure 
Experiment 4.1: Two Trial Elevated Plus-maze 
Animals were administered, 30 minutes prior to maze exposure, a single intraperitoneal 
injection either of; DMSO, chlordiazepoxide (3.0mg.kg-1) or LY-288513 (10.0mg.kg-1) and 
underwent near identical handling procedures. Animals were then exposed to the elevated 
plus-maze for either a five-minute or a ten-minute session. A subgroup of rats administered 
with DMSO were then injected with 0.3mg.kg-1 Scopolamine Hydrochloride intraperitoneally 
immediately after a five minute exposure to the plus-maze. Treatment groups defined are 
represented in table 4.1 
Table 4.1 Protocol Group Classification Two Trial Elevated Plus-maze (Experiment 1) 
Drug Administration (dose in mg.kg-1) 








1 DMSO    
2 chlordiazepoxide (3.0)    
3 LY-288513 (3.0)    
4 DMSO   DMSO 
5 DMSO   chlordiazepoxide (3.0) 
6 DMSO   LY-288513 (10.0) 
7  DMSO  DMSO 
8  DMSO  chlordiazepoxide (3.0) 
9  DMSO  LY-288513 (10.0) 
10 DMSO  Scopolamine (0.3) DMSO 
11 DMSO  Scopolamine (0.3) chlordiazepoxide (3.0) 
12 DMSO  Scopolamine (0.3) LY-288513 (10.0) 
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Twenty-four hours later the animals were again exposed to the plus-maze. 30 minutes prior to 
this session animals were administered either DMSO, chlordiazepoxide at 3.0mg.kg-1 or LY-
288513 at 10.0mg.kg-1. This further group division is represented in table 4.1 
Experiment 4.2: Prevention of Development of Chlordiazepoxide Insensitivity within the 
Two Trial Elevated Plus-Maze by LY-288513  
Animals were exposed to the elevated plus-maze for a five-minute test session. 30 minutes 
prior to this session the animals were administered a single intraperitoneal injection of DMSO 
and underwent near identical handling procedures. The rats were subdivided and randomly 
assigned into two groups, one administered DMSO post-exposure and the other administered 
10.0mg.kg-1 LY-288513 immediately post- exposure. Twenty-four hours later the animals 
were again exposed to the plus-maze after injection of chlordiazepoxide at 3.0mg.kg-1 (30 
minutes before the session). 
Experiment 4.3: Elevated Plus-maze Reward Manipulation 
Experimental manipulations of the elevated plus-maze were carried out in hope of introducing 
a sweetened foodstuff as an incentive onto the open arms.  
4.3.1: Rats after one week fed ad libitum with standard maize pellets, were supplied either a 
fixed number of sugar lumps or a sweetened maize cereal coated in a honey, sugar and 
cinnamon paste. The time of consumption was measured in order to determine both preference 
for each type and ease of consumption (given the relatively short time of the plus-maze 
session). The maize cereal was consumed within a home cage of five rats more rapidly than 
sugar lumps. Therefore, the cereal was chosen as a food incentive for use upon the elevated 
plus-maze. Both food types were consumed eagerly within home cages.  
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4.3.2: Rats after one week plus feeding ad libitum standard maize pellets, were tested on the 
elevated plus-maze with six cereal pellets placed on each open arm. The placement of these 
pellets was such that one was placed at a fastening screw position extending about 15cm from 
the central platform, and the remaining five were placed in a floret pattern surrounding another 
fastening screw 15cm from the end. It was hoped that the first pellet, within distance of any 
stretch posture from the central platform would provide an initial incentive, whilst the outlying 
pellets would bring the animal onto the open arm entirely. The animals failed to consume any 
pellets, despite entry onto the open arm. The rats would sniff and then ignore any pellets. 
4.3.3: Rats, after one-week food deprivation, were tested on the elevated plus-maze with six 
cereal pellets placed on each open arm. Food deprivation encompassed a schedule of 80% 
normal chow consumption, calculated by measuring weight of food consumed per each cage 
housing five rats in 24 hours. These cages were then provided with 80% of this weight in chow 
each day for one week. Water was provided ad libitum. Sixteen rats were tested on the plus-
maze yet only three pellets were consumed by three individual rats (one pellet each). 
Moreover, these were the pellets lying proximal to the central platform, and were carried by 
each rat to the central platform before consumption. These animals were tested again, 24 hours 
later on the elevated plus-maze, as described in experiment one, with either DMSO or 
chlordiazepoxide (3.0mg.kg-1) administered intraperitoneally 30 minutes pre-trial. 
4.3.4: Rats underwent the same protocol as in experiment 4.3.3 (above) except that the 
experimenter handled them for one minute immediately prior to feeding time for one week 
before the plus-maze exposure. These animals failed to consume any pellets within the plus-
maze. 
4.3.5: Rats underwent the same protocol as in experimental 4.3.3 (above) except that they were 
allowed a 30-minute exposure to the plus-maze. A similar pellet consumption was observed to 
that of a five-minute session. 
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Experiment 4.4: Elevated Plus-maze Induced Fear Potentiated Startle  
Several different protocols were carried out in order to ascertain whether elevated plus-maze 
exposure exerts a "fear potentiated startle" like activity.  Animals naïve to the plus-maze or 
those immediately following either a first or second exposure, were placed in the acoustic 
startle chamber. Animals underwent acclimatisation for three minutes in the presence of 
constant white noise (70dB).  Following this period each animal was immediately exposed to 
twenty-five 100-millisecond bursts of white noise at 120dB punctuated with an eight second 
period of 70dB white noise between each burst. The peak amplitude of the startle response 
measure was taken. This procedure measures auditory startle habituation over the twenty-five 
noise burst stimuli that are plotted on a chart versus the sequential 120dB noise burst. Program 
listings are recorded in appendix C-2.  
Table 4.2 Protocol Group Classification Two Trial Elevated Plus-maze exposure effects on acoustic 
startle (Experiment 4) 









1 Saline    
2  Saline   
3 DMSO    
4  DMSO   
5   DMSO  
6    DMSO 
7 chlordiazepoxide (3.0)    
8  chlordiazepoxide (3.0   
9   chlordiazepoxide (3.0)  
10    chlordiazepoxide (3.0) 
11  LY-288513 (10.0)   
12   LY-288513 (10.0)  
13    LY-288513 (10.0) 
Rats were randomly assigned each drug treatment group from within each group housed cage. 
Number randomisation was achieved via use of the aforementioned computer program. All 
animals were administered drugs or vehicle 35 minutes prior to acoustic startle sessions. The 
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thirty-five minute period was chosen in order to emulate a profile whereby animals are tested 
post plus-maze. Thirteen different protocols were examined concurrently and are summarised 
in table 4.2.  
Experiment 4.5: Shock induced Fear Potentiated Startle 
4.5.1: Apparatus naïve animals were placed in the acoustic startle chamber and underwent 
identical procedures to that described for experiment 4.4. Immediately after the acoustic startle 
trial the animal was placed in a single shuttle box chamber (as described in chapter 5). The 
animal was placed in a lit compartment and left for a ten second adaptation period. 
Subsequently a scrambled sine wave shock was delivered to the cage floor continuously for a 
period of thirty seconds. The shock intensity to be delivered is calculated by the following 
formula; y = mx + b; where y = shock intensity (milliamps); m = slope (0.004); x = animal 
weight (g); and b = y-axis intercept (- 0.4). This calculation allows a pseudo dosing effect of 
shock intensity with regard to animal weight. Immediately after this shock period the animal 
was removed and injected intraperitoneally under a series of protocols detailed below. In order 
to maintain experimental controls, the animals post-shock were placed in a holding cage in 
order to isolate them from the other animals prior to experimentation. It is observed that 
shocked animals exhibit high levels of aggression immediately afterwards. Only when all the 
animals within a home cage had been tested were they placed back into their home cages and 
immediately returned to the animal housing block. Seventy-two hours later, animals underwent 
an identical acoustic startle procedure. This test attempted to measure a conditioning response 
whereby the startle apparatus is associated with an impending shock. An index of retention 
startle amplitude divided by acquisition startle amplitude was calculated. A series of 
experiments carried out are detailed below. 
4.5.2:  An experiment was performed whereby an animal post acoustic startle testing on trial 
one was either submitted to electric shock as per the aforementioned protocol, or was placed in 
THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS OF CHOLECYSTOKININ 
 145
the shuttle box chamber for the 40-second period without administration of electric shock. 
Subsequently, immediately following shuttle box exposure the animals were administered 
DMSO intraperitoneally and returned to holding cages. Seventy-two hours later the two groups 
were retested for acoustic startle. The acoustic startle index was calculated. 
4.5.3: A repeat of experiment 4.5.1 was performed with the introduction of scopolamine 
hydrochloride (0.3mg.kg-1) administration. Four groups were tested:  DMSO administered post 
exposure without shock; DMSO administered post shock; Scopolamine administered post 
exposure without shock; Scopolamine administered post shock. 
4.5.4: Effects of a dose range of CCK-4, 0.0125 to 0.1mg.kg-1, on shock potentiated acoustic 
startle. Animals post acoustic startle testing on trial one were submitted to electric shock as per 
the aforementioned protocol. Immediately following shock exposure, the animals were 
administered either DMSO or CCK-4 (specified dose range) intraperitoneally and returned to 
holding cages under the aforementioned schedule. Seventy-two hours later the two groups 
were retested for acoustic startle. An acoustic startle index was calculated. 
4.5.5: Effects of a dose range of CCK-8us, 0.001 to 0.1mg.kg-1, on shock potentiated acoustic 
startle. An identical procedure to that in experiment 4.5.4 was performed.  
4.5.6: Effects of a dose range of CCK-8s, 0.0005 to 0.01mg.kg-1, on shock potentiated acoustic 
startle. An identical procedure to that in experiment 4.5.4 was performed. 
Statistical Analysis 
Statistical analysis was performed using statistical software (SPSS V9.0, SPSS inc. USA). The 
data were subjected to a one-way analysis of variance (ANOVA), followed by a Bonferroni 
post hoc analysis of group differences. Probability (p <0.05) was considered statistically 
significant.  
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Results and Data 
Experiment 4.1 
Figure 4.1.1 – Percentage Time Spent 
Time Spent on Open Arm:  
Administration of Chlordiazepoxide,  at 3.0 mg.kg-1 and LY-288513, at 10.0 mg.kg-1, produced 
a statistically significant increase in time spent on open arms of naïve rats compared to the 
DMSO vehicle (group 1); chlordiazepoxide (group 2); 3.0mg.kg-1, (F11,90=13.66, p<0.01); LY-
288513 (group 3); 10.0mg.kg-1, (F11,90=13.66, p<0.05). However, both drugs when 
administered to rats with prior maze experience were unable to exact these effects in a 
subsequent plus-maze trial; groups 5 and 6 respectively. Administration of scopolamine, at 
0.3mg.kg-1, immediately following first plus-maze exposure, was able to restore the significant 
increases in percentage time spent in the open arm by chlordiazepoxide (group 11) in trial two, 
3.0 mg.kg-1  (F11,90=13.66, p<0.01) but not for LY-288513 groups (group 12).  
Group comparison between each drug treatment versus plus-maze exposure protocol, yielded 
the following differences with regard to percentage time spent on the open arms. With DMSO 
administered rats it was observed that prior plus-maze exposure exerted inhibition of open arm 
exploration, although failing significance. Significant differences within the chlordiazepoxide-
administered protocols were observed. Chlordiazepoxide in trial one exerted a significant 
increase in open arm exploratory behaviour but failed to produce any changes in plus-maze 
trial two; group two versus groups five and eight (F11,90=13.66, p<0.001). Administration of 
scopolamine immediately post-trial one, reinstated chlordiazepoxide sensitivity within trial 
two, (increased exploratory activity in the open arm). 
An increase in open arm exploratory behaviour observed for LY-288513 in trial one was not 
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observed in trial two; significant difference between group three and groups six and nine 
(F11,90=13.66, p<0.001). Administration of scopolamine immediately post trial one failed to 
reinstate an increased exploratory activity in the open arms produced by LY-288513 upon 
maze naïve rats; group three versus group twelve (F11,90=13.66, p<0.001). 
Time Spent on the Central Platform:  
No significant differences were observed between either drug groups or between protocols. 
Time Spent on the Closed Arms: 
Significant increases in closed arm exploratory behaviour (percentage time spent) were 
observed between the groups (5 & 8) administered chlordiazepoxide (figure 4.1.1) on trial two 
compared to the group administered chlordiazepoxide on trial one (maze naïve rats; 
F11,90=4.26, p<0.05). Closed arm exploratory behaviour was significantly increased in group 12 
(administered LY-288513 on trial two with scopolamine administration) compared to group 3 
(LY-288513 in maze naïve rats; F11,90=4.26, p<0.05).  
Scopolamine administration was able to reinstate chlordiazepoxide activity at trial two (group 
five versus eleven; F11,90=13.66, p<0.05). 
Figure 4.1.2 - Number of Arm Entries 
Open Arm Entries: 
Administration of Chlordiazepoxide,  at 3.0 mg.kg-1 and LY-288513, at 10.0 mg.kg-1, produced 
a statistically significant increase in number of entries into the open arms compared to the 
DMSO control, with an initial exposure of naïve rats to the elevated plus-maze (Figure 4.1.2); 
chlordiazepoxide; 3.0mg.kg-1, (F11,90=9.34, p<0.01); LY-288513; 10.0mg.kg-1, (F11,90=9.34, 
p<0.01). However, both drugs when administered in a subsequent plus-maze trial after prior 
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maze exposure, (either five or ten minutes), were unable to exact these effects. Administration 
of scopolamine, at 0.3mg.kg-1, immediately following first plus-maze exposure (5 minute 
trial), was not able to restore the significant increases in number of entries in the open arm by 
chlordiazepoxide, 3.0 mg.kg-1 (F11,90=9.34, p<0.001) that was observed for percentage time 
spent. DMSO vehicle showed no differences between protocols except in a trend observed, 
whereby plus-maze exposure exerted inhibition of number of open arm entries. Significant 
differences were observed between chlordiazepoxide control (group 2), versus 
chlordiazepoxide on trial two (Groups 5 & 8; F11,90=9.34, p<0.001). Administration of 
scopolamine immediately post trial one (group 11) failed to reinstate the increased open arm 
entries produced by chlordiazepoxide within trial one (F11,90=9.34, p<0.001). 
An increase in open arm exploratory behaviour produced by LY-288513 was not observed in 
trial two (group 3 versus group 6; F11,90=9.34, p<0.001) and (group 3 versus group 9; 
F11,90=9.34, p<0.01). Administration of scopolamine failed to reinstate, increased exploratory 
activity in the open arms (group 3 versus group 12; F11,90=9.34, p<0.001).  
Closed Arm Entries: 
Plus-maze exposure exerted inhibition of open arm exploration (number of open arm entries) 
in DMSO groups; group 1 versus group 4 (F11,90=7.67, p<0.001), but not with group 7. 
Scopolamine administration exerted no effect on closed arm entries (group 1 versus group 10; 
F11,90=7.67, p<0.001). Number of closed arm entries were  significantly decreased upon 
exposure of chlordiazepoxide administered groups; (group 1 versus group 5 and versus group 
8; F11,90=7.67, p<0.001). Scopolamine failed to reinstate increased closed arm entries produced 
by chlordiazepoxide within trial one (group 1 versus group 11; F11,90=7.67, p<0.001). Number 
of closed arm entries were significantly decreased upon exposure of LY-288513 administered 
groups; (group 1 versus group 6; F11,90=7.67, p<0.001). Scopolamine failed to reinstate 
increased closed arm entries produced by LY-288513 within trial one (group 1 versus group 
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12; F11,90=7.67, p<0.001). Chlordiazepoxide showed no significant differences between 
exposure protocols, except in a trend observed (p=0.054), comparing group 2 with group 8. 
LY-288513 showed no differences between protocols, in number of closed arm entries. 
No significant differences were observed for number of closed arm entries with scopolamine 
administration .  
Total Arm Entries: 
No differences between drug groups were observed with regard to total number of arm entries. 
Rats pre-exposed to a five minute plus-maze session showed a significant decrease in total arm 
entries on trial two versus total entries observed in maze naïve rats under the same drug 
protocol; DMSO (F11,90=9.09, p<0.001), chlordiazepoxide (F11,90=9.09, p<0.001), LY-288513 
(F11,90=9.09, p<0.01). Administration of scopolamine produced a significant decrease in total 
arm entries on trial two compared to total entries observed in maze naïve rats under the same 
drug protocol; DMSO (F11,90=9.09, p<0.001), chlordiazepoxide (F11,90=9.09, p<0.001), LY-
288513 (F11,90=9.09, p<0.01). Significant differences within drug groups between rats pre-
exposed to a five minute plus-maze session with administration of scopolamine following 
immediately, versus those pre-exposed to a five minute plus-maze session without 
scopolamine were not observed. 
Experiment 4.2: 
No statistically significant differences were observed (figures 4.2.1 and 4.2.2), except for a 
trend, narrowly missing statistical significance. Percentage open arm time in trial two for the 
LY-288513 post-exposure administered group was increased with chlordiazepoxide 
administration when compared to a group undergoing the same protocol less LY-288513 post-
exposure administration (F1,14=4.43, p<0.054). 
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Experiment 4.3: 
No statistically significant differences were observed in any of the sampled variables. 
Experiment 4.4: 
No significant differences or any trends were observed for saline versus DMSO in either maze 
naïve or in the single maze exposure group (figure 4.4.1). Chlordiazepoxide (3.0mg.kg-1), in 
maze naïve rats, (figure 4.4.1 and 4.4.6) produces a significant decrease in startle amplitudes 
compared to DMSO in maze naïve rats; F12,106=7.82, p<0.05 (Trial block 1).  This is no longer 
observed with maze exposure. LY-288513 does not exhibit any significant effects in maze 
naïve rats upon startle amplitudes.  
No significant differences are observed between saline administered groups naïve to the plus-
maze and post five-minute exposure (figure 4.4.2).   
A second exposure to the elevated plus-maze, DMSO administered, produced a statistically 
significant increase in startle amplitudes compared to the plus-maze naïve DMSO control 
(Figure  4.4.3); F12,106=7.82, p<0.05 (Trial block 1).  
Analysis of differences between chlordiazepoxide administered protocols (figure 4.4.4), 
demonstrates a significant increase in startle amplitudes after the second plus-maze exposure 
when compared to maze naïve chlordiazepoxide administered rats; F12,106=7.82, p<0.001 (Trial 
block 1). This is also observed when compared to amplitudes post first exposure; F12,106=7.82, 
p<0.05 (Trial block 1) although this is of questionable value given the latter measures drugged 
exposure. 
Analysis of differences between LY-288513 administered protocols (figure 4.4.5), also 
demonstrates a significant increase in startle amplitudes after the second plus-maze exposure 
when compared to amplitudes 24 hours post first exposure in LY-288513 administered rats; 
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F12,106=7.82, p<0.05 (Trial block 1). 
No significant differences are observed between drug treatments for animals post-initial 
exposure to the plus-maze. Chlordiazepoxide exhibits a trend towards a decrease in startle 
amplitudes when compared to DMSO but this misses a significant analysis. 
Experiment 4.5 
 A series of preliminary validation experiments were conducted. Effects in rats of electric 
shock induction (post conditioning trial) on a retention index of; acoustic startle peak 
amplitude in the retention session divided by that in the conditioning (acquisition) session, for 
individual rats, over twenty-five trials. Dimethylsulphoxide (DMSO) was administered post 
acquisition session as control. Five consecutive trial blocks are shown for each protocol. These 
each represent the means of five individual retention index values for response to acoustic 
stimuli. Induction of shock produced a statistically significant increase in retention index 
compared to the nonshocked control (Figure 4.5.1); Shocked group; F1,13=49.03, p<0.001 
(Trial block 1); F1,13=7.36, p<0.05 (Trial block 2), F1,13=10.18; p<0.01 (Trial block 4).  
 Effects in rats of scopolamine (0.3mg.kg-1) on the aforementioned retention index with both 
shocked and nonshocked rats showed significant differences (figure 4.5.2). Scopolamine, 
administered post-shock was shown to significantly decrease the index values compared to 
DMSO administered post-shock, F3,30=14:00, p<0.001 (Trial block 1), F3,30=4.05, p<0.05 (Trial 
block 2). The nonshocked DMSO control group showed a significant decrease in index value 
from the shocked DMSO group, F3,30=14:00, p<0.001 (Trial block 1), F3,30=4.05, p<0.05 (Trial 
block 2), F3,30=4.06, p<0.05 (Trial block 4). The nonshocked scopolamine group also showed 
significant decreases in index value from the DMSO shocked group,  F3,30=14:00, p<0.001 
(Trial block 1 only), but did not when compared to the scopolamine shocked group nor the 
DMSO nonshocked group. Perhaps significantly, index values for the scopolamine-unshocked 
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group approached a mean of 1 (with <9.6% standard error). 
 Administration of the cholecystokinin form; CCK-4 (figure 4.5.3), at doses, 0.0125, 0.025, 
0.05 and 0.1 mg.kg-1) failed to produced any significant changes in index values when 
compared to DMSO (control) although a decrease in index value at 0.0125 mg.kg-1 narrowly 
missed significance in trial block 1, F4,34=2.51, p=0.052.  
 CCK-8us at doses, 0.001, 0.005, 0.01, 0.05 and 0.1 mg.kg-1 (figure 4.5.4) failed to produce 
any significant changes in index value or any trends. 
CCK-8s at doses, 0.0005, 0.001, 0.005 and 0.01 mg.kg-1, (figure 4.5.5) also failed to produce 
any significant changes in index value but showed a trend towards an increase in index value 
at 0.005 mg.kg-1, F4,32=2.33, p=0.074.  
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 FIG 4.1.1.: Effects on behaviour within the elevated plus-maze of a prior pre-exposure to the maze. Group numbers correspond with protocols detailed in table 4.1. Measures 
of time spent in specific areas of the maze as a percentage of total trial duration are shown. Lightly shaded portions, bottommost section, correspond to percentage time spent 
in open arms; Grey shaded portions, middle section, correspond to percentage time spent in the central platform area; Dark grey shaded portions, uppermost section, 
correspond to percentage time spent in the closed arms. Results are presented as mean with light bars representing standard error of the mean (SEM). SEM bars atop the open 
arm time section represent SEM for percentage time spent in the open arm. SEM bars beneath the closed arm time section represent SEM for percentage time spent in the 
closed arm. SEM bars for percentage time spent on the central platform not shown. Significant differences from the each specific drug administered to naïve rats are compared 
with the same drugs administered post-trial; ***p<0.001 for DMSO, †p<0.05, †††p<0.001 for chlordiazepoxide; ‡p<0.05, ‡‡p<0.01, ‡‡‡p<0.001 for (Bonferroni post hoc 
analysis after significant one-way ANOVA). 
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FIG 4.1.2: Effects on behaviour within the elevated plus-maze of a prior pre-exposure to the maze. Group numbers correspond with protocols detailed in table 4.1. Measures 
of numbers of entries into specific areas of the maze are shown. Lightly shaded portions, lower section, correspond to numbers of entries into open arms; dark grey shaded 
portions, upper section, correspond to numbers of entries into the closed arms. Results are presented as mean with light bars representing standard error of the mean (SEM). 
SEM bars atop the open arm entries section projecting downward represent SEM for number of open arm entries. SEM bars atop the open arm entries section projecting 
upwards represent SEM for number of entries into the closed arm.  SEM bars atop the closed arm entries section projecting both upward and downward for total number of 
entries into both arms. Significant differences from the each specific drug administered to naïve rats are compared with the same drugs administered post-trial; ***p<0.001 for 
DMSO, †p<0.05, †††p<0.001 for chlordiazepoxide; ‡p<0.05, ‡‡p<0.01, ‡‡‡p<0.001 (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG 4.2.1: Effects on behaviour within the 
elevated plus-maze of a prior pre-exposure 
to the maze. Protocol groups represented are 
as follows: chlordiazepoxide [CDP],  , 
(3.0mg.kg-1) pre-trial at second exposure 
after a five minute pre-exposure; 
chlordiazepoxide pre-trial at second 
exposure after a five minute pre-exposure 
followed immediately with administration 
of LY-288513 (10.0mg.kg-1). Measures of 
time spent in specific areas of the maze as a 
percentage of total trial duration are shown. 
Lightly shaded portions, bottommost 
section, correspond to percentage time spent 
in open arms; Lighter grey shaded portions, 
middle section, correspond to percentage 
time spent in the central platform area; Dark 
grey shaded portions, uppermost section, 
corresponds to percentage time spent in the 
closed arms. Results are presented as mean 
with light bars representing standard error 
of the mean (SEM). SEM bars atop the open 
arm time section represent SEM for 
percentage time spent in the open arm. SEM 
bars beneath the closed arm time section 
represent SEM for percentage time spent in 
the closed arm. Significant differences from 
the chlordiazepoxide pre-trial two group 
were not found. 
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FIG 4.2.2: Effects on behaviour 
within the elevated plus-maze of a 
prior pre-exposure to the maze. 
Protocol groups represented are as 
follows: chlordiazepoxide [CDP], 
(3.0mg.kg-1) pre-trial at second 
exposure after a five minute pre-
exposure; chlordiazepoxide pre-
trial at second exposure after a five 
minute pre-exposure followed 
immediately with administration of 
LY-288513 (10.0mg.kg-1). 
Measures of arm entries within the 
maze are shown. Lightly shaded 
portions (bottommost section) 
correspond to number of entries 
into the open arms; dark grey 
shaded portions (uppermost 
section) correspond to number of 
entries into the closed arms. The 
results are presented as mean with 
light bars representing standard 
error of the mean (SEM). SEM bars 
atop the open arm time section 
represent SEM for percentage time 
spent in the open arm. SEM bars 
beneath the closed arm time section 
represent SEM for percentage time 
spent in the closed arm. Significant 
differences from the 
chlordiazepoxide pre-trial two 
group were not found. 
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FIG 4.3.1: Effects on behaviour within the 
elevated plus-maze of a prior pre-
exposure to the maze. Two distinct groups 
are represented are as follows: 
chlordiazepoxide, [CDP], (3.0mg.kg-1) 
pre-trial at second exposure after a five 
minute pre-exposure to a clear plus-maze; 
chlordiazepoxide, (3.0mg.kg-1) pre-trial at 
second exposure after a five minute pre-
exposure to a plus-maze containing a food 
incentive. Measures of time spent in 
specific areas of the maze as a percentage 
of total trial duration are shown. Lightly 
shaded portions, bottommost section, 
correspond to percentage time spent in 
open arms; Lighter grey shaded portions, 
middle section, correspond to percentage 
time spent in the central platform area; 
Dark grey shaded portions, uppermost 
section, corresponds to percentage time 
spent in the closed arms. Results are 
presented as mean with light bars 
representing standard error of the mean 
(SEM). SEM bars atop the open arm time 
section represent SEM for percentage time 
spent in the open arm. SEM bars beneath 
the closed arm time section represent 
SEM for percentage time spent in the 
closed arm.  No significant differences 
from the chlordiazepoxide pre-trial two 
group after exposure to a clear plus-maze 
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FIG 4.4.1: Startle amplitudes are shown for animals either naïve to the plus-maze (groups 1, 3 and 7), following an initial exposure to the plus-maze (groups 2, 4, 8, 11), 
twenty four hours after initial plus-maze exposure (groups 5, 9, and 12), and following a second plus exposure; twenty-four hours after the first (groups 6, 10, 13). Animals 
were administered either; saline (groups 1 and 2), DMSO (groups 3 to 6), chlordiazepoxide [CDP] at 3.0mg.kg-1 (groups 7 to 10) or LY-288513 at 10.0mg.kg-1 (11 to 13) 
prior to acoustic startle sessions. The effects of these group protocols  (summarised in table 4.2) on acoustic startle peak amplitude over twenty-five trials are shown. Five 
consecutive trial blocks are shown for each treatment. These each represent the means of five individual responses to acoustic stimuli (results presented as mean with SEM). 
Consecutive trial blocks are represented from left to right and with increased shading. Significant differences from the plus-maze naïve DMSO group (3) are shown; *p<0.05; 
(Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG 4.4.2: Startle 
amplitudes are shown 
for vehicle -
administered animals 
either naïve to the plus-
maze or following an 
initial exposure to the 
plus-maze. The effects 
of plus-maze exposure 
on acoustic startle peak 
amplitude over twenty-
five trials are shown. 
Five consecutive trial 
blocks are shown for 
each treatment. These 
each represent the 
means of five 
individual responses to 
acoustic stimuli (results 
presented as mean with 
SEM). Consecutive 
trial blocks are 
represented from left to 
right and with increased 
shading. No significant 
differences from the 
plus-maze naïve saline 
group (3) are observed 













































IG 4.4.3: Startle amplitudes are 
own for animals either naïve 
F
sh
to the plus-maze, following an 
initial exposure to the plus-
maze, twenty four hours after 
initial plus-maze exposure and 
following a second plus-maze 
exposure; twenty-four hours 
after the first. Animals were 
administered DMSO prior to 
acoustic startle sessions. The 
effects of these group protocols   
on acoustic startle peak 
amplitude over twenty-five trials 
are shown. Five consecutive trial 
blocks are shown for each 
treatment. These each represent 
the means of five individual 
responses to acoustic stimuli 
(results presented as mean with 
SEM). Consecutive trial blocks 
are represented from left to right 
and with increased shading. 
Significant differences from the 
plus-maze naïve DMSO group 
(3) are shown; *p<0.05, 
(Bonferroni post hoc analysis 
after significant one-way 
ANOVA). 
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maze, following an initial exposure to 
the plus-maze, twenty four hours after 
initial plus-maze exposure and 
following a second plus-maze 
exposure; twenty-four hours after the 
first. Animals were administered 
chlordiazepoxide [CDP] (3.0mg.kg-1) 
prior to acoustic startle sessions. The 
effects of these group protocols on 
acoustic startle peak amplitude over 
twenty-five trials are shown. Five 
consecutive trial blocks are shown for 
each treatment. These each represent 
the means of five individual responses 
to acoustic stimuli (results presented as 
mean with SEM). Consecutive trial 
blocks are represented from left to right 
and with increased shading. Significant 
differences from the plus-maze naïve 
chlordiazepoxide group (3) are shown, 
***p<0.001 (Bonferroni post hoc 
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FIG 4.4.5: Startle amplit-udes are shown for animals either following an initial exposure to the plus-maze, twenty four hours after initial plus-maze exposure and following a 
second plus-maze expos-ure; twenty-four hours after the first. Animals were admin-istered LY-288513 (10.0mg.kg-1) prior to acoustic startle sessions. The effects of these 
group protocols on acoustic startle peak amplitude over twenty-five trials are shown. Five consecutive trial blocks are shown for each treatment. These each represent the 
means of five individual responses to acoustic stim-uli (results presented as mean with SEM). Consec-utive trial blocks are represented from left to right and with increased 
shading. Signif-icant differences from the post first exposure LY-288513 group (3) are shown; *p<0.05, (Bonferr-oni post hoc analysis after significant one-way ANOVA). 
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FIG 4.5.1: Effects in rats of electric shock induction (post conditioning trial) versus non-shocked exposure to the shock chamber on a retention index of; acoustic startle peak 
amplitude in retention session divided by that in conditioning (acquisition) session, for individual rats, over twenty-five trials versus DMSO administered post exposure. Five 
consecutive trial blocks are shown for each protocol. These each represent the means of five individual retention index values for response to acoustic stimuli (results 
presented as mean with SEM). Consecutive trial blocks are represented from left to right and with increasingly darkened shading. Significant differences from the non-
shocked group are shown; *p<0.05, **p<0.01, ***p<0.001 (Bonferroni post hoc analysis after significant one-way ANOVA).   
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FIG 4.5.2: Effects in rats of 
electric shock induction (post 
conditioning trial) on a 
retention index of; acoustic 
startle peak amplitude in 
retention session divided by 
that in conditioning 
(acquisition) session, for 
individual rats, over twenty-
five trials versus scopolamine 
(0.3mg.kg-1) administered post 
shock. Five consecutive trial 
blocks are shown for each 
protocol. These each represent 
the means of five individual 
retention index values for 
response to acoustic stimuli 
(results presented as mean 
with SEM). Consecutive trial 
blocks are represented from 
left to right and with 
increasingly darkened 
shading. Significant 
differences from the DMSO 
shocked group are shown; 
*p<0.05, **p<0.01, 
***p<0.001 (Bonferroni post 
hoc analysis after significant 
one-way ANOVA).   
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FIG. 4.5.3: Effects in rats of a range of doses (in mg kg-1) of CCK-4 with DMSO vehicle, on a retention index of; acoustic startle peak amplitude in retention session divided 
by that in conditioning (acquisition) session, for individual rats, over twenty-five trials, versus the effect of DMSO alone; drugs administered post shock. Five consecutive 
trial blocks are shown for each protocol. These each represent the means of five individual retention index values for response to acoustic stimuli (results presented as mean 
with SEM). Consecutive trial blocks are represented from left to right and with increasingly darkened shading. Significant differences from the DMSO group were not 
observed. (Bonferroni post hoc analysis after one-way ANOVA).  
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FIG. 4.5.4: Effects in rats of a range of doses (in mg kg-1) of CCK-8us with DMSO vehicle, on a retention index of; acoustic startle peak amplitude in retention session 
divided by that in conditioning (acquisition) session, for individual rats, over twenty-five trials, versus the effect of DMSO alone; drugs administered post shock. Five 
consecutive trial blocks are shown for each protocol. These each represent the means of five individual retention index values for response to acoustic stimuli (results 
presented as mean with SEM). Consecutive trial blocks are represented from left to right and with increasingly darkened shading. Significant differences from the DMSO 
group were not observed. (Bonferroni post hoc analysis after one-way ANOVA). 
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FIG. 4.5.5: Effects in rats of a range of doses (in mg kg-1) of CCK-8s with DMSO vehicle, on a retention index of; acoustic startle peak amplitude in retention session divided 
by that in conditioning (acquisition) session, for individual rats, over twenty-five trials, versus the effect of DMSO alone; drugs administered post shock. Five consecutive 
trial blocks are shown for each protocol. These each represent the means of five individual retention index values for response to acoustic stimuli (results presented as mean 
with SEM). Consecutive trial blocks are represented from left to right and with increasingly darkened shading. Significant differences from the DMSO group were not 
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Discussion 
Chlordiazepoxide, at 3.0mg.kg-1 was able to produce a statistically significant increase in time 
spent on open arms compared to the DMSO control. This is a commonly reported activity for 
major benzodiazepines.  
Previously I have shown that LY-288513 has some anxiolytic activity at high doses within the 
plus-maze (see chapter 3 - unconditioned fear). The dose of 10mg.kg-1 was chosen in the 
present study because of the stability of its' anxiolytic property. In confirmation of the previous 
study, LY-288513 at the prescribed dose produced a significant increase in both percentage 
time spent within and entries into the open arms. These are proposed to be measures of 
anxiolytic-like behaviour within the maze.  
Both drugs when administered in a subsequent plus-maze trial after the initial maze exposure, 
with the initial exposure either five or ten minutes in duration, were unable to produce these 
"anxiolytic" effects. It has been observed in previous studies that chlordiazepoxide is no longer 
active in subsequent trials after an initial exposure to the plus-maze of two or more minutes 
(Lister, 1987; File, 1990; File et al., 1990). This is however a first report of LY-288513, a 
cholecystokinin2 receptor specific antagonist, having similar effects.  
Administration of scopolamine following the initial plus-maze exposure was able to restore the 
significant increases in percentage time spent in the open arm by chlordiazepoxide but not LY-
288513 or control groups. Scopolamine appears therefore to restore sensitivity to 
chlordiazepoxide but not to LY-288513. This leads to an inference that the site at which 
benzodiazepine driven anxiolysis is gated, lies upstream of a site gating cholecystokinin gated 
anxiolysis within the neuronal organisation. According to this hypothesis, this upstream site 
would be in connection to neuronal organisations influenced by the cholinergic system, 
particularly muscarinic antagonists, whereas the downstream site (cholecystokinin 
organisation) would not be susceptible to muscarinic influences (i.e.: not connected to 
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cholinergic organisations). Furthermore, it may be proposed that chlordiazepoxide and 
possibly other benzodiazepine agonists achieve their anxiolytic profile through activity upon 
the cholecystokinin system.   
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An experiment in which a blockade of the cholecystokinin organisation by an antagonist, LY-
288513 was performed. This protocol attempted to prevent development of desensitisation to 
chlordiazepoxide following the aforementioned hypothesis. However, this was deemed a 
flawed protocol. Given the anxiolytic activity of specific CCK2 antagonists, administration of 
such a ligand subsequent to the first plus-maze exposure, as was scopolamine, would produce 
effects that would interfere with activity upon the aforementioned neuronal organisation. For 
example, LY-288513 might produce an anxiolytic state wherein the anxiety inducing 
experience produced within the plus-maze, would be repressed. It is very likely that this 
anxious state allows development of chlordiazepoxide insensitivity, and without such a state, 
this phenomenon would not occur. Logically development of a phobia would not occur if the 
anxiety-producing stimulus was unable to elicit an anxious state. Therefore, the findings of the 
second experiment were deemed pre-experimentally as of questionable validity. The fact that 
LY-288513 administration post exposure was able to partially prevent (trend observed, just 
missing significance) development of tolerance to chlordiazepoxide is analysed and remains 
inconclusive. The blockade of the cholecystokinin component of tolerance development is alas 
perhaps unachievable.  
In confirmation of studies by File et al., (1993), the scores of control animals remain stable 
over repeated tests. The control group in this study (DMSO) showed no differences between 
protocols. However, some credence must also be given to the conflicting reports regarding 
either presence or absence of differences, given that a non-significant trend was observed 
whereby prior plus-maze exposure exerted some inhibition of open arm exploration (time 
spent). With measurement of variables pertaining to ostensibly the same behaviour, yet 
differing in approach, for example recording percentage time spent on the open arm (as by File 
et al., 1993) and quantification of the actual distance travelled by the rats in the maze (as by 
Dawson et al., 1994), this trend observed with time spent, within my own study, might reach 
statistical significance with determination of the distance travelled variable. Therefore, these 
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seemingly incompatible observations may not be contradictory per se. However, the 
persistence of chlordiazepoxide sensitivity observed within trial two by Dawson et al., (1994) 
is not confirmed by nor is implied by this study or by a majority of data.   
In contrast to that previously reported by File et al., (1993), chlordiazepoxide increased open 
arm exploratory behaviour was not observed in trial two post ten-minute initial exposure. This 
is however, in accordance with the study by Holmes and Rodgers (1999) where trial two 
chlordiazepoxide insensitivity was maintained following the aforementioned protocol. Only 
when the second trial was increased to ten minutes in duration was the anxiolytic profile of 
chlordiazepoxide restored to a statistically significant degree in the Holmes and Rodgers study. 
This restoration of sensitivity was also not observed in the LY-288513 group.  
Fernandes and File (1996) observed that chlordiazepoxide had significant anxiolytic effects on 
trial one only in a maze without ledges, and on trial two only in the maze with ledges. A 
behavioural mechanism underlying the aversion elicited by an absence of ledges, compared to 
a proposed lack of phobic conditioning in the presence of ledges may be offered. Whereby 
absence of ledge elicits a phobic conditioning experience, analogous to walking the plank, 
offering a real fear of danger from falling, the motivation for investigation, inhibited by fear, 
within this arm will be repressed in late trial one and within whole of trial two. The presence of 
ledges offers an environment of relative safety analogous to "walking upon a veranda". 
Consequently, a plus-maze with ledges provides an environment with fundamentally different 
aversive cues. The multidimensional aspects of the fear experience present upon the un-walled 
plus-maze may be in part, a combination of a fear of "open spaces" and a fear of falling. A 
suitable hypothesis for elucidation of mechanisms underlying the sensitivity to 
chlordiazepoxide tolerance within the enwalled maze, might be whereby the generation of a 
proposed phobic state is initiated by fear of falling and not by fear of open spaces.  
Furthermore it may be noted that the implications of each fear are somewhat different. 
Cognitive processes will dictate that falling will deliver a possible injury, and is thus a realistic 
THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS OF CHOLECYSTOKININ 
 172
fear. Fear of open spaces, is perhaps, a fallaciously perceived threat, driven by an innate fear of 
predation within the open field. The likelihood from each fear of a catastrophic outcome may 
therefore differ in intensity.   
Interestingly, a disparity with the Fernandes and File (1996) study and my own is noted. Their 
study claimed that rats pre-exposed to a maze, with 0.5cm ledge surrounding the open arm, did 
not develop chlordiazepoxide insensitivity on a subsequent trial, whereas a ledge free maze 
induced such an occurrence. My own studies have constantly used a maze with open arms 
surrounded by a 1cm clear Perspex™ ledge. This was used in order to minimise falls from the 
open arm, which were at a surprisingly high level during preliminary trials. However, my own 
studies have shown that chlordiazepoxide insensitivity on trial two is produced using a maze 
with ledges, and that chlordiazepoxide sensitivity is indeed exhibited during trial one. This 
might perhaps be seen as an irreconcilable difference, however, I believe it to be significant 
that the Fernandes and File maze platforms are constructed with wood, whilst my maze 
platforms were constructed from Perspex™, as adapted from Lister (1987). This difference 
may explain both the initial high level of falling from the maze and the development of 
chlordiazepoxide insensitivity. Speculation of reasoning processes underlying behaviour of an 
individual rat may lie in a perceived probability of falling. The Perspex™ platform 
undoubtedly presents less friction than a wooden platform. Thus the perceived probability of 
slipping and falling would be deemed greater in the Perspex™ constructed platform. In 
addition, it may also be of significance that the ledges constructed on my maze were composed 
of transparent Perspex™, whereas within the Fernandes and File study it is not noted. A 
transparent construction may indeed confer distinct cues with regard to the nature of the open 
space, whereas an opaque material may impart a perception of a more enclosed area. This, in 
turn, might alter any perceived threat of falling. 
No significant differences were observed between either drug groups or between exposure 
protocols with regard to central platform time. Time spent on the central platform may be 
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indicative of risk assessment behaviour. This probing pre-empts entry onto the arms of the 
maze, particularly onto the open arms.   
Measures of arm entries showed broad similarity regarding group distribution to that of time 
spent, with some notable exceptions. As with time measures, maze naïve rats, administered 
chlordiazepoxide or LY-288513 produced statistically significant increases in the number of 
entries into the open arms compared to the control. This is thought to confirm the anxiolytic 
properties of both drugs.  
Once again, both drugs when administered in a subsequent plus-maze trial after prior maze 
exposure, were unable to exact these effects, hence supporting the hypothesis of drug 
insensitivity. However, unlike with time measures, administration of scopolamine, 
immediately following initial exposure failed to restore the increases in open arm entries by 
chlordiazepoxide with maze naïve rats. Furthermore, the total number of entries for the 
scopolamine-chlordiazepoxide group remains significantly inhibited. These measures reveal 
the relative lack of exploration between arms whilst spending time within each arm. This 
difference appears to highlight a peculiarity, where these two measures are generally assumed 
to represent the same or very similar aspects of the anxious response within the maze. 
Moreover, the total number of entries of all the pre-exposed groups is significantly inhibited. 
This indicates therefore, either an inhibition of locomotor activity or an increase in anxiety 
directed towards the maze in its entirety. An underlying cause of this phenomenon however, 
might lie in motivational changes with regard to exploration. Furthermore, motivational factors 
underlying an open arm entry would be a combination of incentive driven motivation and fear 
aversion. Factors underlying total entry numbers would be to a lesser degree fear aversion, and 
with a far greater component of incentive driven motivation. Scopolamine activity upon 
conditioning processes involved in plus-maze exposure, may prevent development of phobia 
(conditioned fear) but is unable to preclude reward circuit conditioning. It might be proposed 
that decreased exploration (arm entries) apparent in trial two, and late trial one as observed by 
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Rodgers et al., (1996) may be as a result of a lack of incentive value tied to the maze. The 
animal will undoubtedly learn that the plus-maze contains no incentive value and is partly 
aversive in nature (with particular reference to the open arm), thus exploration within 
subsequent trials will be inhibited. This argument is given some credence whereby the number 
of total entries is significantly decreased in maze pre-exposed animals, and accordingly a 
decrease in total maze exploration. Furthermore, although chlordiazepoxide has been shown 
clinically to lack efficacy in phobic disorders, it is also plainly not efficacious in restoring 
motivation. This matter was hoped to be elucidated upon with a protocol in which open arms 
of the maze on the first exposure, contained a sweetened cereal pellet, as an incentive. It was 
anticipated that, alike the food incentive driven radial arm maze, the plus-maze open arm 
would be awarded incentive value with regard to motivation surrounding exploration in 
subsequent trials. Several revisions of this protocol were performed, without a successful 
training trial. Rats were averse to consuming sweetened food incentives within the plus-maze 
in any sector, even when food deprived. Of a fairly large sample group (n = 32 rats) not more 
than a single pellet was consumed upon the plus-maze, and even then was carried from the 
open arm to the central platform. Upon retesting these animals, unsurprisingly, no differences 
in exploration were observed from the other pre-exposed groups. This protocol, in hindsight, 
was condemned to failure given previous findings by Holson (1986) who observed a feeding 
neophobia of rats in maze conditions, particularly pertinent to unhandled animals. However, 
despite extensive animal handling, rats were still averse to foodstuff consumption within the 
maze. It may appear logical that an animal will be reluctant to feed within a perceptually 
"perilous" environment with other factors underlying their motivation, and this I believe is the 
underlying cause. In a recent study, by Pereira et al., (1999), pairing an aversive stimulus to 
presence within the closed arm retained chlordiazepoxide sensitivity on the subsequent trial. 
The saline administered groups were not affected on the second trial.  This study provides 
fairly strong evidence as to the nature of the chlordiazepoxide tolerance phenomenon. 
However, it does not take account of the possible amnestic efficacy or ability to produce 
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attentional deficits of chlordiazepoxide, as does my own protocol. In addition, their study did 
not produce avoidance of the closed arm in any group which is unexpected, given that 
conferring an aversive stimulus to the closed arm, might be predicted to balance the aversive 
properties of both the open and closed arms. This suggests that the aversive experience of the 
open arm is at a far greater intensity than that of the closed arm plus air puff. Therefore, I tried 
to achieve the same feat using an opposite methodology. Introducing an incentive value, I had 
hoped to partially withdraw the aversive component from the open arm, rather than introduce 
one to the closed arm. In addition, this was hoped to increase exploratory motivation within the 
maze rather than decreasing this component as in the Pereira study. With an increase in 
motivation to explore, the inhibition of total arm entries observed previously was hoped to be 
reversed, and the question of, "does a decreased motivation to explore underlie the one trial 
tolerance to chlordiazepoxide?" would be addressed.  Nevertheless, this study by Pereira et al., 
(1999) whose inspiration lay contemporaneous and independent from myself, has provided 
some interesting scope for further investigation.      
The absence of neophobic feeding, with regard to inducing incentive value within the maze, is 
possibly resolved by using female rat odour within the open arms of the maze. This procedure 
however was not achievable at the time of the experiment with regard to logistical concerns.  
Effects of Elevated Plus-Maze Exposure on Acoustic Startle 
The absence of any significant differences observed for saline versus DMSO in either maze 
naïve or in the single exposure group demonstrates firstly that use of DMSO, as a vehicle is 
acceptable. In line with plus-maze studies, chlordiazepoxide produces an anxiolytic-like 
response in maze naïve rats. However, quite unlike its profile within the plus-maze, LY-
288513 does not exhibit any significant effects compared to DMSO, upon startle amplitudes.  
Interestingly, for each drug group, neither an initial exposure to the plus-maze nor testing 
twenty-four hours later produced any significant increases in startle amplitudes. However, with 
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startle sessions conducted after a second exposure to the plus-maze, a statistically significant 
increase in startle amplitudes was observed in all three drug administered groups. This is 
noteworthy in that, firstly an anxiety-like state observed is conferred by only a second 
exposure to the plus-maze, and secondly, neither chlordiazepoxide nor LY-288513 are unable 
to counteract this effect. This reproduces findings within the plus-maze with regard to 
anxiolytic drug effects, and also demonstrates that a considerable increase in anxiety-like 
behaviour can be induced by a second exposure to the plus-maze. This increase in anxiety-like 
behaviour, indicative of a phobic state, is thought to underlie the nature of chlordiazepoxide 
and related benzodiazepine insensitivity on trial two of the plus-maze. This is supported with 
these findings. Furthermore, given that chlordiazepoxide fails to exhibit an anxiolytic profile 
after trial one onwards, it may be proposed that development of chlordiazepoxide insensitivity 
occurs within trial one, as is proposed by Rodgers et al., (1996). It may also be notable that a 
trend toward lowering of startle amplitudes by chlordiazepoxide can be observed for all 
exposure groups. This might imply that some anxiolytic activity is observed for 
chlordiazepoxide in post trial two startle amplitudes, although this missing statistical 
significance by quite a degree.  Perhaps we can ignore the fact that LY-288513 fails to produce 
any anxiolytic like effects within the startle paradigm after exposure to the plus-maze. In 
experiments detailed within chapter two, it was demonstrated that LY-288513, despite 
producing an anxiolytic-like activity within the plus-maze at specific doses, was unable to 
produce a like effect within the acoustic startle paradigm at these doses.  
It is perhaps also of note that significant increases were not observed in startle responding 
twenty four hours post trial one. The animals underwent precisely identical procedures as those 
tested after trial two, with the exception of a second plus-maze exposure of course. This shows 
that it is not the experience of handling, test room exposure and injection that gates the 
increase in startle amplitudes observed post trial two. It can be inferred that the anxiety-state 
observed is provoked to a very large degree by a second plus-maze exposure in itself. 
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Data observed for animals post trial one for chlordiazepoxide and LY-288513 administered 
groups, is provided through flawed methodology, in that, the animals, by nature of the protocol 
itself, did not undergo an nondrugged exposure to the plus-maze. This data was merely 
collected as an indicator of possible anomalies. Statistical analyses must therefore examine 
comparisons between either maze naïve or post maze (after twenty-four hours) with post trial 
two groups.     However, although not reaching statistical significance chlordiazepoxide 
drugged exposure to the plus-maze produced a slight increase in startle responding which may 
indicate that an anxious state may not be required in order to produce development of phobia. 
This would have to be investigated further with drugged exposure to the plus-maze.  In 
summary this experiment was able to confirm an anxiety-like activity provoked by a second 
plus-maze exposure, which substantiates evidence for perhaps a more intense form of anxiety 
observed within trial two.  This observation provides scope for further study regarding 
manipulation of maze exposure time as was performed by Rodgers et al., (1996).  This 
evidence does seem to support that the animal perceives the plus-maze as a highly aversive 
environment. This might indicate that indeed there is some phobic development upon multiple 
exposures. However this also does not discount motivational deficits producing subsequent 
plus-maze behaviour, but implies that multiple factors are underlying.   
Shock Induced Fear Potentiated Startle 
The series of validation experiments demonstrated that shock exposure within a separate 
chamber, immediately following the initial exposure to the acoustic startle apparatus and 
startle protocol, was able to produce a fear potentiated startle response when compared to rats 
undergoing exposure to the shock chamber in absence of the shock itself.  In addition, this 
series also showed that scopolamine, a muscarinic acetylcholine antagonist, commonly used as 
an amnestic agent, was able to inhibit this fear potentiated startle response. Moreover, 
scopolamine may have extended its’ amnestic properties to blocking habituation to the startle 
stimuli between trials one and two in the nonshocked rats, although significant differences 
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between the nonshocked groups are not observed. 
Evidence against any activity upon anxiety by scopolamine has been provided in a range of 
studies. Scopolamine did not produce anti-conflict effects in the Vogel conflict test (Umezu 
1999), nor any effects on anxiety-like behaviour in the elevated plus-maze (Thiel et al., 1999). 
Scopolamine also had no effects in the light-dark transition test of anxiety (Shimada et al., 
1995), nor the shock probe/ burying test (Treit 1990). Although scopolamine does produce 
locomotor stimulation (Sansone 1980), this observation is probably irrelevant in indicating an 
alteration of anxious behaviour. Thus, it is probable that scopolamine acts via an amnestic 
mechanism rather than a mood alteration in blocking fear potentiated startle. 
In a study by Tsutsumi et al., (1999) rats were individually subjected to 30 min of inescapable 
electric footshock. After a period of twenty-four hours the rats were again placed in the 
chamber and observed for a 5-minute period without shocks. It was observed that 
administration of the CCK2 antagonist, PD-135158, 30-minutes prior to the conditioned fear 
retention session and 30-minutes prior to the conditioning (acquisition) session, significantly 
reduced freezing behaviour. However, administration of PD-135158 5-minutes after the 
acquisition did not significantly reduce freezing behaviour. Izumi (1998) observed that 
subcutaneous administration of the CCK2 specific antagonist, LY-288513, 30-minutes before 
footshock (0.3 mg.kg-1) and 30 min before conditioned fear stress (0.03-0.3 mg.kg-1) reduced 
conditioned freezing in rats. A similar protocol to that used by Tsutsumi et al., (1999) was 
utilised here with the exception of a 5-minute shock exposure. The authors of these 
experiments (Izumi and Tsutsumi) stated that their studies "indicate that LY-288513 and PD-
135158 blocked not only the acquisition but also the expression of conditioned fear". This 
conclusion however is highly questionable. Given that my own studies have shown that 
cholecystokinin agonists are unable to exert any effects on fear potentiated startle when 
administered after the shock session, as with PD-135158, administered post-conditioning 
session, the inference arises that cholecystokinin does not therefore exert an effect upon the 
THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS OF CHOLECYSTOKININ 
 179
acquisition or expression of conditioned fear. It is also plausible that effects upon anxiety level 
thus, freezing behaviour itself, within the retention sessions, and that state effects on perhaps, 
either nociception or attention induced by PD-135158 / LY-288513 administered prior to the 
conditioning session, are responsible for the observations made by these authors. Freezing 
behaviour in response to environmental stress has been documented with cat exposure in rats 
(Farook et al., 2001) so thus would not be unexpected after shock exposure. Furthermore, it 
may also be possible that the first exposure initiates a coping mechanism that is activated 
within the retention session. This coping mechanism may involve habituation to anxiety 
effects, or nociceptive desensitisation, as a preparative measure for the ensuing shock or 
expectation of such. Particular drug treatments may as well manipulate these factors as they 
might alter mnestic properties. In order for a categorical statement, that an agent is able to 
effect processes involved in acquisition / retention of a conditioned fear, to be partially 
acceptable, the agent must be able to alter behaviour in the retention trial when administered 
after the acquisition trial only. With this method it would be hoped to ensure that effects of the 
drug on subjective experiences within the acquisition trial, and / or effects on activity within 
the retention trial are ruled out. This ideal had underlain my assessment of the paradigm upon 
beginning this series of experiments. However, recently (post validation) serious doubts had 
arisen as to the nature of observed differences within this protocol. It is possible that drugs 
administered after the acquisition session itself may also exhibit state effects on the paradigm. 
Rather than demonstrate a connection between the specific drug activity and neural pathways 
fundamental to the gating of a conditioned fear response, they may also add to the aversion 
experience proceeding the acquisition session. If for example, a drug, which produces an 
anxiogenic-like response, is administered subsequent to the acquisition, the anxious experience 
may further augment any anxiety-like behaviour within the retention session itself. This 
observation could then be incorrectly interpreted as a facilitation of memory rather than an 
intensification of the aversive experience. Likewise, an anxiolytic agent might lead to 
interpretation of an amnestic activity, where in effect a lessening of a deleterious experience by 
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reducing anxiety may be apparent. Unfortunately, the vast majority of studies using avoidance 
/ conditioned fear paradigms have overlooked this seemingly fundamental issue of 
interpretation. All-encompassing statements that a particular putative agent has been 
characterised in animal studies, then to often fail at clinical examination. This issue may be the 
explanation behind the lack of success in this field.  
The experiment carried out within this study, aimed to demonstrate whether, cholecystokinin 
forms, which have a well-characterised anxiogenic activity at specific doses, are able to 
augment the intensity of aversive experience subsequent to the acquisition session. The dose 
range itself was determined by my own studies of anxiogenic activity of cholecystokinin and 
those of proposed effects upon memory retention of cholecystokinin. A combination of the 
shock exposure and the anxious state might augment behaviour within the retention sessions 
when compared to shock exposure in isolation. This was found however, not to occur, at least 
significantly under statistical analysis, across the dose range tested. The trend observed for a 
decrease in index value by CCK-4 (0.0125 mg.kg-1) which narrowly missed significance, may 
be of some importance given the proximity to the anxiety- provoking dose within the elevated 
plus-maze.  In hindsight, it seems that study of pharmacological agents and their effects upon 
attenuation or augmentation of fear potentiated startle measures will be infeasible given the 
aforementioned argument. For any agent to have claim to activity upon developmental 
processes in conditioned fear, they must have been proven to not exhibit any activity on 
anxiety itself.   
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CHAPTER FIVE - CHOLECYSTOKININ EFFECTS UPON MEMORY 
ACQUISITION AND RETENTION 
Introduction 
Initial studies implicating a role for cholecystokinin in alteration of memory processes were 
conducted in the early nineteen-eighties.  Fekete et al., (1981) observed that the sulphated 
cholecystokinin octapeptide, CCK-8s, and it's non-sulphated analogue CCK-8us, administered 
intracerebroventricularly, increased active avoidance retention latency, thus implying an 
amnestic activity. Further work by Fekete et al., (1982b) showed that the same effects are 
maintained with systemic administration, via a subcutaneous route. Cohen et al., (1982) 
observed these same effects with intraperitoneal administration of CCK-8s but only when 
administered within fifteen minutes prior to the retention trial. Intraventricular administration 
(Fekete et al., 1981) and subcutaneous administration (Fekete et al., 1982b), of CCK-8us and 
CCK-8s both impaired the acquisition of, and facilitated the extinction of active avoidance. 
CCK-8 antisera delayed the extinction of active avoidance and conditioned feeding response, 
while ineffective on acquisition and maintenance stages (Fekete et al., 1982a). Combined 
injection of CCK-8 (320 micrograms.kg-1 i.p.) and haloperidol (75 micrograms.kg-1 i.p.) 
reduced avoidance significantly more than either drug alone (Cohen et al., 1982). CCK-8 has 
been found to improve retention when administered intraperitoneally in normal but not in 
vagotomised mice whereas CCK-8 enhanced retention in mice with cortical lesions but not in 
mice with stria terminalis lesions (Flood et al., 1995). 
Investigations of two-way step-through active avoidance have shown that CCK-8 depresses 
avoidance responding and that with chronic administration of CCK-8 within the intervening 
period, tolerance to CCK-8 is conferred (Cohen et al., 1983). Hadjiivanova et al., (1995) also 
observed that CCK-4, administered post-acquisition session, was not able to affect two-way 
active avoidance retention, twenty-four hours after a fifty trial acquisition session.  
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Concurrent studies however, generated some quite contrary observations. Kadar et al., (1981) 
demonstrated that CCK-8s and CCK-8us, administered intracerebro-ventricularly, at periods 
before or after acquisition and pre-retention trial, in contrast increased passive avoidance 
retention latency, indicative of improved retention. This was also confirmed with systemic 
intraperitoneal administration (Fekete et al., 1982). Subsequent, studies showed that a range of 
cholecystokinin analogues, from the tetrapeptide form (CCK-4), to CCK-5, -6, -7 and both 
forms of CCK-8, administered both intracerebroventricularly and intraperitoneally, also 
increased passive avoidance latency (Fekete et al., 1984). Hadjiivanova et al., (1995) also 
observed that CCK-4, administered post-acquisition session, was able to impair passive 
avoidance retention, three hours after a one trial acquisition session, but not when tested 
twenty-four hours or seven days afterward.  
CCK-8 (30-500g) injected immediately following acquisition sessions produced an increase in 
the passive avoidance latency of rats. Proglumide, a non-selective cholecystokinin antagonist, 
(5mg.kg-1) was able to block CCK-8 effects on rat passive avoidance conditioning. Proglumide 
by itself at a dose of 2 mg.kg-1 decreased the latency to enter the darkened chamber. In 
addition, CCK-8 was able to prevent extinction within a passive avoidance paradigm (Deupree 
and Hsiao 1988). Passive avoidance behaviour was facilitated following subcutaneous 
administration of 10 micrograms of CCK-8s and CCK-8us administered up to 1 hour before a 
retention test. Administration into the nucleus accumbens (0.3 pg) however attenuated passive 
avoidance behaviour (Van Ree et al., 1983). An increase in passive avoidance latencies is 
indicative of enhanced memory retention, the antithesis of observations within the active 
avoidance paradigm. 
These contrasting phenomena are complicated further by observations by Fekete et al., (1984) 
that while microinjection of CCK-8s or CCK-8us into the nucleus accumbens facilitated the 
extinction of active avoidance behaviour and attenuated the retention of passive avoidance 
behaviour, microinjection of these peptides into the central amygdaloid nucleus caused 
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opposite effects on these behavioural tests. The cholecystokinin tetrapeptide amide (CCK-4) 
injected into the lateral cerebral ventricle before the first retention test of a one-trial passive 
avoidance test caused a shortened latency to response.  Chronic infusion into the lateral 
ventricle shortened the latency of the response to almost baseline level (Katsuura and Itoh 
1986b). However, unilateral injection into the central nucleus of the amygdala (CeA) of CCK-
8s (1 ng) or Boc-CCK-4 (20 ng), immediately post-trial, examined within a one-trial uphill 
avoidance task was found to improve the retention performance, whereas lower and higher 
doses had no effect, nor does injection performed 5 hours post-trial. This model is effectively a 
passive avoidance paradigm, whereby the animal placed facing downward, learns to avoid 
turning to face upwards for fear of shock. The intra-amygdala injections of Boc-CCK-4 and 
CCK-8s at these doses did not influence behaviour upon the elevated plus-maze model of 
anxiety nor upon the conditioned corral preference model of reinforcement (Huston et al., 
1998). After bilateral 6-OHDA lesions to the central amygdala (Winnicka and Wisniewski 
1999) and 6-OHDA lesions to the hippocampus (Winnicka and Wisniewski 2000) the 
facilitatory effect of CCK-8us and caerulein on retention of passive avoidance behaviour was 
abolished. 
Interestingly while cholecystokinin octapeptides facilitated the extinction of active avoidance 
behaviour and retention of passive avoidance behaviour, both of which were reversed by 
anxiolytic chlordiazepoxide pre-treatment (Fekete et al., 1984).  
Credence may however be added to the view that cholecystokinin exerts some effects upon 
memory retention for evidence from studies using an endogenous nonapeptide V-9-M (Val-
Pro-Val-Glu-Ala-Val-Asp-Pro-Met). This peptide produced from procholecystokinin within 
the brain was observed to exert effects upon memory processes of rat performing a one-trial 
passive avoidance task and a platform jumping active avoidance task. The results indicate that 
injection of V-9-M into the lateral ventricle of the rat prevents experimental amnesia induced 
by electroconvulsive shock in passive avoidance testing and that it causes a long-lasting 
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enhancement of memory in the active avoidance task (Takashima and Itoh 1989). V-9-M may 
however be a distinct species from that of cholecystokinin given that their chemical structures 
are quite different, and thus receptors for these two peptides are probably not the same. This 
would certainly a wealth of differences between the two peptides both biochemically and 
functionally (Itoh and Takashima 1990). In addition, Itoh et al., (1989) observed that a single 
subcutaneous injection of caerulein (10-100ng.kg-1) immediately after the learning trials of an 
active avoidance test, inhibited extinction of the acquired task by twice and at a dose of 
1mg.kg-1 by thrice compared to the vehicle group. In the passive avoidance response, both 
electroconvulsive shock (ECS)-induced amnesia and scopolamine-induced amnesia was 
partially prevented by CCK-8 (0.1-1 µg.kg-1 s.c.) and attenuated in whole by caerulein (>0.1 
µg.kg-1).  
Effects of cholecystokinin on experimentally induced Amnesia   
Kadar et al., observed that both CCK-8s and CCK-8us appear to be able to partly attenuate 
amnesia when injected intracerebroventricularly into rats prior to electroconvulsive shock as 
measured in a one-trial step-through passive avoidance paradigm. Only the 0.8-picomole dose 
of CCK-8us, within a dose range, administered immediately after ECS, significantly prevent 
retrograde amnesia. CCK-8 administered prior to retention testing had no effects (Kadar et al., 
1984). 
Katsuura and Itoh (1986b), later observed in a passive avoidance paradigm that CCK-8 in 
doses from 1 ng to 1 microgram had no effect on the response when injected before the 
training trials, immediately after foot shock or before the first retention test. However, 
proglumide, a cholecystokinin receptor antagonist induced marked amnesia when injected 
prior to the training trials and before the first retention test, though not subsequent to foot 
shock. ECS given immediately after the foot shock caused amnesia in retention tests, which 
could be prevented by CCK-8 injected prior to the training trials, following ECS and before 
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the first retention test. Maurice et al., (1994) demonstrated caerulein (1-100 µg.kg-1 s.c.) 
administered 30 min before carbon monoxide (CO) exposure, significantly prevented the CO-
induced impairment of performance 7 days afterward using a step-down passive avoidance 
test. Caerulein exhibited the highest efficacy followed by CCK-8S, CCK-8us, and CCK-4 
respectively. Caerulein was less effective when injected immediately after CO exposure.  
Spatial Memory Paradigms  
Ingestion of food in mice following training on T-maze footshock avoidance enhanced 
memory retention and is blocked by a specific cholecystokinin antagonist, L-364718, which in 
turn neither impaired or improved retention when given alone. This study provided evidence 
that activation of cholecystokinin receptors plays a physiological role in the mediation of meal-
induced enhancement of memory retention, although perhaps only associated with spatial 
memory testing (Flood and Morley 1989). 
Harro and Oreland (1993) examined cholecystokinin specific drugs given immediately after 
each training session in the radial arm maze with retention testing, drug-free, during a 2-week 
period. Proglumide (1-10 mg.kg-1) and devazepide, (a selective CCK1 receptor antagonist; 
0.01-1.0 mg.kg-1), caerulein (0.01-1 µg.kg-1) and CCK-4 (a selective CCK2 receptor agonist; 
25 - 50 µg.kg-1) had no reliable effects administered subcutaneously. Maurice et al., 1994 
observed that caerulein (1-100 µg.kg-1 s.c.) administered 30 min before carbon monoxide 
exposure, significantly prevented the CO-induced impairment of performance examined by 
using a Y-maze test 5 days afterward. Caerulein exhibited the highest efficacy followed by 
CCK-8S, CCK-8us, and then CCK-4. Caerulein was less effective when injected immediately 
after a single CO exposure. 
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Methods and Materials 
Animals 
Male Sprague Dawley rats (Laboratory Animal Centre, National University of Singapore, 
Singapore), weighing 280-350g were housed in groups of five to seven and maintained with 
free access to food and water ad libitum, in an animal room for one week prior to 
experimentation. Room lights were on from 07:00 to 19:00 hours. The test room and housing 
block were maintained at a standard temperature throughout the experiments.   Animals were 
weighed daily at an appointed time for one week prior to experimentation and during the post 
acquisition period. This constituted animal handling whereby each animal was allocated the 
same handling style and weighing sequence.  Animals were randomly assigned treatment 
groups using a simple computer program random number sequence generator (Random 
Number Generator for Q-Basic by Colin Greengrass, 1998). This simple program (see 
Appendix C.1 for listing) generated random whole numbers within a range corresponding to an 
assigned treatment group (see chapter 2 for further details).  
Test Room Conditions 
Animals were tested in each apparatus within a particular test room with constants of 
temperature at 25OC, lighting intensity, and background white noise generation (at 70dB). 
Animals were exposed within their home cages to the test room for two hours prior to each test 
session. 
 
Drugs and Administration 
Scopolamine hydrobromide (Sigma, USA) was dissolved in dimethylsulphoxide (DMSO; 
Merck). Cholecystokinin peptide agonists; CCK-4       (Trp-Met-Asp-Phe-NH2); CCK-8us 
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(Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2; Biotechnology Centre, National University of 
Singapore); CCK-8s (Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2; American Peptide 
Company and Princeton Biomolecules, USA) were dissolved in DMSO. The drugs or vehicle 
were administered by intraperitoneal injection in a volume of 1ml per kg body weight. Drugs 
were administered immediately following the avoidance acquisition sequence sessions.  
cholecystokinin peptide was stored under desiccation at -70oC. cholecystokinin peptide 
solutions were prepared freshly each day approximately two hours prior to testing.  Powdered 
peptide was dissolved in DMSO and specific concentrations prepared through serial dilution 
with thorough vortex mixing at each stage. 
Apparatus 
Shuttle Box Shock Chamber: A computer-controlled two-compartment step-through 
shuttlebox (San Diego Instruments, Inc.) was used. The Gemini II shuttle box is a two 
compartment acrylic chamber of dimensions: 53cm (width) x 53cm (height) x 32cm (depth) 
with a steel grid floor and a steel, computer controlled, sliding door between compartments. A 
scrambled sine wave electric shock is delivered through the steel cage floor. The shock 
intensity is adjusted manually and calculated by the following formula: y = mx + b; where y = 
shock intensity (mV); m = slope (0.004); x = animal weight (g); and b = y-axis intercept (- 0.4) 
therefore an animal weighing 350g, receives a shock intensity of (350 x 0.004) - 0.4 = 1.0 mV. 
This calculation allows a pseudo dosing effect of shock intensity with regard to animal weight. 
Gemini II operational program coding for these series of experiments is listed in appendix C. 
Experimental Procedure 
Experiment One: Passive Avoidance Paradigm 
Acquisition Session: Tests were performed whereby an animal was placed in a lighted 
compartment (60 Watt bulb) for a 10- second adaptation period. After this period, a gate 
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separating the two compartments was opened thus allowing entry into the adjacent unlit 
compartment. Rats tend to exhibit an innate affinity for darkened areas over lit areas. Hence 
rats will have a propensity to enter the adjacent compartment. Upon entry the animal breaks an 
infrared light beam triggering the door to close automatically. After the gate closed a 
scrambled electric current was applied to the cage floor (see aforementioned formula). This 
constituted the end of a trial. Each individual trial session was held for a maximum duration of 
60 seconds. Subsequent to each trial the animal was placed back into a holding cage for a 
period of 30 seconds. The animal was then retested in consecutive trials until they achieved the 
criterion necessary for completion of the trial, with a maximum of 15 trials. A definition of this 
criterion is that the animal remained in the lighted compartment for three consecutive 60-
second trials. Once this criterion is satisfied the sequence of trials ends for that animal. 
Animals failing to satisfy this criterion were rejected. Animals were administered, either; 
DMSO, Scopolamine Hydrobromide (0.3mg.kg-1), CCK-4 (0.0125 or 0.025mg.kg-1), CCK-8us 
(0.005 to 0.01mg.kg-1), or CCK-8s (0.0005 to 0.001mg.kg-1) either singularly or in 
combination, immediately subsequent to the last acquisition trial session.  
Retention Trial: A retention test was performed 72 hours later where the animal was placed in 
the lit "safe" compartment. Immediately following an manual operation of an external button, 
the gate separating the compartments was opened. The door remained open for 300 seconds (5 
minutes). The latency period, for which the animal to cross over to the shock compartment, 
was measured. The animals post session were placed in a holding cage in order to isolate them 
from the other animals prior to experimentation. Data is presented as number of trials fulfilling 
criterion (failure to traverse compartments within a 60 second period) in acquisition training 
and the crossing latency in retention testing (time taken to cross compartments).  
Experiment Two: Active Avoidance Paradigm 
Acquisition Session - Initiation Trial: with bright house lighting (60 watt bulb) on only in the 
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"safe" compartment and constant white noise within both chambers, the animal was placed in 
the unlit shock compartment (facing away from the door), and left for a ten second period. 
After this period, the gate separating the compartments was automatically opened. 
Simultaneously a scrambled sine wave shock was delivered to the steel cage floor for a period 
of 30 seconds (shock intensity in accordance with the aforementioned formula).  
Foot-shock continued until the animal escaped through the open doorway. If the animal failed 
to escape during the shock period then it was gently actuated through. The animal 
subsequently remained in the lighted "safe" compartment for 30 seconds (defined as an inter-
trial interval) before immediate removal and placement back into the unlit "shock" 
compartment.  
The second and subsequent trials measure successful active avoidances (pre-shock period 
escape). The methodological differences between these and the initiation trial are necessary to 
prevent exploration driven crossing within the ten second pre-shock period, and consequently 
ensuring that shock is the primary motivation underlying crossing behaviour. The lighting 
arrangement is organised as such in order to induce an aversion to the safe compartment. 
Rodents exhibit aversive behaviour with regard to lit areas and prefer dimly lit or darkened 
chambers. In this regard the animal will be reluctant to explore the lit "safe" chamber but will 
be forced into entry by shock application within the unlit area. This innate aversion to lighted 
areas is thus utilised so that transfer to the safe compartment is driven by shock application 
alone and not through any other predilection. 
Acquisition Session - Avoidance Trials: The animal was placed in the unlit shock 
compartment where immediately proceeding manual operation of an external push button, the 
door separating the compartments was opened. After a period of 10 seconds a scrambled sine 
wave shock was delivered to the cage floor for a period of 30 seconds. Shock intensity was 
determined as of the abovementioned formula. The footshock continued until the animal 
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escaped through the open doorway. If the animal failed to escape through the open doorway 
during the shock period then it was gently actuated through. If the animal was able to escape 
through the doorway within the 10-second period prior to the shock this fulfilled the criterion 
for avoidance. Immediately following entry into the "safe" compartment the inter-trial interval 
was initiated. The animal remained in the "safe" compartment for 30 seconds before placement 
back into the "shock" compartment. This active avoidance trial procedure was repeated fifteen 
times in succession. 
After the final acquisition session, the animal was administered with a specified 
pharmacological agent and was placed in a holding cage with other animals that had been 
tested. The group housing of tested and naïve animals together is not permitted due to a 
heightened aggressive state of shocked animals. The percentage of acquisition avoidances for 
each animal must be above 33% (5 in 15 trials) in order for the animal to be retested. Several 
animals, around five percent, who failed to satisfy this criterion were not retested in retention 
tests and their data is not shown. Animals were administered, either DMSO, Scopolamine 
Hydrobromide (0.3mg.kg-1), CCK-4 (0.0125 to 0.1mg.kg-1), CCK-8us (0.001 to 0.1mg.kg-1), or 
CCK-8s (0.0005 to 0.01mg.kg-1), immediately subsequent to the last acquisition trial session. 
Only when all the animals within a home cage had been tested were they placed back into their 
home cages and immediately returned to the animal-housing block.  
Retention Test: A retention test was performed 72 hours later where the animal was placed in 
the unlit shock compartment where immediately following an external button operation the 
door separating the compartments was opened. The door remained open for 300 seconds (5 
minutes) without application of the shock. The latency period, for which the animal to cross 
over to the safe compartment, was measured. Subsequent to crossing the "re-cross" latency, 
with a maximum 300 seconds, was measured (whereby an animal crosses back into the 
"shock" compartment). If the animal failed to traverse through the doorway during first the 
five-minute period then it was gently actuated through. The animals post session were placed 
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in a holding cage in order to isolate them from the other animals prior to experimentation.  
 
Statistical Analysis 
Statistical analysis was performed using statistical software (SPSS V9.0, SPSS inc. USA). The 
data were subjected to a one-way analysis of variance (ANOVA), followed by a Bonferroni 
post hoc analysis of group differences. Probability (p <0.05) was considered statistically 
significant. 
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Results and Data 
Passive Avoidance Paradigm  
No differences were observed between means of trials to criterion in nondrugged rats within 
the one-way step through passive avoidance paradigm. The criteria are satisfied where within 
three sixty second sessions, held in succession, the animal fails to cross into the unlit shock 
compartment. The trial number at which the last of these consecutive sessions occurs is noted 
and this variable is analysed. No group differences were observed in nondrugged sessions 
between groups administered drugs post-trial. Administration of scopolamine hydrobromide 
(0.3 mg.kg-1 i.p.) significantly shortened retention trial crossing-latency compared to the 
dimethylsulphoxide (DMSO) vehicle group (associated with amnestic activity; Figure 5.1); 
scopolamine hydrobromide; 0.3mg.kg-1, (F13,98=12.83, p<0.05).  Cholecystokinin tetrapeptide 
at 0.025mg.kg-1 (CCK-4) narrowly missed significance with an increase in crossing latency 
(F13,98=12.83, p<0.073). Cholecystokinin sulphated octapeptide at 0.001mg.kg-1 (CCK-8s) 
alone and in combination with cholecystokinin unsulphated octapeptide (CCK-8us; 0.01mg.kg-
1) produced a significant increase in crossing latency (Both F13,98=12.83, p<0.05), associated 
with enhanced memory retention.  
Active Avoidance Paradigm 
Within studies of CCK-8us, CCK-8s or CCK-4 dose ranges, no significant differences were 
observed in acquisition sessions, between groupings pre-drug administration for mean number 
of avoidances This indicates an equivalent acquisition profile across all groups.  
Figure 5.2.1: Significant inhibition of crossing latency, indicative of amnesia, at the active 
avoidance retention test was observed for scopolamine hydrobromide at 0.3mg.kg-1 (F6,49=8.84, 
p<0.001), and for CCK-8us at doses 0.005mg.kg-1 (F6,49=8.84, p<0.001); 0.01mg.kg-1 
(F6,49=8.84, p<0.001); 0.05mg.kg-1 (F6,49=8.84, p<0.01); 0.1mg.kg-1 (F6,49=8.84, p<0.001). The 
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lowest dose of 0.001mg.kg-1 failed to show any differences from the DMSO vehicle group.   
Figure 5.2.2: Re-crossing latency was found to also be enhanced by scopolamine, indicative 
again of amnesia (F6,49=2.75, p<0.05), while CCK-8us doses failed to alter re-crossing latency 
(implying lack of amnestic properties).  
Figure 5.3.1: Significant inhibition of crossing latency, indicative of amnesia, at the active 
avoidance retention test was observed for CCK-8s at doses 0.001mg.kg-1 (F4,35=31.57, 
p<0.001); 0.005mg.kg-1 (F4,35=31.57, p<0.001); 0.01mg.kg-1 (F4,35=31.57, p<0.001). The 
lowest dose of 0.0005mg.kg-1 failed to show any differences from the DMSO vehicle group.   
Figure 5.3.2: CCK-8s doses failed to alter re-crossing latency (implying lack of amnestic 
properties).  
Figure 5.4.1: Significant inhibition of crossing latency, indicative of amnesia, at the active 
avoidance retention test was observed for CCK-4 at doses 0.0125mg.kg-1 (F4,35=6.74, p<0.05); 
0.025mg.kg-1 (F4,35=6.74, p<0.01); 0.05mg.kg-1 (F4,35=6.74, p<0.05); 0.1mg.kg-1 (F4,35=6.74, 
p<0.05) .  
Figure 5.4.1: CCK-4 doses failed to alter re-crossing latency (implying lack of amnestic 
properties). 
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FIG 5.1: Means of crossing latency at passive avoidance retention test. Drug administration groups are labelled on the x-axis; doses in mg.kg-1 within parentheses. Drugs 
tested are scopolamine hydrobromide at 0.3 mg.kg-1 (2), cholecystokinin tetrapeptide (CCK-4) at 0.0125 (3) & 0.025mg.kg-1 (4); cholecystokinin octapeptide (CCK-8us) at 
0.005 (5) & 0.01mg.kg-1 (6); and cholecystokinin sulphated octapeptide (CCK-8s) at 0.0005 (7) & 0.001mg.kg-1 (8) are dissolved in dimethylsulphoxide (DMSO) vehicle (1). 
Drugs are administered both alone and in combinations; CCK-4 at 0.0125mg/g with CCK-8us at 0.005mg.kg-1 (9); CCK-4 at 0.025mg/g with CCK-8us at 0.01mg.kg-1 (10); 
CCK-4 at 0.0125mg/g with CCK-8s at 0.0005mg.kg-1 (11); CCK-4 at 0.025mg/g with CCK-8us at 0.01mg.kg-1 (12); CCK-8us at 0.005mg/g with CCK-8s at 0.0005mg.kg-1 
(13); CCK-8us at 0.01mg/g with CCK-8s at 0.001mg.kg-1 (14). Results are presented as means with light bars representing standard error of the mean (SEM). Significant 
differences from the DMSO pre-trial one group (1) are shown; *p<0.05, (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG 5.2.1: Means of crossing latency at active avoidance retention test. Drugs administrated are labelled on the x-axis; doses in mg.kg-1 within parentheses. Drugs tested are 
Scopolamine Hydrobromide (0.3 mg.kg-1), and cholecystokinin octapeptide at doses between 0.001 and 0.1mg.kg-1 (CCK-8us) and are dissolved in dimethylsulphoxide 
(DMSO) vehicle. Results are presented as means with light bars representing standard error of the mean (SEM). Significant differences from the DMSO group are shown;  
**p<0.01, ***p<0.001 (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG 5.2.2: Means of re-crossing latency at active avoidance retention test whereby animals are initially placed in the non-shock compartment. Drugs administrated are 
labelled on the x-axis; doses in mg.kg-1 within parentheses. Drugs tested are scopolamine hydrobromide (0.3 mg.kg-1), and cholecystokinin octapeptide at doses between 
0.001 and 0.1mg.kg-1 (CCK-8us) and are dissolved in dimethylsulphoxide (DMSO) vehicle. Results are presented as means with light bars representing standard error of the 
mean (SEM). Significant differences from the DMSO group are shown; *p<0.05, (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG 5.3.1: Means of crossing latency at active avoidance retention test. Drugs administrated are labelled on the x-axis; doses in mg.kg-1 within parentheses. A range of doses 
of cholecystokinin sulphated octapeptide at doses between 0.0005 and 0.01mg.kg-1 (CCK-8s) and are dissolved in dimethylsulphoxide (DMSO) vehicle. Results are presented 
as means with light bars representing standard error of the mean (SEM). Significant differences from the DMSO pre-trial one group (1) are shown; ***p<0.001 (Bonferroni 
post hoc analysis after significant one-way ANOVA). 
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FIG 5.3.2: Means of re-crossing latency at active avoidance retention test whereby animals are initially placed in the non-shock compartment. Drugs administrated are 
labelled on the x-axis; doses in mg.kg-1 within parentheses. A range of doses of cholecystokinin sulphated octapeptide at doses between 0.0005 and 0.01mg.kg-1 (CCK-8s) and 
are dissolved in dimethylsulphoxide (DMSO) vehicle. Results are presented as means with light bars representing standard error of the mean (SEM). No significant 
differences from the DMSO group are shown (Bonferroni post hoc analysis after significant one-way ANOVA). 
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FIG 5.4.1: Means of crossing latency at active avoidance retention test. Drugs administrated are labelled on the x-axis; doses in mg.kg-1 within parentheses. A range of doses 
of cholecystokinin tetrapeptide at doses between 0.0125 and 0.1mg.kg-1 (CCK-4) and are dissolved in dimethylsulphoxide (DMSO) vehicle. Results are presented as means 
with light bars representing standard error of the mean (SEM). Significant differences from the DMSO group are shown; *p<0.05, **p<0.01, ***p<0.001 (Bonferroni post 
hoc analysis after significant one-way ANOVA). 
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FIG 5.4.2: Means of re-crossing latency at active avoidance retention test. Drugs administrated are labelled on the x-axis; doses in mg.kg-1 within parentheses. A range of 
doses of cholecystokinin tetrapeptide at doses between 0.0125 and 0.1mg.kg-1 (CCK-4) and are dissolved in dimethylsulphoxide (DMSO) vehicle. Results are presented as 
means with light bars representing standard error of the mean (SEM). No significant differences from the DMSO group are shown (Bonferroni post hoc analysis after 
significant one-way ANOVA). 
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Discussion 
It was demonstrated in initial studies using a passive avoidance paradigm that doses 
corresponding to those exhibiting anxiogenic potency in the elevated plus-maze are able to 
induce an increased crossing latency. This increase might be interpreted as  improved memory 
retention in isolation. Together with matching data for plus-maze anxiogenesis (chapter 3) at 
these doses, this supposition appears somewhat contradictory when tied in with improved 
memory retention. It is quite possible that the anxiogenic state produced by these doses of 
cholecystokinin may in turn confer a state of heightened awareness with post-trial 
administration. This heightened sentience could therefore be implicit in strengthening 
consolidatory processes involved. This experiment may have therein joined the large number 
of studies implying a role of cholecystokinin in memory consolidatory processes, but for an 
observation that these animals exhibiting significantly lengthened latencies were prone to 
almost total inactivity when placed within the apparatus. This freezing behaviour is indicative 
of a profound anxiety state and would concur strongly with anxiogenic-like effects upon the 
plus-maze of these same cholecystokinin doses. The administration of drugs immediately after 
the training session block was designed to avoid behavioural state effects upon the learning 
processes and provide a view of activities upon internal memory consolidative processes. 
However, a question arose as to whether this post-trial administration would be able to, in the 
place of pro-mnestic activity, actually augment the conditioning of fear surrounding the shock 
chamber experiences. This would cause the same behavioural characteristics within a passive 
avoidance paradigm as enhanced memory retention, (i.e. an increased crossing latency). 
Scopolamine as per expectation was able to produce a significant level of amnesia with the 
retention session. Significance of combinations of cholecystokinin forms is discussed primarily 
within chapter three, with regard to anxiety state on the elevated plus-maze. The combination 
effects appear to imply a duality regarding mechanisms of cholecystokinin anxiogenesis. 
These also confirm findings of Katsuura and Itoh (1986b) that CCK-8 is able to antagonise the 
THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS OF CHOLECYSTOKININ 
 202
effects of CCK-4. 
Subsequent to the observation of freezing behaviour within passive avoidance experiments, a 
minor, yet apparently novel, variation of the active avoidance paradigm was developed 
whereby, in addition to measurement of crossing latency, a measure of re-crossing latency was 
taken. Pro-mnestic activity would be demonstrated within the active avoidance paradigm 
retention trial as a decrease in latency (whereby an animal has learned to traverse 
compartments in order to avoid a shock). However, dose response profiles for each 
cholecystokinin species examined showed an amnestic activity within an active avoidance 
paradigm. This observation was previously made by Fekete et al., where CCK-8s and CCK-
8us following peripheral administration (Fekete et al., 1982b), were able to considerably 
impair acquisition of active avoidance behaviour compared to the control. In addition, Fekete 
et al., (1982b), observed that intraperitoneal administration of CCK-8s and CCK-8us increased 
the latency of passive avoidance in each treatment group. These two seemingly incompatible 
observations were explained by a proposal of duality of cholecystokinin activity within the two 
paradigms. These observations, which I have repeated in this study, can be explained simply 
by an induction of freezing behaviour underlying increased latencies in both paradigms. 
Furthermore, the measure of recrossing latency within the active avoidance paradigm adds 
credence to this proposition. An animal exhibiting amnesia with regard to avoidance of the 
shock chamber, as is proposed with single measurement of crossing latency, will then upon 
placement in the non-shock compartment re-cross back into the shock compartment (given the 
strong lighting within the safe compartment). This is demonstrated significantly by 
scopolamine, but is lacking in the cholecystokinin administered groups. Effectively, the 
animals administered cholecystokinin neither cross nor recross within the chamber, which are 
two wholly contradictory behaviours, unless explained by induction of freezing behaviour. 
This observation is very important in that since 1981, a role for cholecystokinin within 
memory consolidation processing has been proposed. This supposition maintained throughout 
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almost twenty years of work, appears to be negated by this series of experiments.  Table 5.1 
summarises supporting research.  
Drugs Tested Route Effect on Avoidance 
Retention Latency 
Reference 
CCK-8s & CCK-8us ICV Increased Active Latency Bernard et al., 2000 
CCK-8s & CCK-8us SC Increased Active Latency Fekete et al., 1982b 
CCK-8s IP Increased Active Latency Camello et al., 2000 
CCK-8s & CCK-8us ICV Increased Passive Latency Yamamoto et al., 2000 
CCK-8s & CCK-8us IP Increased Passive Latency Rozengurt and Walsh, 2001 
CCK-4, -5, -6, -7, -8 ICV & IP Increased Passive Latency Schweiger et al., 2000 
CCK-4 IP Increased Passive Latency Aguilera et al., 2000 
Table 5.1; Summary of previous research into cholecystokinin effects upon one-way avoidance 
paradigms 
Intracerebroventricular administration of cholecystokinin-8 antisera is able to delay the 
extinction of active avoidance while ineffective on acquisition and maintenance (Fekete et al., 
1982a). The purported delay in extinction is an antithesis of the activity of cholecystokinin 
ligands (Fekete et al., 1984) which is as expected. Cholecystokinin ligands are able to promote 
extinction probably via an increase in anxiety exhibited within the model. This increase again 
produces freezing, or a similar locomotor inhibition, thus interpreted prima facie as "promoting 
extinction". 
The study of animals receiving chronic daily administration of CCK-8s post two way active 
avoidance training demonstrated that CCK-8s pre-trial, failed to depress avoidance responding 
as with those given "chronic saline" (Cohen et al., 1983). The absence of activity is 
undoubtedly due to development of cholecystokinin drug tolerance over chronic 
administration, but contrary to the conclusions of the authors, tolerance to the anxiogenic 
properties of cholecystokinin is more probable. 
Fekete et al., (1984) overlooked their own finding that the effects of CCK-8 upon passive 
avoidance, were reversed by chlordiazepoxide pre-treatment. This strongly supports my 
hypothesis.  Chlordiazepoxide is of course a well-defined benzodiazepine anxiolytic and 
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would undoubtedly reverse the anxiogenic properties of CCK.  
Katsuura and Itoh (1986b) demonstrated that CCK-4 injected into the lateral cerebral ventricle 
prior to the retention test caused a shortened latency in a one-trial passive avoidance paradigm. 
This is not in contradiction to my own and the findings of Fekete et al., (1984) where central 
ventricular administration must surely be highly sensitive to the site of injection with regard to 
adjacent brain structures. Cholecystokinin with an almost ubiquitous distribution within the 
brain, would almost certainly activate an area adjacent to the site of injection. Subsequently, 
intracerebroventricular administration would appear to be a rather haphazard method by which 
to deliver cholecystokinin forms to the brain. The shortcomings of this methodology are 
further confirmed by Fekete et al., (1984) where microinjection of CCK-8s or CCK-8us into 
the nucleus accumbens facilitated the extinction of active avoidance behaviour and attenuated 
the retention of passive avoidance behaviour, while microinjection of these peptides into the 
central amygdaloid nucleus caused opposite effects on these behavioural tests.  
The observations of Winnicka and Wisniewski (2000) that bilateral 6-OHDA lesions to the 
hippocampus significantly attenuate the "facilitatory effect" of CCK-8us and caerulein on 
retention of passive avoidance behaviour, may provide evidence of the central structures 
involved in development of the proposed conditioned fear. 
Several studies have highlighted a possible role of cholecystokinin in restoring deficits 
conferred by experimentally induced amnesia. Kadar et al., (1984) observed that a 0.8 
picomole dose of CCK-8s (within a range of doses tested), administered pre-retention trial was 
found to significantly restore passive avoidance retention. This is of course also explained by a 
freezing behaviour hypothesis. 
Katsuura and Itoh (1986a) also studied the effects of electroconvulsive shock (ECS) upon 
passive avoidance latencies. CCK-8 injected prior to the training trials, following ECS and 
before the first retention test all "prevented" ECS derived amnesia. Yet again this can be 
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explained by cholecystokinin anxiogenesis, whereby development of conditioned fear may not 
by disrupted by ECS, and thus anxiogenic factors will again be involved in retention sessions. 
However, CCK-8 may provide some protection against ECS (administered pre-ECS) in 
addition to anxiogenic effects pre-retention trial and post-ECS. It is plausible however that 
CCK-8 if it indeed does gate endogenous anxiety responses within the brain, that it might 
exhibit some protective properties. Given that normal reactive anxiety is driven by perceived 
danger, cholecystokinin might exert a protective function within the brain. This is of course 
conjecture but perhaps worthy of investigation.  
Several studies have implicated activation of cholecystokinin receptors within the mediation of 
meal-induced enhancement of memory retention in spatial memory tasks (Flood and Morley 
1989). This form of memory retention is quite different to that of shuttle box shock avoidance 
and given that cholecystokinin is implicated in satiation, it is not surprising that it would exert 
effects upon appetitive tasks.   
In strong support of my proposal is a study by Uvnas-Moberg et al., (1999) where examination 
of the endocrine and behavioural profile of two colonies of rats differing in their ability to 
acquire a conditioned avoidance response was performed. The poor avoidance performing 
animals, interestingly, were characterized by higher reactivity to sensory stimulation: higher 
startle amplitude and shorter startle latency, strongly implying a greater anxiety level. 
The nature of freezing behaviour with subsequent exposure to the shock chamber may lie 
within the following proposition. It may be possible that cholecystokinin administered post-
acquisition session produces an additional noxious state, given that it has been observed to 
produce an anxiety-like state (see chapters two and three), to that induced by shock. This state 
may augment conditioning of fear related to the environment in which shock was 
administered, rather like manipulations within conditioned place preference models. The 
addition of a further noxious element associated with the shock compartment may then 
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augment the intensity of the anxious state exhibited within the retention session exposure, 
resulting in this freezing-like behaviour. If cholecystokinin was to possess an activity upon 
memory consolidative processes directly it would undoubtedly be upon those associated with 
conditioning of fear and not of higher order associative function. Thus, the heightened anxiety 
state observed within retention tests is in all probability induced by enhanced memory 
acquisition associated with fear conditioning.   
Conclusion 
It is shown by various studies that the cholecystokinin forms examined may indeed exhibit 
ostensibly mnestic properties within avoidance paradigms. However, analysis of related 
variables has provided strong evidence of an anxiety-based factor underlying these 
observations. With simple analysis of an initial traversing latency in either passive or active 
avoidance paradigms, it would appear prima facie that these cholecystokinin forms either 
improve memory retention in the passive avoidance paradigm (by increasing latency) and 
exhibit amnestic properties within the active avoidance paradigm (again by increasing 
latency). These phenomena were adjudged incongruous to one another where considering 
activities upon memory retention as the underlying cause.  The experimental findings herewith 
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CHAPTER SIX - RECEPTOR BINDING STUDIES 
Introduction 
Cholecystokinin has a ubiquitous distribution throughout the mammalian brain (Rehfeld 1978; 
Williams et al., 1986). All known neuropeptide receptors conform to a G protein coupled 
superfamily, which is characterised by a heptahelical structure (seven transmembrane spanning 
regions). Studies by Snyder et al., (1981) were the first to characterise two distinct receptors 
for cholecystokinin. Their study demonstrated that "the pancreatic receptor does not react with 
cholecystokinin derivatives of fewer than eight amino acids; i.e. CCK-8 and larger, while the 
brain receptor was unable to recognize pentagastrin, the carboxyl-terminal five amino acids of 
CCK, but interacts with CCK-4, the carboxyl-terminal tetrapeptide of CCK". This study 
subsequently has been shown to exhibit several inaccuracies, but nevertheless was the first to 
show evidence of broad differences between receptor populations both peripherally and 
centrally. Van Dijk et al., (1984) showed that binding sites for the cholecystokinin sulphated 
octapeptide form (CCK-8s) are also distributed throughout the brain.  Central receptor 
subtypes have since been differentiated, on the basis of differing affinities of a range of 
specific ligands, into CCK1 and CCK2 (Moran et al., 1986; Chang et al., 1989; Hill and 
Woodruff, 1990; Hunter et al., 1993). Formerly known as CCK-A and CCK-B, 
cholecystokinin receptors have undergone a recent revision in nomenclature to CCK1 and 
CCK2 respectively (Noble et al., 1999). CCK1 receptors are located in highest concentrations 
in the pancreas, gall bladder and in discrete regions of the brain (Hill et al., 1987) whereas 
CCK2 receptors exhibit an almost ubiquitous distribution throughout the brain. The sulphated 
cholecystokinin octapeptide, CCK-8s exhibits far greater affinity than the non-sulphated CCK-
8us and the tetrapeptide CCK-4, for the CCK1 receptor. The major forms of cholecystokinin, 
CCK-4, pentagastrin, CCK-8us and CCK-8s however, all exhibit similar affinities for CCK2 
receptors (Noble et al., 1999). 
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Neuropeptide receptor antagonists can be divided generally into two main classifications, 
either peptide or non-peptide. The first non-peptide antagonist to be discovered was asperlicin 
in 1986. This substance is a naturally occurring benzodiazepine isolated from the fungus 
Aspergillus alliaceus. Asperlicin was found to be a highly specific CCK1 receptor antagonist 
void of the bioavailability problems usually encountered with peptide antagonists. Many non-
peptide cholecystokinin antagonists have been since synthesised. Specific non-peptide CCK1 
antagonists such as L-364718 and MK-329 bind with a high affinity, whilst demonstrating 
negligible binding at the CCK2 subtype (Hill et al., 1987). Specific synthetic non-peptide 
antagonists such as CI-988, PD-140376 and L-365260 also exhibit a high affinity for CCK2 
receptor subtypes; (Hill et al., 1992).  
Evidence for CCK2 Receptor Subtypes 
Non-peptide cholecystokinin antagonists are chemically quite distinct from the endogenous 
peptide cholecystokinin forms. Until relatively recently, the mechanism by which these 
antagonists exert their effects remained an enigma. However, radioligand binding studies 
combined with mutational analysis of cholecystokinin receptors has revealed the existence of 
distinct binding domains for peptide agonists and non-peptide antagonists (Beinborn et al., 
1993).  These techniques have shown that most peptide agonists interact at sites within the 
extracellular region of the receptor, particularly at the NH2 terminal strand region. Non-peptide 
antagonists, however, appear to interact with sites within the transmembrane region. Hence 
these binding sites are quite distinct and do not overlap. In a study by Schwartz et al., (1995), 
it was proposed that cholecystokinin receptors, like that of other neuropeptide receptors, 
follow an allosteric model. This model purports that specific ligands exhibit effects that shift a 
receptor between either an active or inactive conformational state. Thus, it was proposed 
tentatively that non-peptide antagonists exert their effects by shifting the equilibrium away 
from the active state. The mechanism by which this activation / inactivation is conferred is 
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probably via a coupling / de-coupling respectively of the G protein.  
Evidence for presence of multiple binding sites attributed to the CCK2 receptor in the brain 
arose from several competition experiments performed with selective linear or cyclic CCK-8 
analogues (Durieux et al., 1986; Knapp et al., 1990; Rodriguez et al., 1990). Derrien et al., 
(1994) characterised binding of a peptide based CCK2 agonist [3H]pBC-264 in brain 
membranes of guinea pig, mouse, and rat. The receptor binding profile of [3H]pBC-264 in 
competition with another specific CCK2 agonist, BC-197, was observed to adhere significantly 
more closely to a two site model than to that of a one site model. This was not observed with 
unlabelled BC-264 at the concentrations studied, which adhered more closely to a one-site 
occupancy model. This suggested that BC-197 exhibited differing affinities for putative high 
and low affinity sites, whereas BC-264 exhibits a very similar affinity for both subsites which 
cannot be distinguished at these concentrations (Derrien et al., 1994).  
Further evidence for this mechanism was provided by Harper et al., (1996) with analysis of 
competition profiles obtained by the CCK2 "antagonist" L-365260 and [125I]-BH-CCK-8s in 
guinea-pig gastric gland, and mouse and rat cerebral cortex preparations. Competition curves 
obtained for radiolabelled L-365260 in a mouse cortex assay demonstrated close adherence to 
a one-site model analysis, thus implying presence of a single population of binding sites. This 
confirmed an early study using radiolabelled pentagastrin and CCK-8 probes which bound 
with high affinity to the mouse cerebral cortical suggesting the absence of more than one 
binding site and the lack of cooperativity of cholecystokinin receptor binding (Clark et al., 
1986). However, Harper et al., (1996) showed that within the rat cortex and in guinea-pig 
gastric gland assays, the mean slope of the competition curves was significantly less than one. 
This is consistent with analysis determining expression of two binding sites in this case; a high 
affinity L-365260 specific site and a low affinity site, both for which CCK-8s exhibits affinity.   
Investigation of specific CCK2 receptor ligands; CI-988, PD-140376, YM-022 and JB-93182, 
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in the rat cortex, adhere closely to a one site model (indicative of a homogeneous population of 
CCK2 sites) where Hill slope estimates were not significantly different from unity (Harper et 
al., 1999). This study however found that the estimated affinity values for JB-93182 and YM-
022 in rat cortex were significantly higher, and that for CI-988 was significantly lower, than 
those obtained in the mouse cortex when these radioligands were used. Rat cortex affinity data 
were subsequently interpreted using a two-site model where it was revealed that SR-27897 
expressed approximately 9 fold, CI-988 approximately 13 fold and PD-140376 approximately 
11 fold selectivity for the putative CCK2B site whereas JB-93182 expressed approximately 23 
fold and YM-022 approximately 4 fold selectivity for the CCK2A site. Harper et al., (1999) 
proposed that where CCK2 receptors are of two subtypes, PD-140376, used in this study is 
labelling only one of these subtypes. This might explain data described forthwith.  
Studies of the CCK2 subtype imply that the transmembrane domains of the receptor comprise a 
putative ligand-binding pocket. Amino acid substitutions within this proposed pocket altered 
the affinities and/or functional activities of L-365260, YM-022 and L-740093S (a partial 
agonist). Site-directed mutagenesis of residues within this pocket alters individual affinities but 
fails to modify ligand-gated inositol phosphate production. The cholecystokinin octapeptide 
profile is however unaltered by mutations within this CCK2 pocket (Blaker et al., 2000). 
Binding studies performed using rat brain CCK2 receptor transfected CHO cells showed that 
two affinity states of the CCK2 receptor are discriminated by constrained dipeptoids CCK2 
antagonists (Bellier et al., 1997). Some evidence that CCK2 receptors may even exist in three 
different affinity states has also been provided (Huang et al., 1994). Brain CCK2 receptors 
have been demonstrated via radioligand binding studies, to exist in three different affinity 
states. Two of these states, exhibiting a high or low affinity to CCK-8 were detected. A third 
state of very low affinity was detected using [3H]-L-365260. The third state represents a much 
larger percentage of the receptor population than the higher affinity states (Chang et al., 1989).  
This and other studies suggest that non-peptide antagonists may bind with a greater affinity to 
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the G protein uncoupled conformations (low or very low affinity) whereas peptide agonists 
bind with a greater affinity to the high affinity form. Peptide agonists also bind to the G protein 
uncoupled receptor conformation but with a much lower affinity. These different affinity states 
may represent the putative subtypes of CCK2 proposed to underlie behaviour in several models 
within this thesis.  
 
CCK1 Affinity States 
Meanwhile, the idea of two distinct states of the peripheral CCK1 receptor is well established. 
Iodine labelled TN-CCK-9 (cholecystokinin nonapeptide) bound to high (with a KD 0.17 nM) 
and low (with a KD 13 nM) affinity receptors in dispersed rat pancreatic acini. Its dissociation, 
in the presence of unlabelled TN-CCK-9, showed a rapid binding component, associated with 
low affinity receptors and a slow binding kinetic component, by default associated with high 
affinity receptors. These receptors were further characterised with one class exhibiting a high 
affinity and a low capacity for CCK, while the other class having a low affinity and a high 
capacity for cholecystokinin (Winand et al., 1991). 
Studies of binding of 125I-Bolton-Hunter-labeled cholecystokinin non-sulphated octapeptide 
(125I-BH-CCK-8) to guinea pig pancreatic acini, revealed that non-sulphated agonist profiles 
were biphasic with 20% tracer bound to high affinity sites with relative potencies: gastrin-17-I 
; pentagastrin; CCK-8s; and much lower  CCK-4; 80% was bound to low-affinity sites with the 
following potencies: CCK-8s; then gastrin-17-I equivalent to pentagastrin far greater than 
CCK-4. Despite analysis of the dose-inhibition curve for CCK-8 adhering to a two binding site 
profile, comparison with the analysis in the presence of a high (0.1 micromolar) concentration 
of gastrin-17-I suggested three binding sites. The gastrin-17-I dose-inhibition curve actually 
fitted a three-site model significantly closer than a two-site model (Yu et al., 1990). 
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N-terminal truncations of the human CCK1 receptor, lacking the first 37 amino acids displayed 
a pharmacological profile identical to that of the full receptor. A truncated form lacking the 
first 42 amino acids however, did not bind agonist CCK-9 with high affinity. This ligand 
however, could compete for binding at low affinity sites (Kennedy et al., 1995). It may be 
inferred from this study that this N-terminal site is essential for the high affinity interaction 
with cholecystokinin whereas low affinity binding occurs upstream. Site directed mutagenesis 
experiments conducted by Gigoux et al., (1998) in conjunction with three-dimensional 
modelling, provided evidence that methionine 195 of the CCK1 receptor is an essential amino 
residue for interaction with the aromatic ring of the sulphated tyrosine of CCK-8s. This 
appears to interact with the sulphated tyrosine-7 (at the seventh position from the carboxyl 
terminal) of the cholecystokinin peptide and is crucial for cholecystokinin binding to the CCK1 
receptor. The unsulphated octapeptide form (CCK-8us) exhibits poor affinity for the CCK1 
receptor so much that the CCK1 receptor were highly selective (800-fold) toward sulphated 
versus nonsulphated CCK, whereas low and very low affinity sites were poorly selective (10- 
and 18-fold). The site-directed mutagenetic exchange of Met-195 for a leucine residue 
however caused a minor (2.8-fold) decrease in the affinity of the high affinity sites for 
sulphated CCK-9 but a strong decrease (73%) of receptor density.  However this exchange 
produced a 30-fold decrease on the affinity of the low and very low affinity sites for sulphated 
CCK-9, with no change in their number. The mutation also caused a 54-fold decrease of the 
potency of the receptor to induce inositol phosphate production. In addition, the mutant 
exhibited affinity and efficacy towards the unsulphated cholecystokinin form identically to the 
wild-type receptor. The authors postulate that Met-195 interacts with the aromatic ring of the 
sulphated tyrosine to correctly position the sulphated group of cholecystokinin in the binding 
site of the receptor. This interaction is essential for CCK-dependent transition of the CCK1 
receptor to a high affinity state.  
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Interactions between Sites  
These high and low affinity receptor populations are quite probably efficacious via discrete 
second messenger cascades. An indicator of this may lie indirectly within a study by Suman-
Chauhan et al., (1996) using the highly CCK2 specific radioligand [3H]PD-140376 labelling 
cholecystokinin receptors in guinea-pig brain and gastric glands. In the presence of the guanyl 
nucleotide 5'-guanylimidodiphosphate (GppNHp), cholecystokinin agonist affinity in binding 
competition in gastric glands but not in the brain was significantly inhibited. This study 
implied that despite the cholecystokinin labelling receptor sites in the brain and gastric glands 
(CCK2/gastrin subtype) being of the same molecular structure (Wank 1995), receptors in the 
two respective tissues appear to differ in the nature of post-receptor coupling. It may thus be 
possible that two proposed subtypes within the brain are indeed efficacious via two different 
second messenger cascades given the case in point. Furthermore, post-receptor coupling 
appears to effect affinity for the radioligand.  
Thus there is a mounting body of evidence for multiple binding sites present within both CCK1 
and CCK2 receptors. This was hoped to be demonstrated using the ligands studied within these 
experiments  
During the course of these studies the methodology was refined using several different 
protocols. Variations included addition of peptidase inhibitors, phenyl methyl sulphonyl 
fluoride, amastatin, actinonen and interchanging buffer solutions for Krebs-Ringer phosphate 
(as both a wash and an incubation buffer). The aforementioned revised method was used in all 
experiments after determination of that which allows optimal binding efficiency of the 
radioligand. 
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Methods and Materials 
Animals 
Sprague-Dawley rats weighing between 300-370g were housed in identical conditions to those 
used in behavioural experiments.   
Chemical Preparation 
cholecystokinin peptide was stored under desiccation at -70oC. cholecystokinin peptide 
solutions were prepared freshly each day approximately two hours prior to testing.  Powdered 
peptide was dissolved in a minimal volume of DMSO with subsequent addition of buffer 
solution. Specific concentrations were prepared through serial dilution with thorough vortex 
mixing at each stage. Radioligand solutions were prepared through direct dilution from a stock 
solution.     
Tissue Acquisition: Rats were sacrificed by direct decapitation using a Stoetling small animal 
guillotine and brains were quickly removed. Brain dissection with removal of the cerebellum 
and brain stem from the cerebral cortices provided the whole brain minus cerebellum, which 
was used in biochemical studies.  
Tissue preparation: Protocols are adapted from Hunter et al., (1993). Brain structures are 
immediately placed in a test tube containing a 50mM Tris-HCl buffer A containing 5mM 
MgCl2 at pH 6.9 stored at 4oC (pH adjusted by addition of Hydrochloric acid) and kept on ice 
throughout the entire preparatory procedure. Tissue was diluted under 20 volumes of tissue 
wet weight (g) / volume (ml), therefore, 7 g of tissue suspended in 140ml of buffer. Brain 
structures are homogenised using a Kinomatica Polytron for two 10-second periods (setting 6). 
The resulting homogenate is shaken using the vortex unit and then placed in a Beckman 
ultracentrifuge J25-I at 40,000g for 15 minutes at 4oC. Immediately after centrifugation 
samples are removed and placed on ice. The Pellet is re-suspended in excess buffer after 
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pouring and pipetting away the supernatant. The remaining pellet is washed with 10 volumes 
of buffer A (original wet weight / volume). The pellet is resuspended in buffer by 
homogenisation as per previous instruction. The homogenate again undergoes centrifugation 
under identical conditions to those abovementioned. The final pellet in re-suspended in 10 
volumes (original wet weight), of a buffer (Buffer B = 10mM HEPES, 130mM NaCl, 4.7mM 
KCl, 5mM MgCl2, 1mM EGTA, 0.025% Bacitracin, and Phenyl-Methyl-Sulphonyl Fluoride, 
PMSF (1mM) at pH 7.2 and 22oC) and is homogenised and shaken as by the abovementioned 
method.  
Incubation: Incubation tubes are divided and labelled. Solutions documented within 
subsequent individual sections are added in the order, buffer B; then unlabelled competitive 
component; then tissue homogenate; lastly the radiolabelled component is added. Solutions are 
incubated for 45 minutes at 25oC in a temperature maintained water bath and lightly shaken.  
Filtration: Filter papers (Whatman GF-B) are soaked in ice cold buffer A and stored on ice at 
4oC.  Within the last 5 minutes of the incubation period the wet filter papers were placed onto 
the vacuum filter and vacuum dried of excess buffer for a 10 second period. At the end of the 
incubation period sequentially labelled tubes were emptied into corresponding wells, tubes are 
washed once with 4ml of ice cold buffer (4oC) with the contents emptied into the well. Tubes 
were placed upside down in each corresponding well. Upon completion of this procedure for 
each of the tubes, sequential washing begins again with 4ml of 4oC buffer twice more (making 
a total of three washes). The vacuum filtration is maintained after the last wash for fifteen 
seconds and each filter paper is carefully removed with tweezers and placed in a corresponding 
scintillation vial. This procedure is completed for subsequent batches of incubated samples.  
Scintillation Counting: Each vial, containing filter paper is filled with 8ml of Beckman HP 
Scintillation fluid and shaken using both hand shaking in order to submerge the filter paper, 
and vortex apparatus to aid absorption. After a period of twenty-four hours, vials are placed in 
THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS OF CHOLECYSTOKININ 
 216
a Beckman scintillation counter.  
Protein Assay 
Modified from Lowry et al., (1951). Reaction Mixture minus protein consists of solution A 
which is prepared as per the following:  15ml of 2% Na2CO3 in 0.1M NaOH with addition of 
0.15ml of 2% Na-K Tartrate. After waiting for a few minutes 0.15ml of CuSO4 is added. 
Bovine Serum Albumin standard solutions of 1mg/ml concentration were added to the reaction 
mixture in volumes; 10µl, 30µl, and 50µl in order to provide a standard spectrophotometry 
curve. The protein sample diluted 1 in 10 is added (30µl) to the reaction mixture.  10 minutes 
later 0.5ml of Folin-Ciocaltens Phenol (FCP) reagent is added to each tube. Each BSA 
standard and protein sample are performed in triplicate. After a period of 90 minutes 
spectrophotometric measurement of absorbance (=500nm (visible spectrum); W lamp 
(tungsten filament) was carried out for each tube. In order to achieve a reliable measure of 
absorbance differences, each absorbance measure is subtracted from absorbance of a blank 
solution (Solution A and FCP without protein). The protein sample is plotted on a slope of 
BSA concentration versus absorbance. 
Data Analysis 
Binding analysis was performed using GraphPad Prism version 3.00 for windows, (GraphPad 
Software, California USA). This software allows specific non-linear curve fit regression, linear 
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Results and Data 
Experiment 6.1  
In rat cerebral cortex membranes, [3H]-PD-140376 demonstrated saturable binding to 
apparently a single population of receptors. This is shown by close adherence to a one-site 
model analysis with Prism 3.00 software analysis. This software is able to analyse nonlinear 
regression curves. Therefore linear regression analysis via schild and scatchard charts is not 
deemed necessary (see Avoid Scatchard, Lineweaver-Burke and similar transforms in 
Graphpad manual. Copyright (c) 1994-1999 by GraphPad Software). Total binding is shown in 
figure 6.1.1 within a range of concentrations from 0.1 to 8.0nM. With competition from 
pentagastrin at a concentration of 200µM, specific binding is determined. Chart 6.1.2 shows 
specific binding data for [3H]-PD-140376 by subtraction of total binding from the linear 
regression plot for pentagastrin competition data. Figure 6.1.2 shows that [3H]-PD-140376 has 
a KD value of 1.087nM (0.2061 S.E.M.) and a BMAX of 862.8 counts per minute (53.98 
S.E.M.). This non-linear regression analysis did not deviate significantly from a one site 
binding model analysis but deviated to a significant degree from that of a multiple site model 
analysis.  
Experiment 6.2 
A concentration range of the peptoidal CCK2 antagonist CI-988 was examined in competition 
with [3H]-PD-140376 at 4.0nM. Analysis confirmed that binding adheres closely to a one site 
binding competition model compared to two-site competition analysis. An EC50 of 0.747 nM 
CI-988 was determined. This experiment was deemed necessary to compare binding of peptide 
(pentagastrin) and non-peptide (CI-988) binding in competition with [3H]-PD140376. Both 
appear therefore to exhibit affinity for the same CCK2 binding site at the concentrations tested.  
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Experiment 6.3 
[3H]-CCK-8s at concentration of 1.5nM in competition versus unlabelled CCK-4, CCK-8us or 
CCK-8s. All three cholecystokinin forms versus radiolabelled CCK-8s appeared to adhere to 
one site competition model analysis, except for certain anomalies with regard to very high 
concentrations of competing ligands. At concentration in a range of 0.1 to 1.0mM upwards, 
radioligand binding seemed to increase or unlabelled competition appeared to decrease. This is 
represented statistically by either a loss of significance compared to lower concentrations 
within the exponential phase, which in itself is not truly conclusive. With CCK-4 however, 
high doses of 10 and 20mM are significantly greater than counts measured with the plateau 
phase at 0.01 to 1.0mM; F11,36=40.732, P<0.05 and P<0.01.  The possible significance of this 












THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS OF CHOLECYSTOKININ 
F ig u re  6 .1 .1
0 1 2 3 4 5 6 7 8
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
T o ta l B in d in g  C PM
µM
[PD 1 4 0 3 7 6 ] n M
C
PM
F ig u re  6 .1 .2






1 0 0 0




FIG 6.1.1 shows total binding data for [3H]-PD-140376 over a log10 conce
competition with 200µM Pentagastrin with ± S.E.M. A non-linear line of regress
these data is also shown. 
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FIG 6.3 shows binding data for [3H]-CCK-8s in competition with unlabelled CCK-8s over a log10 
concentration range with ± S.E.M. A non-linear line of regression in representation of these data is also 
shown. 
FIG 6.4 shows binding data for [3H]-CCK-8s in competition with unlabelled CCK-8us over a log10 

















Figure 6.5 shows binding data for [3H]-CCK-8s in competition with unlabelled CCK-4 over a log10 
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Within rat cerebral membranes, [3H]-PD-140376 demonstrated saturable binding to apparently 
a single population of receptors. This is not however in contradiction of hypotheses for two 
subtypes of CCK2 receptors. As postulated by Harper et al., (1999) if CCK2 receptors are of 
two subtypes, PD-140376, used in this study is labelling only one of these subtypes. 
Determination of specific binding with competition from pentagastrin shows that a resulting 
non-linear regression analysis did not deviate significantly from a one site binding model 
analysis but deviated to a significant degree from that of a multiple site model analysis. 
Furthermore, binding analysis of a concentration range of the peptoidal CCK2 antagonist CI-
988 confirmed close adherence to a one site binding competition model compared to two-site 
competition analysis. This experiment was deemed necessary to compare binding of peptide 
(pentagastrin) and non-peptide (CI-988) binding in competition with [3H]-PD-140376. Both 
appear therefore to exhibit affinity for the same CCK2 binding site at the concentrations tested. 
These experiments were conducted some time before publication of the aforementioned article 
by Harper et al., (1999). In the light of this very comprehensive study it was decided that no 
further experiments were to be conducted using PD-140376.  At the time of these experiments 
only this and the CCK2 antagonist L-365260 were available for commercially. These ligands 
were both shown to adhere to single site binding models and were obviously not of use in 
determination of potential CCK2 receptor subtypes / subsites. Binding data for [3H]-CCK-8s, 
being an endogenous form of cholecystokinin, was subsequently analysed within multiple 
binding site models in competition with unlabelled CCK-4, CCK-8us or CCK-8s. All three 
cholecystokinin forms in competition with radiolabelled CCK-8s appeared to adhere to one 
site competition model analysis, with the exception of certain anomalies with regard to very 
high concentrations of competing ligands. At concentrations in a range of 0.1 to 1.0mM 
upwards, radioligand binding seemed to increase, or unlabelled competition appeared to 
decrease, resulting in larger radioactivity counts observed. This is represented statistically by 
either a loss of significance compared to lower concentrations within the exponential phase, 
which in itself is not truly conclusive. With CCK-4 however, high doses are significantly 
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greater than counts measured within the plateau phase.  This finding is peculiar, seemingly 
only to this receptor group. It might be possible that cholecystokinin at very high doses 
exhibits affinity for a very low affinity receptor site. Activation of this site may then confer 
either increased affinity at the higher affinity site, or at the very low affinity site itself. It is 
more likely however that binding at a very low affinity site would not change binding at this 
site itself in particular. It has been postulated previously that CCK1 receptors may exhibit a 
high affinity active site and a lower affinity G-protein decoupling sites. This lower affinity site 
is postulated to act as a de-activating site, which decouples the second messenger system (G 
protein) from the receptor and decreases affinity of the high affinity site to that of very low 
affinity. This would confirm findings by Talkad et al., (1994) that the CCK1 receptor exists 
within three affinity states; high, low and very low affinity.   It has been also confirmed that at 
least two, a high and low affinity state, exist for CCK2 receptors (Huang et al., 1994). The lack 
of evidence for a dual site binding within the whole brain minus cerebellum is also at odds 
with presence of a distinct population of CCK1 receptors for which CCK-8s exhibits a fairly 
equivalent level of affinity to that of CCK2.    This observation may be due to a radioligand 
concentration, which confers binding only at the highest affinity site. This would certainly 
produce a binding profile in competition adhering to a one-site model. The possibility of using 
higher radioligand concentrations were prohibited by both high cost and relatively low CCK-
8s concentrations of samples available commercially. These data do not discount a hypothesis 
for multiple binding sites given a body of evidence precluding to such. These are merely 
unable to categorically provide evidence by several aforementioned limiting factors.    
Activation of the non-peptide site may then produce in addition to a proposed decoupling of 
the G-protein second messenger, an alteration in affinities at the peptide site. Schwartz et al., 
(1995) proposed that an allosteric mechanism alters the conformation of the receptor structure 
for other neuropeptide receptors. This mechanism may therefore account for the anomalies 
observed at very high concentrations of cholecystokinin ligands whereby binding competition 
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with the radioligand CCK-8s is attenuated. This concentration may thus have some kind of 
activity in inhibiting binding at the non-peptide site or may be at a level where affinity towards 
the deactivated site is observed. This could then produce further binding of the radioligand, 
which exhibits a greater affinity at the receptor than the CCK-8us and CCK-4 forms, thus 
radioligand binding will outweigh the competitive ligand effects at decreasing radioactivity 
counts. 
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Figure 6.6 represents a proposed model of physiological effects of binding at the “non peptide” (CCK-8 
low affinity) site. The G-protein coupled form (left of the equilibrium) is an active conformation with a 
high affinity peptide site (for CCK-8). The G-protein de-coupled form (right of the equilibrium) is an 
inactive conformation possibly with a structurally altered peptide specific binding site (conferring very 
low affinity to CCK-8). This model would account for presence of two affinity populations of receptor: 
active; high affinity for CCK-8 at peptide site, low affinity for CCK-8 at non-peptide site: inactive; very 
low affinity for CCK-8 at altered peptide site; cholecystokinin occupancy at non-peptide site required 
for maintenance of the de-activated state.   
The putative mechanism represented in figure 6.6 should eventually yield data for four binding 
sites; two in the high affinity state (peptide and non-peptide specific) and two in the low 
affinity decoupled state (the same peptide and non-peptide specific). The existence of only 
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three binding states, as postulated by Huang et al., (1994) and Chang et al., (1989)  is possibly 
not correct. This and similar studies are probably measuring two sites in the activated receptor 
with CCK-8s binding with highest affinity at the peptide specific followed by the non-peptide 
specific site, and then measuring the peptide site at the decoupled (deactivated) receptor. 
Therefore further study may provide ligands that would be able to bind also at the non-peptide 
decoupled receptor sites.  One of the several cholecystokinin derivatives, the tetrapeptide form 
has been adapted by bismethylation of its carboxyl terminal in order to increase peptidase-
resistance. Any further modifications of the terminal moieties decreased the CCK2 receptor 
binding affinity (Weng et al., 1996). The receptor binding profile of this compound however, 
was examined within studies assuming a one-site binding model, any alteration of this 
proposed dual site binding has not obviously been characterised. With the assumption that 
endogenous CCK-4 is able to bind within this dual site model to both sites, as it might be 
assumed of endogenous cholecystokinin ligands, the bismethylated form was therefore not 
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CHAPTER SEVEN - CONCLUSIONS 
Animal Models of Anxiety  
The administration of chlordiazepoxide showed consistent anxiolytic-like activity in both 
acoustic startle and elevated plus-maze models via either decreasing acoustic startle amplitudes 
or increasing time spent in the open arms respectively. Cholecystokinin forms; CCK-4, CCK-
8us and CCK-8s, within an extremely narrow dose range reversed chlordiazepoxide activity 
within both models. Given the wealth of evidence of clinical activity of CCK-4 in 
panicogenesis, it may be proposed that cholecystokinin forms produce anxiogenic-like 
behaviour in rats within these models. Studies of both startle and plus-maze models showed 
that activation at the CCK2 receptor is critical in cholecystokinin peptide induced anxiety-like 
behaviour. The specific antagonists, CI-988 and LY-288513, were able to attenuate the effects 
of those anxiogenic cholecystokinin forms.  
Interestingly, despite significant anxiogenic-like activity within the plus-maze model, CCK-
8us alone appears to be largely inactive in the acoustic startle paradigm. Furthermore, although 
CCK-8us decreased anxiety-like behaviour induced by CCK-4 in the plus-maze at specific 
doses, no activity was observed regarding CCK-8us affecting CCK-4 increased acoustic startle 
amplitudes. It would thus appear, prima facie, from this evidence that CCK-8us is almost 
entirely inactive within the acoustic startle model. This however is not entirely accurate, as is 
discussed later.   
The chronological sequence of animal testing was firstly using the plus-maze, in late 1997, 
followed by acoustic startle testing, in late 1998, using the same peptide supply for CCK-4 and 
CCK-8us, and a fresh CCK-8s supply. These chemicals, specifically CCK-4 and -8us were 
stored under identical conditions, which would imply that both are free of significant 
degradation, in order for one to be efficacious and the other not to be. However, chemical 
differences may confer a greater degradation for CCK-8us, thus rendering it inactive in the 
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acoustic startle model. This however is disregarded with regard to positive CCK-8us activity in 
the passive and active avoidance and in social isolation experiments that were performed later 
still. This would therefore imply that CCK-8us is genuinely inactive in acoustic startle. That 
may imply that plus-maze anxiogenic-like activity control is through a separate mechanism to 
that of acoustic startle. Alternatively, given that there is a slight increase in amplitude observed 
for CCK-8us, although far from significant, suggests that the acoustic startle model may be 
less sensitive to measurement of anxiogenic-like behaviour than the plus-maze. Therefore, it 
may be inferred that relative intensity of the anxiety state generated by cholecystokinin forms 
is in the order, CCK-8s > CCK-4 > CCK-8us (CCK-8s having the strongest effect). This 
would also be shown to some extent in the plus-maze where CCK-8s only is able to inhibit 
chlordiazepoxide induced increases in open arm entries. The other forms despite effecting 
measures of time spent in the open arms are not efficacious with regard to open arm entries, 
thus implying that CCK-8s induces a greater intensity of anxiety than CCK-4 and -8us.  
However given that CCK-8s exhibits affinity for the CCK1 receptors, the CCK1 gated factor of 
inhibition of locomotor activity must be acknowledged within these models.  
Co-administration of cholecystokinin forms yielded similar data in both models with regard to 
CCK-4 and CCK-8s combinations. This particular combination negated the anxiogenic-like 
activity of either alone and did not produce any activity with combinations at half doses in 
both models. As discussed previously, a CCK-8us appears to have no activity within the 
acoustic startle paradigm. This is highlighted whereby, in the plus-maze combinations of 
CCK-4 with CCK-8us negated anxiogenic-like activity of either alone, but in the acoustic 
startle paradigm, CCK-8us did not alter activity of CCK-4.  However, a further complication 
arises where CCK-8us is able to attenuate the anxiogenic-like activity of CCK-8s in the startle 
paradigm. This implies that CCK-8us is certainly chemically active within the paradigm, and 
supports both hypotheses of; either differing anxiety intensity induced by each cholecystokinin 
form, or of distinct systems controlling anxiogenic-like behaviour on the plus-maze and in the 
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acoustic startle paradigm. The latter hypothesis does however strongly support existence of 
multiple cholecystokininergic configurations underlying different anxiogenic pathologies. 
Ostensibly, it might not be surprising that behaviour within the plus-maze, which may 
duplicate clinical phobia to some degree, and naïve acoustic startle, which is probably akin to 
symptoms within generalised anxiety disorder, are controlled via different mechanisms.  
An interesting finding showed that in the acoustic startle paradigm, CCK2 antagonists, LY-
288513 and CI-988 both exhibited an inverse bell shaped dose response curve with regard to 
anxiogenic-like behaviour. These findings are both complementary to those of CI-988 and 
contrary to those of LY-288513 in the plus-maze. A dose of 0.02mg.kg-1 of CI-988 produces 
anxiogenic-like startle behaviour and also inhibits chlordiazepoxide-induced increases in open 
arm exploration, also indicative of an anxiogenic response. However, a dose of 0.001mg.kg-1 
LY-288513 both produces increases in startle and increases in open arm exploration. Hence 
the former is indicative of anxiogenesis and the latter of anxiolysis. This would again imply 
that the two models are measuring distinct forms of anxiety, which are indeed gated through 
different cholecystokininergic mechanisms. Plus-maze anxiogenesis is proposed to be 
controlled by equilibrium between activities of CCK-4 and CCK-8 specific receptors, thought 
to be putative CCK2 subpopulations. According to evidence herein, acoustic startle 
anxiogenesis would be controlled by an imbalance between CCK-4 and only CCK-8s, with 
CCK-8us possessing ability to inhibit the activity or antagonise CCK-8s specific receptors. 
Evidence of contrary data using LY-288513 has indicated that anxiety-like behaviour in the 
plus-maze and in the acoustic startle models are not complementary to each other. A poignant 
question to be raised would thus be whether anxiety itself is measured at the critical dose of 
0.001mg.kg-1, or whether this is some other behavioural characteristic. At higher doses of LY-
288513 within the plus-maze, anxiolytic-like activity is observed and in acoustic startle, 
activity is normalised.  Interestingly, CI-988 produces an increase in startle amplitude at the 
dose, 0.002mg.kg-1 at which no effect is observed within the plus-maze. This provides further 
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evidence of the dissimilarity of underlying mechanisms controlling either plus-maze behaviour 
or acoustic startle. While CI-988 induced differences in dose response studies can be explained 
perhaps by chlordiazepoxide co-administration in the plus-maze test, LY-288513 produces 
inversed behavioural profiles at the same doses in both models and in the vehicle solely. 
Interestingly, for LY-288513, a trend towards inhibition of total number of arm entries is 
observed at 0.01mg.kg-1. This would imply, given the increases in startle at this dose, that a 
form of freezing behaviour is apparent in the plus-maze, thus inhibiting exploration. However, 
this cannot be attributed to the lower dose, so the enigma remains. The similarity between 
behaviour exhibited within the plus-maze and acoustic startle is therefore not as simple as at 
first sight. Where anxiety would be expected a priori to be a singular entity prevalent in both 
models, it is unquestionably clear that this anxiety-like behaviour is quite distinct in both 
models.  Whether this can be applied to clinical conditions that these models attempt to 
represent is problematical. It might be predicted that an agoraphobic individual would 
experience increased propensity for increased startle behaviour, however, this cannot be 
directly applied to rodent behaviour, which is undoubtedly attuned to very different 
environmental variables and risk factors.  An example of which may be in examination of the 
aversive nature of the plus-maze, whereby a rodent, for fear of predation or falling, will not 
explore the areas of potentially perilous open arms, with an option of relatively safe closed arm 
areas. Within this potentially predatory environment, startle would serve as an escape 
mechanism. Furthermore, it may be possible that anxiety itself is not actually measured within 
the plus-maze environment. Despite, a state of unrealistic risk assessment underlying clinical 
phobias, rodent open arm avoidance behaviour on the plus-maze may be as a result of a wholly 
realistic risk assessment. It cannot be assumed that unrealistic risk assessment in humans, 
known as phobia, is a state analogous to seemingly normal behaviour in rodents. Previous 
studies have not attempted to show whether benzodiazepines increase motivation to explore 
within the plus-maze and that cholecystokinin decreases this. The plus-maze has for the most 
part been validated pharmacologically with the observations that particular drugs that are 
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clinically active as anxiolytics are also active within the maze. This possibly far-fetched 
supposition, that the plus-maze actually measures anxious behaviour and not just 
pharmacological effects, has not been tested in great detail. Acoustic startle however may be a 
more realistic measure of anxious behaviour in that this is a simple reaction to a rapid stimulus, 
which is altered in intensity by a change in anxiety level. 
With an attempt to equate these findings to the human condition, it may be speculated that 
activation of one cholecystokinin or other neurotransmitter subsystem may confer certain 
behavioural changes indicative of particular anxiety disorders, whereas activation of another 
may produce changes related to a different set of anxiety-like symptoms. This may partly 
explain the range of different anxiety disorders in the clinical condition, although this is highly 
speculative. 
An interesting finding that LY-288513, with anxiolytic-like properties on naïve exposure to the 
plus-maze is no longer active when administered on subsequent exposures. This in itself 
demonstrates activity identical to that of chlordiazepoxide. However, administration of 
scopolamine following the initial plus-maze exposure was able to restore chlordiazepoxide 
activity but not that of LY-288513. This evidence may allow an insight into the nature of 
neural circuitry controlling these phenomena. This would imply that benzodiazepine neuronal 
circuitry lies either upstream, or in parallel to cholecystokinin circuitry underlying anxiety.  
This sequence of activation is however contradicted with evidence that CI-988 was not able to 
inhibit activity of the benzodiazepine inverse agonist FG-7142. This implies that FG-7142 
induced anxiogenesis is either independent or is downstream from structures gating 
cholecystokinin-induced anxiogenesis. This apparent contradiction would imply that indeed 
the underlying neural circuitry, by which either cholecystokinin ligands or benzodiazepines 
achieve their effects upon anxiety, is distinct and separate. These projections possibly would 
intercept at an end structure through which anxiety itself is gated. Furthermore, evidence 
implies that differential activation of distinct cholecystokinin receptor subpopulations 
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controlling anxiogenesis, and attenuation of some of the resulting anxiogenic pathologies by 
benzodiazepines, may underlie anxiety. Evidence of plus-maze-induced increases in acoustic 
startle amplitudes is lacking. This increase is only distinctly demonstrated after the second 
exposure. This finding would imply that other factors such as repeated testing and handling, in 
addition to plus-maze exposure, might underlie resulting behaviour or at least add a further 
stress component. However, it may equally be assumed that changes in startle amplitudes are 
not sensitive to single plus-maze exposure and that only the anxiety level induced by 
cumulative exposures are of an intensity producing significant increases. This is probably more 
likely than acoustic startle exhibiting sensitivity only to a distinct type of anxiety exhibited in 
the second exposure.  
Animal Models of Learning and Memory 
Experiments within this thesis have attempted to provide a clear explanation for seemingly 
contradictory data implicating cholecystokinin in either amnestic or promnestic activity in 
memory acquisition.  The data and discussion therein has strongly refuted claims of activity for 
cholecystokinin in learning and memory of associative, non-appetitive tasks.   
The examination of differences in receptor binding between animals exhibiting differeing 
behaviour within the models examined was not examined in this thesis. However I have 
suggested this, in hindsight, as a possible avenue of research and this is being carried out 
currently by other researchers.  
Complications 
A recent paper by Rehfeld (2000) drew attention to a lack of evidence as to whether CCK-4 
itself is an endogenous peptide. There is insufficient evidence according to the author that 
CCK-4 is synthesised endogenously, and may merely be an artefact of in-vivo degradation of, 
probably CCK-5.  Rehfeld proposed that CCK-4 is an exogenous test substance. Whether this 
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is exact is perhaps mostly irrelevant in this study. Although CCK-4 may indeed be only an 
exogenous compound, the fact remains that clearly CCK-4 and CCK-8 achieve their 
anxiogenic-like profile via distinct and separate mechanisms, possibly via different CCK2 
receptor subpopulations. In the case that CCK-4 is not an endogenous factor in anxiety, surely 
this distinct mechanism described must have a role within anxiety. It may be possible that 
CCK-4 and CCK-8 differ only in their permeability to the blood brain barrier, where one may 
activate peripheral receptors and the other central receptors. In this case, there must still be a 
purpose for these different populations. It may also be quite possible that CCK-4, being as 
proposed a degradation product of CCK-5 would exert effects via the same receptor 
populations. Therefore, the possibility that the effects of CCK-4 can be transposed to those of 
CCK-5 should be examined in future study.   The possibility that any form of cholecystokinin 
injected peripherally may be degraded to another active by product may also require further 
investigation.  
Given the numerous neurotransmitter classes thought to control different aspects of both 
clinical and experimental anxiety, pathology underlying the array of distinct clinical anxiety 
disorders cannot be assumed to involve a simple elevation of specific neurotransmitter activity. 
This diversity of clinical anxiety disorders in itself implies several neurotransmitter systems, 
distinct regions within these, and interactions between receptor subtypes as involved in a 
strikingly complex underlying mechanism. Early hypotheses stating particular overly 
simplistic mechanisms underlying not only a single, but also an entire range of anxiety 
disorders, are certainly to be discounted. Study of the brain and behaviour, until very recently, 
has been prone to this over simplistic view of this highly complex structure. Neuroscience has 
been plagued with reductionist ideas, in the sense that the complexity of the brain relating to 
similarly complex behaviours has not been appreciated sufficiently.  With millions of 
individual neurones and in turn billions of intricate interconnections, still simplistic ideas 
surrounding neurotransmitter function, related to behaviour, are alluded to. This reductionist 
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approach is indeed useful when considering distinct elements involved in a specific pathology, 
but should not be viewed in isolation. Furthermore, where various studies are found to 
contradict one another, detailed examination of experimental differences must occur. To 
merely state that a particular research group were incorrect in their findings is a wholly 
ineffectual standpoint. Failure to examine causes of these variations allows further misuse of 
valuable resources in carrying out, with hindsight, meaningless experiments.  
In conclusion experimental data provided within this thesis has hopefully addressed some of 
the points of issue within the field studied. With certainty, many questions have been raised 
which it is hoped will be elucidated upon in future study. 
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APPENDIX A.1.1: CHOLECYSTOKININ RECEPTOR AGONISTS USED WITHIN 
THIS THESIS. 
CCK-8s: Cholecystokinin Sulphated Octapeptide; [Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-
Phe-NH2] 
CCK-8us: Cholecystokinin Sulphated Octapeptide; [Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-
NH2] 
CCK-4: Cholecystokinin Tetrapeptide;  [Trp-Met-Asp-Phe-NH2] 
THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS OF CHOLECYSTOKININ 














THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS OF CHOLECYSTOKININ 
 291
APPENDIX B.1: WIRING DIAGRAM FOR ELEVATED PLUS-MAZE COUNTER 
TIMER DEVICE 
Elevated Plus-maze Data Collection Device 
The counter / timer unit was used for collection of elevated plus-maze data. This was a 
rectangular box with two top mounted buttons of one touch on and one touch off operation. 
One such button was operated when the animal entered the open arms (button marked O) and 
the other button was operated when the animal entered the closed arm (button marked C). The 
box also consisted of two sets of timers (OMRON H7ET self powered RESET button only); 
two sets of counters (OMRON H7EC self powered RESET button only); and a centrally 
positioned countdown timer (OMRON H3CA), which was set for a specific period of time. 
After this period had elapsed the counter and timer units ceased operation. Each timer and 
counter unit was switched on or off via the top mounted buttons and counter /timer units were 
dedicated to either open arm buttons or closed arm buttons. 
When the countdown timer inactivated the counter /timer units each thus displayed entry 
numbers or time spent in either open or closed arms of the maze.   
The wiring diagram for the control box is represented overleaf.   
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APPENDIX C.1: PROGRAM LISTINGS 
Random Number Generator Programs 
These programs served to randomise drug treatment groups for consecutive animals. First 
using Microsoft Quick basic, Revision 2 was refined in order to provide a range of drug group 
number other than that starting a zero. This was deemed necessary when particular treatment 
groups were allocated their maximum number of animals and random number generation was 
required within a narrower range. The program was rewritten for Microsoft Visual Basic in 
order to provide an easily executable program.  
1. Random Number Generator v.1 by C.J Greengrass, (1997) for Quick Basic 4.5 
10 REM PRESS F5 TO RUN 
20 REM SELECT File AND Exit TO QUIT 
30 CLS 0: COLOR 15, 0, 1 
40 PRINT "NUMBER RANDOMISER V.1 By C.J.Greengrass (c) 1997" 
50 INPUT "Enter the Range Minimum"; a 
60 INPUT "Enter the Range Maximum"; b 
70 INPUT "How Many Random Numbers <70"; n 
80 BEEP 
90 RANDOMIZE TIMER 
100 FOR y% = 1 TO n 
110 D% = INT(RND * b) 
120 c% = INT(RND * 6) + 9 
130 COLOR c%, 0, 0 
140 IF D% <= a THEN D% = D% + a 
150 PRINT D%, 
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160 NEXT y% 
170 COLOR 15, 1, 1 
180 LINE INPUT "again Y/N    ", y$ 
190 IF y$ = "y" THEN GOTO 40 ELSE GOTO 200: 
200 PRINT "Cheerio": END 
 
2. Random Number Generator v.2 by C.J Greengrass, (1997) for Quick Basic 4.5 
10  REM PRESS F5 TO RUN 
20 REM SELECT File AND Exit TO QUIT 
30 CLS 0 
40 COLOR 15, 0, 1 
50 PRINT "NUMBER RANDOMISER V.2 By C.J.Greengrass (c) 1997" 
60 INPUT "Enter the Range Minimum"; a 
70 INPUT "Enter the Range Maximum"; b 
80 INPUT "How Many Random Numbers <70"; n 
90 RANDOMIZE TIMER 
100 FOR y% = 1 TO n 
110 D% = INT(RND * b) 
120 c% = INT(RND * 6) + 9 
130 COLOR c%, 0, 0 
140 IF D% <= a THEN D% = D% + a 
150 PRINT D%, 
160 NEXT y% 
170 COLOR 15, 1, 1 
180 LINE INPUT "again Y/N    ", y$ 
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190 IF y$ = "y" THEN GOTO 3 ELSE GOTO 50: 
200 PRINT "Cheerio": END 
 
3. Random Number Generator by C.J Greengrass, (1999) for Visual Basic 6.0 
Dim a As Integer 
Dim b As Integer 
Dim X As Object       'create Word object 
Dim n As Integer 
Dim y1 As Integer 
Dim d1 As Integer 
Dim c1 As Integer 




Private Sub cmdStart_Click() 
Set X = CreateObject("Excel.Application") 'open excel 
X.Visible = True 'make it visible 
X.workbooks.Add    'open a new workbook 
a = txtMin.Text     ' choose a as min 
b = txtMax.Text 
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For y1 = 1 To n 
d1 = Int((b - a + 1) * Rnd + a) 
 
X.Range("A" & y1).Select 
X.ActiveCell.FormulaR1C1 = d1 
Next y1 
End Sub 
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APPENDIX C-2 SAN DIEGO INSTRUMENTS SOFTWARE PROGRAM LISTING 
AND OPERATING INSTRUCTIONS 
The software prompts for variables required within the protocol, on-screen notifications, 
without input facility, are shown in lower case; on-screen notifications, with input prompting, 
are shown in as capitalised; variables and key operations are shown in bold text and are 
underlined; and annotation is in parenthesis. (↵ represents the return (enter) key) 
C.2.1 SR-Lab Software Program Listing PSR2.EXE 
C.2.1.1: The following dedicated computer software program dictated a sequence of twenty-
five 100-millisecond bursts of 120dB white noise with an intermittent background noise level 
of 70dB. There was an eight second interval between 120dB bursts.  
Session Definition 
From the main menu;  
SELECT F2 (Definition Menu) 
SELECT F5  (Sessions Definition):  
Session Name: “asrsess1” 
Background Noise Level?: 420  
(A noise level of 420 corresponds to 70dB as a background noise level) 
Number of Record Samples?: 250
Sample Intervals (Milliseconds)?: 1
(Between stimulus bursts 250 samples of animal movement data are recorded separated by one 
millisecond) 
Inter-trial Interval #1 (Seconds)?:  8
(The interval between stimulus noise bursts) 
Inter-trial Interval #2 (Seconds)?:  ↵ 
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Trial #1: “asrtrl1” ↵
Sequence Repetitions?: 25 ↵ 
(Number of bursts of noise stimulus during the trial) 
Acclimatisation Period (Minutes)?: 3 ↵ 
(Period during which the animal is placed in the apparatus prior to the first noise burst. This 
period is necessary in order to allow acclimatisation to the apparatus.  Hence, any change in 
the level of responding measured will be in response predominantly to the noise burst stimuli.  
IS THIS CORRECT Y/N?: Y ↵ 
 
Trial Definition 
From the main menu;  
SELECT F2 Î (Definition Menu) 
SELECT F1 Î (Build a TRIAL definition)  
TRIAL NAME: “asrtrl1” ↵ 
SELECT F1 Î NOISE LEVEL?: 720 ↵ 
(A noise level of 720 corresponds to 120dB) 
SELECT F4 Î Record Data  
(This begins immediate data recording of the animal’s reflexive response to the noise) 
SELECT F3 Î WAIT TIME (MS)? 10 ↵ 
(Length of stimulus) 
SELECT F2 Î Background 
(Revert to background noise level of 70dB) 
PRESS Escape 
DO YOU WANT TO SAVE THE TRIAL Y/N?: Y
 
Execution Protocol   
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From the main menu;  
SELECT F1 Î (Execution Menu) 
SELECT F1 Î SESSION NAME?: “asrsess1”  
CHAMBERS 1-8: SELECT F1 (indicating chamber 1 only) 
Identification codes: (User specified) 
RESULT FILENAME: (User specified) 
Display Waveforms Y/N? n
Are your Subjects ready Y/N? y  
(Session Proceeds) 
 
C.2.1.2: The following dedicated computer software program dictated a sequence of twenty-
five 100-millisecond bursts of 70dB white noise with an intermittent background noise level of 
70dB.  There was an eight second interval between 120dB bursts. The stimulus and 
background noise are identical in volume amplitude. This is a pseudo-startle paradigm in order 
to measure spontaneous locomotor activity within the apparatus. The session definition and 
execution protocol listings are identical except in trial name and session name respectively. 
Trial Definition 
From the main menu;  
SELECT F2 Î (Definition Menu) 
SELECT F1 Î (Build a TRIAL definition):  
TRIAL NAME: “trial2” ↵
SELECT F1 Î NOISE LEVEL?: 420 ↵ 
(A noise level of 420 corresponds to 70dB) 
SELECT F4 Î Record Data  
(This begins immediate data recording of the animal’s reflexive response to the noise) 
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SELECT F3 Î Wait Time (Ms)? 10 ↵
(Length of stimulus) 
SELECT F2 Î Background 
(Revert to background noise level also of 70dB) 
SELECT Escape 
DO YOU WANT TO SAVE THE TRIAL Y/N?: Y
  
C.3.1: The following dedicated computer software program dictated a 30-second shock 
sequence while utilising SR-LAB and Gemini II apparatus in the shock induced fear 
potentiated startle paradigm. The acoustic startle program listing C.2.1 was used although on 
two consecutive trials, pre and post-shock. This program listing uses the GEMINI II apparatus 
and the GEMII.exe program 
From the main menu;  
Session Definition 
SELECT F2 Î (Definition Menu) 
SELECT F4 Î “Build a SESSION definition”:  
SESSION NAME: “shkfpsr1” ↵ 
START GATE OPEN OR CLOSED? O/C: C Gate Starting Position: CLOSED 
ENTER NEXT ITI IN SECONDS: 0 Inter Trial Interval 1: 0 
Enter next ITI in seconds: ↵ 
ENTER NEXT TRIAL NAME: “shkfpsr1” ↵  
ENTER NEXT TRIAL NAME: ↵  
Sequence Repetitions: 1 
Acclimation Period Following Button Press in Seconds: 0
Trial Definition 
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SELECT F2 Î (Definition Menu) 
SELECT F1 Î (Build a TRIAL definition)  
TRIAL NAME: “shkfpsr1” ↵ 
BEGINNING of Start Block. 
SELECT M  (Mark Side) 
SELECT H (House Lights) M (Light on marked side) 1 (Light on) U (Untimed) 
SELECT G  (Gate) C (Closed) U (Untimed) 
SELECT W (Wait for) B (button press) 
SELECT S (shock) O (on) M (Marked side) 1 (on) T (timed) 
Milliseconds to maintain Marked Shock On:  30000 ↵ 
SELECT W (Wait for) I (interval) 
ENTER WAIT TIME IN MILLISECONDS: 30000 ↵ 
SELECT J (Jump to Start of Finish Block) 
END of Start Block. 
BEGINNING of Finish Block. 
END of Finish Block. 
 
C.3.2. Gemini II: One Way Step-Through Passive Avoidance using the PA2.exe program. 
Acquisition Trial 
SELECT ALT/C.   
Primary Data site? X:\
Total Enclosures Connected? 1 
Use Shock (s), Airstim (A) or Both (B)?: S
Duration of Shock (seconds)? 1
Query User Questions (Y or N)? N
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Top level menu message? Trial name and message
(C)LASSIC or (T)RIALS TO CRITERION? T 
Stop Session if can’t get Trials to criterion (y/n)?  n 
At Main Menu: 
SELECT 1 TO Set Up Header For Test  
FILENAME? “xxxxxxxxx” (8 characters) 
Number of Trials? 8 
Trials to Criterion? 3 
Enclosures used to test? 1 
Adaptation period (seconds)? 10 
Maximum Trial length (seconds)? 60 
SELECT 2 TO START TEST SESSION 
 
Retention Trial 
SELECT ALT/C.   
Primary Data site? X:\
Total Enclosures Connected? 1 
Use Shock (s), Airstim (A) or Both (B)?: S
Duration of Shock (seconds)? 0
Query User Questions (Y or N)? N
Top level menu message? “Trial name and message”
(C)LASSIC or (T)RIALS TO CRITERION? C 
 
SELECT 1 TO Set Up Header For Test 
Filename (8 characters)? “xxxxxxxxx” 
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Enclosures used to test? 1 
Is this a training session (Shock on) Y/N? N (for first session only) 
Adaptation period (seconds)? 10 
Maximum Trial length (seconds)? 300 




C.2.4. Gemini II: One Way Step-Through Active Avoidance for GEMII.EXE program 
Training Trial Definition 
Initiation Trial 
SELECT F2 Î (Definition Menu) 
SELECT F1 Î Build a TRIAL definition:  
TRIAL NAME: “shkfpsr1” ↵ 
BEGINNING of Start Block. 
Mark Side.UnMarked House Lights On. 
Wait 10000 mSecs. 
Marked Shock On. 
Gate Open. 
END of Start Block. 
Until Timeout, DO Condition Block #1 IF 
Subject Crosses, 
Otherwise, DO Default Block. 
Timeout at 40 seconds. 
THE NEUROPHARMACOLOGY AND BEHAVIOURAL EFFECTS OF CHOLECYSTOKININ 
 304
BEGINNING of Condition Block #1. 
Gate Closed. 
Jump to Start of Finish Block. 
END of Condition Block #1. 
BEGINNING of Default Block. 
END of Default Block. 
BEGINNING of Finish Block. 
END of Finish Block. 
 
Avoidance Trial 
SELECT F2 Î (Definition Menu) 
SELECT F1 Î Build a TRIAL definition:  
TRIAL NAME: “shkfpsr2” ↵ 
BEGINNING of Start Block. 
Both House Lights On. 
Wait for Button Press. 
Mark Side. 
Gate Open. 
Clear Interval Timer A. 
Start Interval Timer A. 
END of Start Block. 
Until Timeout, DO Condition Block #1 IF 
Subject Crosses, 
Otherwise, 
DO Condition Block #2 IF 
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Interval Timer A >= 10000 Milliseconds, 
Otherwise, DO Default Block. 
Timeout at 45 seconds. 
BEGINNING of Condition Block #1. 
Jump to Start of Finish Block. 
END of Condition Block #1. 
BEGINNING of Condition Block #2. 
Marked Shock On. 
END of Condition Block #2. 
BEGINNING of Default Block. 
END of Default Block. 
BEGINNING of Finish Block. 
Marked Shock Off. 
Gate Closed. 
END of Finish Block. 
 
Session Definition  
Gate Starting Position: CLOSED 
Inter Trial Interval 1: 30 
Inter Trial Interval 2: 30 
Inter Trial Interval 3: 30 
Inter Trial Interval 4: 30 
Inter Trial Interval 5: 30 
Inter Trial Interval 6: 30 
Inter Trial Interval 7: 30 
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Inter Trial Interval 8: 30 
Inter Trial Interval 9: 30 
Inter Trial Interval 10: 30 
Trial 1: SHOCKER1 
Trial 2: SHOCKER2 
Trial 3: SHOCKER2 
Trial 4: SHOCKER2 
Trial 5: SHOCKER2 
Trial 6: SHOCKER2 
Trial 7: SHOCKER2 
Trial 8: SHOCKER2 
Trial 9: SHOCKER2 
Trial 10: SHOCKER2 
Trial 11: SHOCKER2 
Sequence Repetitions: 1 
Acclimation Period: 0 
 
Retention Trial  
Due to problems involving programming this protocol. Retention sessions were manually 
operated and timing was recorded using electronic timers and screen observation.  
 
 
 
